Attention deficit hyperactivity disorder (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Attention deficit hyperactivity disorder" in English language version.

refsWebsite

Global rank English rank

399nih.gov

4^th place

282doi.org

2^nd place

81semanticscholar.org

11^th place

8^th place

54web.archive.org

1^st place

26worldcat.org

5^th place

12handle.net

102^nd place

76^th place

12books.google.com

3^rd place

8loc.gov

70^th place

63^rd place

5cdc.gov

218^th place

212^th place

5harvard.edu

18^th place

17^th place

5apa.org

1,220^th place

1,102^nd place

3kcl.ac.uk

3,833^rd place

2,331^st place

3fda.gov

447^th place

338^th place

3who.int

195^th place

302^nd place

2nature.com

234^th place

397^th place

2ru.nl

9,179^th place

6,972^nd place

2europepmc.org

8,929^th place

8,063^rd place

2webmd.com

1,169^th place

1,075^th place

2nhs.uk

1,989^th place

1,528^th place

2psu.edu

207^th place

136^th place

2psychiatrictimes.com

9,815^th place

7,507^th place

1heysigmund.com

low place

1thelancet.com

2,393^rd place

3,174^th place

1archive.org

6^th place

1archive.today

14^th place

1uclan.ac.uk

low place

1rug.nl

2,779^th place

1,997^th place

1guidelines.gov

low place

1healthcentral.com

low place

1uptodate.com

3,771^st place

2,605^th place

1lu.se

4,012^th place

4,295^th place

1sdu.dk

9,605^th place

9,125^th place

1uiowa.edu

3,018^th place

1,865^th place

1childmind.org

low place

1soton.ac.uk

6,219^th place

4,029^th place

1cell.com

2,814^th place

6,533^rd place

1wiley.com

222^nd place

297^th place

1aappublications.org

3,763^rd place

3,602^nd place

1ahrq.gov

9,469^th place

6,259^th place

1merckmedicus.com

low place

1camh.ca

low place

1ima.org.il

low place

1consumerreports.org

4,720^th place

2,843^rd place

1creativecommons.org

1,010^th place

612^th place

1nottingham.ac.uk

4,422^nd place

2,579^th place

1jaacap.org

low place

1dundee.ac.uk

low place

8,938^th place

1zenodo.org

621^st place

380^th place

1researchgate.net

120^th place

125^th place

1nice.org.uk

3,258^th place

2,666^th place

1caddra.ca

low place

1medscape.org

low place

1medscape.com

719^th place

636^th place

1nytimes.com

7^th place

1reuters.com

49^th place

47^th place

1theguardian.com

12^th place

11^th place

aappublications.org

pediatrics.aappublications.org

Millichap JG, Yee MM (February 2012). "The diet factor in attention-deficit/hyperactivity disorder". Pediatrics. 129 (2): 330–337. doi:10.1542/peds.2011-2199. PMID 22232312. S2CID 14925322. Archived from the original on 11 September 2015.

ahrq.gov

effectivehealthcare.ahrq.gov

Peterson BS, Trampush J, Maglione M, Bolshakova M, Brown M, Rozelle M, et al. (2024). "ADHD Diagnosis and Treatment in Children and Adolescents". effectivehealthcare.ahrq.gov. doi:10.23970/ahrqepccer267. PMID 38657097. Retrieved 22 June 2024.

apa.org

psycnet.apa.org

Barkley RA (2011). "Attention-deficit/hyperactivity disorder, self-regulation, and executive functioning.". In Vohs KD, Baumeister RF (eds.). Handbook of self-regulation: Research, theory, and applications (2nd ed.). The Guilford Press. pp. 551–563.
Meta-analysis: https://psycnet.apa.org/record/2010-02209-001
Barkley RA (2004). "Attention-deficit/hyperactivity disorder and self-regulation: Taking an evolutionary perspective on executive functioning.". In Baumeister RF, Vohs KD (eds.). Handbook of self-regulation: Research, theory, and applications. The Guilford Press. pp. 301–323.
Bálint S, Czobor P, Mészáros A, Simon V, Bitter I (2008). "[Neuropsychological impairments in adult attention deficit hyperactivity disorder: a literature review]" [Neuropsychological impairments in adult attention deficit hyperactivity disorder: A literature review]. Psychiatria Hungarica (in Hungarian). 23 (5). Magyar Pszichiátriai Társaság: 324–335. PMID 19129549. PsycNET 2008-18348-001.

apa.org

Crawford N (February 2003). "ADHD: a women's issue". Monitor on Psychology. 34 (2): 28. Archived from the original on 9 April 2017.

archive.org

Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington: American Psychiatric Publishing. 2013. pp. 59–65. ISBN 978-0-89042-555-8.

archive.today

"6A05 Attention deficit hyperactivity disorder". International Classification of Diseases (11th ed.). February 2022 [2019]. Archived from the original on 1 August 2018. Retrieved 8 May 2022.

books.google.com

Tomaska LD, Brooke-Taylor S (2014). "Food Additives – General". In Motarjemi Y, Moy GG, Todd EC (eds.). Encyclopedia of Food Safety. Vol. 3 (1st ed.). Amsterdam: Elsevier/Academic Press. pp. 449–54. ISBN 978-0-12-378613-5. OCLC 865335120.
Dulcan MK, Lake MB (2011). "Axis I Disorders Usually First Diagnosed in Infancy, Childhood or Adolescence: Attention-Deficit and Disruptive Behavior Disorders". Concise Guide to Child and Adolescent Psychiatry (4th illustrated ed.). American Psychiatric Publishing. pp. 34. ISBN 978-1-58562-416-4 – via Google Books.
Caroline SC, ed. (2010). Encyclopedia of Cross-Cultural School Psychology. Springer Science & Business Media. p. 133. ISBN 978-0-387-71798-2. Archived from the original on 22 December 2020. Retrieved 1 February 2016.
Wiener JM, Dulcan MK (2004). Textbook Of Child and Adolescent Psychiatry (illustrated ed.). American Psychiatric Publishing. ISBN 978-1-58562-057-9. Archived from the original on 6 May 2016. Retrieved 2 November 2014.
Szasz T (2001). "Psychiatric Medicine: Disorder". Pharmacracy: medicine and politics in America. Westport, CT: Praeger. pp. 101. ISBN 978-0-275-97196-0 – via Google Books. Mental diseases are invented and then given a name, for example attention deficit hyperactivity disorder (ADHD).
Turkington C, Harris J (2009). "Attention deficit hyperactivity disorder (ADHD)". The Encyclopedia of the Brain and Brain Disorders. Infobase Publishing. pp. 47. ISBN 978-1-4381-2703-3 – via Google Books.
Cowen P, Harrison P, Burns T (2012). "Drugs and other physical treatments". Shorter Oxford Textbook of Psychiatry (6th ed.). Oxford University Press. pp. 546. ISBN 978-0-19-960561-3 – via Google Books.
Faraone SV (2011). "Ch. 25: Epidemiology of Attention Deficit Hyperactivity Disorder". In Tsuang MT, Tohen M, Jones P (eds.). Textbook of Psychiatric Epidemiology (3rd ed.). John Wiley & Sons. p. 450. ISBN 978-0-470-97740-8. Archived from the original on 22 December 2020. Retrieved 1 February 2016.
Crichton A (1976) [1798]. An inquiry into the nature and origin of mental derangement: comprehending a concise system of the physiology and pathology of the human mind and a history of the passions and their effects. United Kingdom: AMS Press. p. 271. ISBN 978-0-404-08212-3. Archived from the original on 3 April 2019. Retrieved 17 January 2014 – via Google Books.
Millichap JG (2010). "Definition and History of ADHD". Attention Deficit Hyperactivity Disorder Handbook (2nd ed.). Springer Science. pp. 2–3. doi:10.1007/978-1-4419-1397-5_1. ISBN 978-1-4419-1396-8. LCCN 2009938108. Archived from the original on 14 January 2023. Retrieved 8 May 2022 – via Google Books.
Weiss M, Hechtman LT, Weiss G (2001). "ADHD in Adulthood: An Introduction". ADHD in Adulthood: A Guide to Current Theory, Diagnosis, and Treatment. Taylor & Francis. pp. 34. ISBN 978-0-8018-6822-1 – via Google Books.
Barkley R (2006). Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. New York: Guilford. pp. 42–5. ISBN 978-1-60623-750-2. Archived from the original on 2 October 2023. Retrieved 19 July 2022.

caddra.ca

"Canadian ADHD Practice Guidelines" (PDF). Canadian ADHD Resource Alliance. Archived (PDF) from the original on 21 January 2021. Retrieved 4 February 2011.

camh.ca

"Adult ADHD: Diagnosis". CAMH. Archived from the original on 21 June 2021. Retrieved 17 April 2022.

cdc.gov

"Facts About ADHD". Centers for Disease Control and Prevention. 6 January 2016. Archived from the original on 22 March 2016. Retrieved 20 March 2016.
CDC (16 March 2016). "Attention-Deficit / Hyperactivity Disorder (ADHD)". Centers for Disease Control and Prevention. Archived from the original on 14 April 2016. Retrieved 17 April 2016.
"State-based Prevalence Data of Parent Reported ADHD". Centers for Disease Control and Prevention. 13 February 2017. Archived from the original on 30 March 2019. Retrieved 31 March 2020.
"ADHD Throughout the Years" (PDF). Center For Disease Control and Prevention. Archived (PDF) from the original on 7 August 2013. Retrieved 2 August 2013.
Staley BS (2024). "Attention-Deficit/Hyperactivity Disorder Diagnosis, Treatment, and Telehealth Use in Adults — National Center for Health Statistics Rapid Surveys System, United States, October–November 2023". MMWR. Morbidity and Mortality Weekly Report. 73 (40): 890–895. doi:10.15585/mmwr.mm7340a1. ISSN 0149-2195. PMC 11466376. PMID 39388378.

cell.com

Baron-Cohen S (June 2002). "The extreme male brain theory of autism". Trends in Cognitive Sciences. 6 (6). Elsevier: 248–254. doi:10.1016/S1364-6613(02)01904-6. PMID 12039606. S2CID 8098723. Archived from the original on 3 July 2013. Retrieved 9 July 2020.

childmind.org

"Is It ADHD or Trauma?". Child Mind Institute. Retrieved 18 April 2024.

consumerreports.org

Consumer Reports, Drug Effectiveness Review Project (March 2012). "Evaluating Prescription Drugs Used to Treat: Attention Deficit Hyperactivity Disorder (ADHD) Comparing Effectiveness, Safety, and Price" (PDF). Best Buy Drugs: 2. Archived (PDF) from the original on 15 November 2012. Retrieved 12 April 2013.

creativecommons.org

Coghill DR, Banaschewski T, Soutullo C, Cottingham MG, Zuddas A (November 2017). "Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder". European Child & Adolescent Psychiatry. 26 (11): 1283–1307. doi:10.1007/s00787-017-0986-y. PMC 5656703. PMID 28429134. Text was copied from this source, which is available under a Creative Commons Attribution 4.0 International License "CC BY 4.0 Deed | Attribution 4.0 International | Creative Commons". Archived from the original on 16 October 2017. Retrieved 22 October 2022.{{cite web}}: CS1 maint: bot: original URL status unknown (link).

doi.org

Faraone SV, Bellgrove MA, Brikell I, Cortese S, Hartman CA, Hollis C, et al. (22 February 2024). "Attention-deficit/hyperactivity disorder". Nature Reviews Disease Primers. 10 (1): 1–21. doi:10.1038/s41572-024-00495-0. ISSN 2056-676X.
Faraone SV, Bellgrove MA, Brikell I, Cortese S, Hartman CA, Hollis C, et al. (22 February 2024). "Attention-deficit/hyperactivity disorder". Nature Reviews Disease Primers. 10 (1): 1–21. doi:10.1038/s41572-024-00495-0. ISSN 2056-676X.
Foreman DM (February 2006). "Attention deficit hyperactivity disorder: legal and ethical aspects". Archives of Disease in Childhood. 91 (2): 192–194. doi:10.1136/adc.2004.064576. PMC 2082674. PMID 16428370.
Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, et al. (September 2021). "The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder". Neuroscience and Biobehavioral Reviews. 128. Elsevier BV: 789–818. doi:10.1016/j.neubiorev.2021.01.022. ISSN 0149-7634. PMC 8328933. PMID 33549739.
Pievsky MA, McGrath RE (March 2018). "The Neurocognitive Profile of Attention-Deficit/Hyperactivity Disorder: A Review of Meta-Analyses". Archives of Clinical Neuropsychology. 33 (2): 143–157. doi:10.1093/arclin/acx055. PMID 29106438.
Schoechlin C, Engel RR (August 2005). "Neuropsychological performance in adult attention-deficit hyperactivity disorder: meta-analysis of empirical data". Archives of Clinical Neuropsychology. 20 (6): 727–744. doi:10.1016/j.acn.2005.04.005. PMID 15953706.
Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K (February 2013). "Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects". JAMA Psychiatry. 70 (2): 185–198. doi:10.1001/jamapsychiatry.2013.277. PMID 23247506.
Hoogman M, Muetzel R, Guimaraes JP, Shumskaya E, Mennes M, Zwiers MP, et al. (July 2019). "Brain Imaging of the Cortex in ADHD: A Coordinated Analysis of Large-Scale Clinical and Population-Based Samples". The American Journal of Psychiatry. 176 (7): 531–542. doi:10.1176/appi.ajp.2019.18091033. PMC 6879185. PMID 31014101.
Brown TE (October 2008). "ADD/ADHD and Impaired Executive Function in Clinical Practice". Current Psychiatry Reports. 10 (5): 407–411. doi:10.1007/s11920-008-0065-7. PMID 18803914. S2CID 146463279.
Diamond A (2013). "Executive functions". Annual Review of Psychology. 64: 135–168. doi:10.1146/annurev-psych-113011-143750. PMC 4084861. PMID 23020641. EFs and prefrontal cortex are the first to suffer, and suffer disproportionately, if something is not right in your life. They suffer first, and most, if you are stressed (Arnsten 1998, Liston et al. 2009, Oaten & Cheng 2005), sad (Hirt et al. 2008, von Hecker & Meiser 2005), lonely (Baumeister et al. 2002, Cacioppo & Patrick 2008, Campbell et al. 2006, Tun et al. 2012), sleep deprived (Barnes et al. 2012, Huang et al. 2007), or not physically fit (Best 2010, Chaddock et al. 2011, Hillman et al. 2008). Any of these can cause you to appear to have a disorder of EFs, such as ADHD, when you do not.
Antshel KM, Hier BO, Barkley RA (2014). "Executive Functioning Theory and ADHD". In Goldstein S, Naglieri JA (eds.). Handbook of Executive Functioning. New York, NY: Springer. pp. 107–120. doi:10.1007/978-1-4614-8106-5_7. ISBN 978-1-4614-8106-5.
Retz W, Stieglitz RD, Corbisiero S, Retz-Junginger P, Rösler M (October 2012). "Emotional dysregulation in adult ADHD: What is the empirical evidence?". Expert Review of Neurotherapeutics. 12 (10): 1241–1251. doi:10.1586/ern.12.109. PMID 23082740. S2CID 207221320.
Faraone SV, Rostain AL, Blader J, Busch B, Childress AC, Connor DF, et al. (February 2019). "Practitioner Review: Emotional dysregulation in attention-deficit/hyperactivity disorder - implications for clinical recognition and intervention". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 60 (2): 133–150. doi:10.1111/jcpp.12899. PMID 29624671.
Shaw P, Stringaris A, Nigg J, Leibenluft E (March 2014). "Emotion dysregulation in attention deficit hyperactivity disorder". The American Journal of Psychiatry. 171 (3): 276–293. doi:10.1176/appi.ajp.2013.13070966. PMC 4282137. PMID 24480998.
Barkley RA (December 2002). "International Consensus Statement on ADHD". Journal of the American Academy of Child and Adolescent Psychiatry. 41 (12): 1389. doi:10.1097/00004583-200212000-00001. ISSN 0890-8567. PMID 12447019.
Barkley RA, Murphy KR (1 June 2011). "The Nature of Executive Function (EF) Deficits in Daily Life Activities in Adults with ADHD and Their Relationship to Performance on EF Tests". Journal of Psychopathology and Behavioral Assessment. 33 (2): 137–158. doi:10.1007/s10862-011-9217-x. ISSN 1573-3505.
Fleming M, Fitton CA, Steiner MF, McLay JS, Clark D, King A, et al. (July 2017). "Educational and Health Outcomes of Children Treated for Attention-Deficit/Hyperactivity Disorder". JAMA Pediatrics. 171 (7): e170691. doi:10.1001/jamapediatrics.2017.0691. PMC 6583483. PMID 28459927.
Lee YC, Yang HJ, Chen VC, Lee WT, Teng MJ, Lin CH, et al. (1 April 2016). "Meta-analysis of quality of life in children and adolescents with ADHD: By both parent proxy-report and child self-report using PedsQL™". Research in Developmental Disabilities. 51–52: 160–172. doi:10.1016/j.ridd.2015.11.009. PMID 26829402.
Barkley RA, Fischer M (July 2019). "Hyperactive Child Syndrome and Estimated Life Expectancy at Young Adult Follow-Up: The Role of ADHD Persistence and Other Potential Predictors". Journal of Attention Disorders. 23 (9): 907–923. doi:10.1177/1087054718816164. PMID 30526189. S2CID 54472439.
Cattoi B, Alpern I, Katz JS, Keepnews D, Solanto MV (April 2022). "The Adverse Health Outcomes, Economic Burden, and Public Health Implications of Unmanaged Attention Deficit Hyperactivity Disorder (ADHD): A Call to Action Resulting from CHADD Summit, Washington, DC, October 17, 2019". Journal of Attention Disorders. 26 (6): 807–808. doi:10.1177/10870547211036754. PMID 34585995. S2CID 238218526.
Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, et al. (1 September 2021). "The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder". Neuroscience & Biobehavioral Reviews. 128: 789–818. doi:10.1016/j.neubiorev.2021.01.022. ISSN 0149-7634. PMC 8328933. PMID 33549739.
Barkley RA, Murphy KR (1 June 2011). "The Nature of Executive Function (EF) Deficits in Daily Life Activities in Adults with ADHD and Their Relationship to Performance on EF Tests". Journal of Psychopathology and Behavioral Assessment. 33 (2): 137–158. doi:10.1007/s10862-011-9217-x. ISSN 1573-3505.
Groen Y, Priegnitz U, Fuermaier AB, Tucha L, Tucha O, Aschenbrenner S, et al. (December 2020). "Testing the relation between ADHD and hyperfocus experiences". Research in Developmental Disabilities. 107: 103789. doi:10.1016/j.ridd.2020.103789. PMID 33126147.
Ayers-Glassey S, MacIntyre PD (September 2021). "Investigating emotion dysregulation and the perseveration-and flow-like characteristics of ADHD hyperfocus in Canadian undergraduate students". Psychology of Consciousness: Theory, Research, and Practice. 11 (2): 234–251. doi:10.1037/cns0000299.
Barkley RA, Murphy KR (1 June 2011). "The Nature of Executive Function (EF) Deficits in Daily Life Activities in Adults with ADHD and Their Relationship to Performance on EF Tests". Journal of Psychopathology and Behavioral Assessment. 33 (2): 137–158. doi:10.1007/s10862-011-9217-x. ISSN 1573-3505.
Ashinoff BK, Abu-Akel A (February 2021). "Hyperfocus: the forgotten frontier of attention". Psychological Research. 85 (1): 1–19. doi:10.1007/s00426-019-01245-8. PMC 7851038. PMID 31541305.
Ishii S, Takagi S, Kobayashi N, Jitoku D, Sugihara G, Takahashi H (16 March 2023). "Hyperfocus symptom and internet addiction in individuals with attention-deficit/hyperactivity disorder trait". Frontiers in Psychiatry. 14: 1127777. doi:10.3389/fpsyt.2023.1127777. PMC 10061009. PMID 37009127.
Worthington R, Wheeler S (January 2023). "Hyperfocus and offending behaviour: a systematic review" (PDF). The Journal of Forensic Practice. 25 (3): 185–200. doi:10.1108/JFP-01-2022-0005. ISSN 2050-8794. S2CID 258330884.
Larsson H, Anckarsater H, Råstam M, Chang Z, Lichtenstein P (January 2012). "Childhood attention-deficit hyperactivity disorder as an extreme of a continuous trait: a quantitative genetic study of 8,500 twin pairs". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 53 (1): 73–80. doi:10.1111/j.1469-7610.2011.02467.x. PMID 21923806.
Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM, Perlis RH, et al. (September 2013). "Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs". Nature Genetics. 45 (9): 984–994. doi:10.1038/ng.2711. PMC 3800159. PMID 23933821.
Cecil CA, Nigg JT (November 2022). "Epigenetics and ADHD: Reflections on Current Knowledge, Research Priorities and Translational Potential". Molecular Diagnosis & Therapy. 26 (6): 581–606. doi:10.1007/s40291-022-00609-y. PMC 7613776. PMID 35933504.
Nigg JT, Sibley MH, Thapar A, Karalunas SL (December 2020). "Development of ADHD: Etiology, Heterogeneity, and Early Life Course". Annual Review of Developmental Psychology. 2 (1): 559–583. doi:10.1146/annurev-devpsych-060320-093413. PMC 8336725. PMID 34368774.
Brown TE (March 2009). "ADD/ADHD and impaired executive function in clinical practice". Current Attention Disorders Reports. 1 (1): 37–41. doi:10.1007/s12618-009-0006-3. ISSN 1943-457X.
Franke B, Michelini G, Asherson P, Banaschewski T, Bilbow A, Buitelaar JK, et al. (October 2018). "Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan". European Neuropsychopharmacology. 28 (10): 1059–1088. doi:10.1016/j.euroneuro.2018.08.001. PMC 6379245. PMID 30195575.
Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-Quiroga JA, et al. (August 2015). "Attention-deficit/hyperactivity disorder" (PDF). Nature Reviews. Disease Primers. 1: 15020. doi:10.1038/nrdp.2015.20. PMID 27189265. S2CID 7171541.
Larsson H, Chang Z, D'Onofrio BM, Lichtenstein P (July 2014). "The heritability of clinically diagnosed Attention-Deficit/Hyperactivity Disorder across the life span". Psychological Medicine. 44 (10): 2223–2229. doi:10.1017/S0033291713002493. ISSN 0033-2917. PMC 4071160. PMID 24107258.
Sinopoli KJ, Schachar R, Dennis M (August 2011). "Traumatic brain injury and secondary attention-deficit/hyperactivity disorder in children and adolescents: the effect of reward on inhibitory control". Journal of Clinical and Experimental Neuropsychology. 33 (7): 805–819. doi:10.1080/13803395.2011.562864. PMC 3184364. PMID 21598155.
Eme R (April 2012). "ADHD: an integration with pediatric traumatic brain injury". Expert Review of Neurotherapeutics. 12 (4): 475–483. doi:10.1586/ern.12.15. PMID 22449218. S2CID 35718630.
Gerring JP, Brady KD, Chen A, Vasa R, Grados M, Bandeen-Roche KJ, et al. (1998). "Premorbid Prevalence of ADHD and Development of Secondary ADHD After Closed Head Injury". Journal of the American Academy of Child & Adolescent Psychiatry. 37 (6): 647–654. doi:10.1097/00004583-199806000-00015. PMID 9628085.
Faraone SV, Larsson H (April 2019). "Genetics of attention deficit hyperactivity disorder". Molecular Psychiatry. 24 (4): 562–575. doi:10.1038/s41380-018-0070-0. PMC 6477889. PMID 29892054.
Faraone SV, Biederman J (July 2016). "Can Attention-Deficit/Hyperactivity Disorder Onset Occur in Adulthood?". JAMA Psychiatry. 73 (7): 655–656. doi:10.1001/jamapsychiatry.2016.0400. PMID 27191055.
Epstein JN, Loren RE (October 2013). "Changes in the Definition of ADHD in DSM-5: Subtle but Important". Neuropsychiatry. 3 (5): 455–458. doi:10.2217/npy.13.59 (inactive 20 November 2024). PMC 3955126. PMID 24644516.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
Gershon J (January 2002). "A meta-analytic review of gender differences in ADHD". Journal of Attention Disorders. 5 (3): 143–154. doi:10.1177/108705470200500302. PMID 11911007. S2CID 8076914.
Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugué M, Carpentier PJ, et al. (September 2010). "European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD". BMC Psychiatry. 10 (67): 67. doi:10.1186/1471-244X-10-67. PMC 2942810. PMID 20815868.
Carpenter Rich E, Loo SK, Yang M, Dang J, Smalley SL (July 2009). "Social functioning difficulties in ADHD: association with PDD risk". Clinical Child Psychology and Psychiatry. 14 (3): 329–344. doi:10.1177/1359104508100890. PMC 2827258. PMID 19515751.
Bellani M, Moretti A, Perlini C, Brambilla P (December 2011). "Language disturbances in ADHD". Epidemiology and Psychiatric Sciences. 20 (4): 311–315. doi:10.1017/S2045796011000527. PMID 22201208.
Racine MB, Majnemer A, Shevell M, Snider L (April 2008). "Handwriting performance in children with attention deficit hyperactivity disorder (ADHD)". Journal of Child Neurology. 23 (4): 399–406. doi:10.1177/0883073807309244. PMID 18401033. S2CID 206546871.
Peterson RL, Pennington BF (May 2012). "Developmental dyslexia". Lancet. 379 (9830): 1997–2007. doi:10.1016/S0140-6736(12)60198-6. PMC 3465717. PMID 22513218.
Sexton CC, Gelhorn HL, Bell JA, Classi PM (November 2012). "The co-occurrence of reading disorder and ADHD: epidemiology, treatment, psychosocial impact, and economic burden". Journal of Learning Disabilities. 45 (6): 538–564. doi:10.1177/0022219411407772. PMID 21757683. S2CID 385238.
Nicolson RI, Fawcett AJ (January 2011). "Dyslexia, dysgraphia, procedural learning and the cerebellum". Cortex; A Journal Devoted to the Study of the Nervous System and Behavior. 47 (1): 117–127. doi:10.1016/j.cortex.2009.08.016. PMID 19818437. S2CID 32228208.
Walitza S, Drechsler R, Ball J (August 2012). "[The school child with ADHD]" [The school child with ADHD]. Therapeutische Umschau (in German). 69 (8): 467–473. doi:10.1024/0040-5930/a000316. PMID 22851461.
Frazier TW, Demaree HA, Youngstrom EA (July 2004). "Meta-analysis of intellectual and neuropsychological test performance in attention-deficit/hyperactivity disorder". Neuropsychology. 18 (3): 543–555. doi:10.1037/0894-4105.18.3.543. PMID 15291732. S2CID 17628705.
Mackenzie GB, Wonders E (2016). "Rethinking Intelligence Quotient Exclusion Criteria Practices in the Study of Attention Deficit Hyperactivity Disorder". Frontiers in Psychology. 7: 794. doi:10.3389/fpsyg.2016.00794. PMC 4886698. PMID 27303350.
Rommelse N, van der Kruijs M, Damhuis J, Hoek I, Smeets S, Antshel KM, et al. (December 2016). "An evidenced-based perspective on the validity of attention-deficit/hyperactivity disorder in the context of high intelligence". Neuroscience and Biobehavioral Reviews. 71: 21–47. doi:10.1016/j.neubiorev.2016.08.032. hdl:2066/163023. PMID 27590827. S2CID 6698847.
Bridgett DJ, Walker ME (March 2006). "Intellectual functioning in adults with ADHD: a meta-analytic examination of full scale IQ differences between adults with and without ADHD". Psychological Assessment. 18 (1): 1–14. doi:10.1037/1040-3590.18.1.1. PMID 16594807.
Young S, Hollingdale J, Absoud M, Bolton P, Branney P, Colley W, et al. (May 2020). "Guidance for identification and treatment of individuals with attention deficit/hyperactivity disorder and autism spectrum disorder based upon expert consensus". BMC Medicine. 18 (1). Springer Science and Business Media LLC: 146. doi:10.1186/s12916-020-01585-y. PMC 7247165. PMID 32448170.
Hofvander B, Ossowski D, Lundström S, Anckarsäter H (2009). "Continuity of aggressive antisocial behavior from childhood to adulthood: The question of phenotype definition". International Journal of Law and Psychiatry. 32 (4): 224–234. doi:10.1016/j.ijlp.2009.04.004. PMID 19428109. Archived from the original on 17 May 2022. Retrieved 22 November 2021.
Rubia K (June 2011). ""Cool" inferior frontostriatal dysfunction in attention-deficit/hyperactivity disorder versus "hot" ventromedial orbitofrontal-limbic dysfunction in conduct disorder: a review". Biological Psychiatry. 69 (12). Elsevier BV/The Society of Biological Psychiatry: e69–e87. doi:10.1016/j.biopsych.2010.09.023. PMID 21094938. S2CID 14987165.
Wilens TE, Spencer TJ (September 2010). "Understanding attention-deficit/hyperactivity disorder from childhood to adulthood". Postgraduate Medicine. 122 (5): 97–109. doi:10.3810/pgm.2010.09.2206. PMC 3724232. PMID 20861593.
Baud P, Perroud N, Aubry JM (June 2011). "[Bipolar disorder and attention deficit/hyperactivity disorder in adults: differential diagnosis or comorbidity]". Revue Médicale Suisse (in French). 7 (297): 1219–1222. doi:10.53738/REVMED.2011.7.297.1219. PMID 21717696.
Wilens TE, Morrison NR (July 2011). "The intersection of attention-deficit/hyperactivity disorder and substance abuse". Current Opinion in Psychiatry. 24 (4): 280–285. doi:10.1097/YCO.0b013e328345c956. PMC 3435098. PMID 21483267.
Corkum P, Davidson F, Macpherson M (June 2011). "A framework for the assessment and treatment of sleep problems in children with attention-deficit/hyperactivity disorder". Pediatric Clinics of North America. 58 (3): 667–683. doi:10.1016/j.pcl.2011.03.004. PMID 21600348.
Tsai MH, Huang YS (May 2010). "Attention-deficit/hyperactivity disorder and sleep disorders in children". The Medical Clinics of North America. 94 (3): 615–632. doi:10.1016/j.mcna.2010.03.008. PMID 20451036.
Bendz LM, Scates AC (January 2010). "Melatonin treatment for insomnia in pediatric patients with attention-deficit/hyperactivity disorder". The Annals of Pharmacotherapy. 44 (1): 185–191. doi:10.1345/aph.1M365. PMID 20028959. S2CID 207263711.
Merino-Andreu M (March 2011). "[Attention deficit hyperactivity disorder and restless legs syndrome in children]" [Attention deficit hyperactivity disorder and restless legs syndrome in children]. Revista de Neurologia (in Spanish). 52 (Suppl 1): S85–S95. doi:10.33588/rn.52S01.2011037. PMID 21365608.
Picchietti MA, Picchietti DL (August 2010). "Advances in pediatric restless legs syndrome: Iron, genetics, diagnosis and treatment". Sleep Medicine. 11 (7): 643–651. doi:10.1016/j.sleep.2009.11.014. PMID 20620105.
Karroum E, Konofal E, Arnulf I (2008). "[Restless-legs syndrome]". Revue Neurologique (in French). 164 (8–9): 701–721. doi:10.1016/j.neurol.2008.06.006. PMID 18656214.
Wajszilber D, Santiseban JA, Gruber R (December 2018). "Sleep disorders in patients with ADHD: impact and management challenges". Nature and Science of Sleep. 10: 453–480. doi:10.2147/NSS.S163074. PMC 6299464. PMID 30588139.
Long Y, Pan N, Ji S, Qin K, Chen Y, Zhang X, et al. (September 2022). "Distinct brain structural abnormalities in attention-deficit/hyperactivity disorder and substance use disorders: A comparative meta-analysis". Translational Psychiatry. 12 (1): 368. doi:10.1038/s41398-022-02130-6. PMC 9448791. PMID 36068207.
Storebø OJ, Rasmussen PD, Simonsen E (February 2016). "Association Between Insecure Attachment and ADHD: Environmental Mediating Factors" (PDF). Journal of Attention Disorders. 20 (2): 187–196. doi:10.1177/1087054713501079. PMID 24062279. S2CID 23564305. Archived (PDF) from the original on 9 December 2021. Retrieved 22 November 2021.
Becker SP, Willcutt EG, Leopold DR, Fredrick JW, Smith ZR, Jacobson LA, et al. (June 2023). "Report of a Work Group on Sluggish Cognitive Tempo: Key Research Directions and a Consensus Change in Terminology to Cognitive Disengagement Syndrome". Journal of the American Academy of Child and Adolescent Psychiatry. 62 (6): 629–645. doi:10.1016/j.jaac.2022.07.821. PMC 9943858. PMID 36007816.
Barkley RA (January 2014). "Sluggish cognitive tempo (concentration deficit disorder?): current status, future directions, and a plea to change the name" (PDF). Journal of Abnormal Child Psychology. 42 (1): 117–125. doi:10.1007/s10802-013-9824-y. PMID 24234590. S2CID 8287560. Archived (PDF) from the original on 9 August 2017.
Nazar BP, Bernardes C, Peachey G, Sergeant J, Mattos P, Treasure J (December 2016). "The risk of eating disorders comorbid with attention-deficit/hyperactivity disorder: A systematic review and meta-analysis". The International Journal of Eating Disorders. 49 (12): 1045–1057. doi:10.1002/eat.22643. PMID 27859581. S2CID 38002526. Archived from the original on 8 December 2022. Retrieved 26 October 2022.
Schneider M, VanOrmer J, Zlomke K (2019). "Adverse Childhood Experiences and Family Resilience Among Children with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder". Journal of Developmental and Behavioral Pediatrics. 40 (8): 573–580. doi:10.1097/DBP.0000000000000703. PMID 31335581. S2CID 198193637.
Moon DS, Bong SJ, Kim BN, Kang NR (January 2021). "Association between Maternal Adverse Childhood Experiences and Attention-Deficit/Hyperactivity Disorder in the Offspring: The Mediating Role of Antepartum Health Risks". Soa--Ch'ongsonyon Chongsin Uihak = Journal of Child & Adolescent Psychiatry. 32 (1): 28–34. doi:10.5765/jkacap.200041. PMC 7788667. PMID 33424239.
Ford JD, Connor DF (1 June 2009). "ADHD and post-traumatic stress disorder". Current Attention Disorders Reports. 1 (2): 60–66. doi:10.1007/s12618-009-0009-0. ISSN 1943-457X. S2CID 145508751.
Harrington KM, Miller MW, Wolf EJ, Reardon AF, Ryabchenko KA, Ofrat S (August 2012). "Attention-deficit/hyperactivity disorder comorbidity in a sample of veterans with posttraumatic stress disorder". Comprehensive Psychiatry. 53 (6): 679–690. doi:10.1016/j.comppsych.2011.12.001. PMC 6519447. PMID 22305866.
Szymanski K, Sapanski L, Conway F (1 January 2011). "Trauma and ADHD – Association or Diagnostic Confusion? A Clinical Perspective". Journal of Infant, Child, and Adolescent Psychotherapy. 10 (1). Philadelphia PA: Taylor & Francis Group: 51–59. doi:10.1080/15289168.2011.575704. eISSN 1940-9214. ISSN 1528-9168. S2CID 144348893.
Zhang N, Gao M, Yu J, Zhang Q, Wang W, Zhou C, et al. (October 2022). "Understanding the association between adverse childhood experiences and subsequent attention deficit hyperactivity disorder: A systematic review and meta-analysis of observational studies". Brain and Behavior. 12 (10): e32748. doi:10.1002/brb3.2748. PMC 9575611. PMID 36068993.
Nguyen MN, Watanabe-Galloway S, Hill JL, Siahpush M, Tibbits MK, Wichman C (June 2019). "Ecological model of school engagement and attention-deficit/hyperactivity disorder in school-aged children". European Child & Adolescent Psychiatry. 28 (6): 795–805. doi:10.1007/s00787-018-1248-3. PMID 30390147. S2CID 53263217.
Miodus S, Allwood MA, Amoh N (5 January 2021). "Childhood ADHD Symptoms in Relation to Trauma Exposure and PTSD Symptoms Among College Students: Attending to and Accommodating Trauma". Journal of Emotional and Behavioral Disorders. 29 (3): 187–196. doi:10.1177/1063426620982624. ISSN 1063-4266. S2CID 234159064.
Williams AE, Giust JM, Kronenberger WG, Dunn DW (2016). "Epilepsy and attention-deficit hyperactivity disorder: links, risks, and challenges". Neuropsychiatric Disease and Treatment. 12: 287–296. doi:10.2147/NDT.S81549. PMC 4755462. PMID 26929624.
Silva RR, Munoz DM, Alpert M (March 1996). "Carbamazepine use in children and adolescents with features of attention-deficit hyperactivity disorder: a meta-analysis". Journal of the American Academy of Child and Adolescent Psychiatry. 35 (3): 352–358. doi:10.1097/00004583-199603000-00017. PMID 8714324.
Instanes JT, Klungsøyr K, Halmøy A, Fasmer OB, Haavik J (February 2018). "Adult ADHD and Comorbid Somatic Disease: A Systematic Literature Review". Journal of Attention Disorders (Systematic Review). 22 (3): 203–228. doi:10.1177/1087054716669589. PMC 5987989. PMID 27664125.
Gaur S (May 2022). "The Association between ADHD and Celiac Disease in Children". Children. 9 (6). MDPI: 781. doi:10.3390/children9060781. PMC 9221618. PMID 35740718.
Hsu TW, Chen MH, Chu CS, Tsai SJ, Bai YM, Su TP, et al. (May 2022). "Attention deficit hyperactivity disorder and risk of migraine: A nationwide longitudinal study". Headache. 62 (5): 634–641. doi:10.1111/head.14306. PMID 35524451. S2CID 248553863.
Salem H, Vivas D, Cao F, Kazimi IF, Teixeira AL, Zeni CP (March 2018). "ADHD is associated with migraine: a systematic review and meta-analysis". European Child & Adolescent Psychiatry. 27 (3). Springer Science and Business Media LLC: 267–277. doi:10.1007/s00787-017-1045-4. PMID 28905127. S2CID 3949012.
Pan PY, Jonsson U, Şahpazoğlu Çakmak SS, Häge A, Hohmann S, Nobel Norrman H, et al. (January 2022). "Headache in ADHD as comorbidity and a side effect of medications: a systematic review and meta-analysis". Psychological Medicine. 52 (1). Cambridge University Press: 14–25. doi:10.1017/s0033291721004141. PMC 8711104. PMID 34635194.
Cannon Homaei S, Barone H, Kleppe R, Betari N, Reif A, Haavik J (January 2022). "ADHD symptoms in neurometabolic diseases: Underlying mechanisms and clinical implications". Neuroscience and Biobehavioral Reviews. 132: 838–856. doi:10.1016/j.neubiorev.2021.11.012. PMID 34774900. S2CID 243983688.
Brunkhorst-Kanaan N, Libutzki B, Reif A, Larsson H, McNeill RV, Kittel-Schneider S (June 2021). "ADHD and accidents over the life span - A systematic review". Neuroscience and Biobehavioral Reviews. 125. Elsevier: 582–591. doi:10.1016/j.neubiorev.2021.02.002. PMID 33582234. S2CID 231885131.
Vaa T (January 2014). "ADHD and relative risk of accidents in road traffic: a meta-analysis". Accident Analysis and Prevention. 62. Elsevier: 415–425. doi:10.1016/j.aap.2013.10.003. hdl:11250/2603537. PMID 24238842.
González-Bueso V, Santamaría JJ, Fernández D, Merino L, Montero E, Ribas J (2018). "Association between Internet Gaming Disorder or Pathological Video-Game Use and Comorbid Psychopathology: A Comprehensive Review". International Journal of Environmental Research and Public Health. 15 (4). MDPI: 668. doi:10.3390/ijerph15040668. PMC 5923710. PMID 29614059.
Beyens I, Valkenburg PM, Piotrowski JT (2 October 2018). "Screen media use and ADHD-related behaviors: Four decades of research". PNAS USA. 115 (40). National Academy of Sciences: 9875–9881. Bibcode:2018PNAS..115.9875B. doi:10.1073/pnas.1611611114. PMC 6176582. PMID 30275318.
de Francisco Carvalho L, Sette CP, Ferrari BL (2018). "Problematic smartphone use relationship with pathological personality traits: Systematic review and meta-analysis". Cyberpsychology: Journal of Psychosocial Research on Cyberspace. 12 (3). Masaryk University: 5. doi:10.5817/CP2018-3-5.
Li Y, Li G, Liu L, Wu H (2020). "Correlations between mobile phone addiction and anxiety, depression, impulsivity, and poor sleep quality among college students: A systematic review and meta-analysis". Journal of Behavioral Addictions. 9 (3). Akadémiai Kiadó: 551–571. doi:10.1556/2006.2020.00057. PMC 8943681. PMID 32903205.
Dullur P, Krishnan V, Diaz AM (2021). "A systematic review on the intersection of attention-deficit hyperactivity disorder and gaming disorder". Journal of Psychiatric Research. 133. Elsevier: 212–222. doi:10.1016/j.jpsychires.2020.12.026. PMID 33360866. S2CID 229687229.
Gao X, Zhang M, Yang Z, Wen M, Huang H, Zheng R, et al. (2021). "Structural and Functional Brain Abnormalities in Internet Gaming Disorder and Attention-Deficit/Hyperactivity Disorder: A Comparative Meta-Analysis". Frontiers in Psychiatry. 12. Frontiers Media: 679437. doi:10.3389/fpsyt.2021.679437. PMC 8281314. PMID 34276447.
Eirich R, McArthur BA, Anhorn C, McGuinness C, Christakis DA, Madigan S (2022). "Association of Screen Time With Internalizing and Externalizing Behavior Problems in Children 12 Years or Younger: A Systematic Review and Meta-analysis". JAMA Psychiatry. 79 (5). American Medical Association: 393–405. doi:10.1001/jamapsychiatry.2022.0155. PMC 8928099. PMID 35293954.
Santos RM, Mendes CG, Miranda DM, Romano-Silva MA (2022). "The Association between Screen Time and Attention in Children: A Systematic Review". Developmental Neuropsychology. 47 (4). Routledge: 175–192. doi:10.1080/87565641.2022.2064863. PMID 35430923. S2CID 248228233.
Werling AM, Kuzhippallil S, Emery S, Walitza S, Drechsler R (2022). "Problematic use of digital media in children and adolescents with a diagnosis of attention-deficit/hyperactivity disorder compared to controls. A meta-analysis". Journal of Behavioral Addictions. 11 (2). Akadémiai Kiadó: 305–325. doi:10.1556/2006.2022.00007. PMC 9295226. PMID 35567763.
Thorell LB, Burén J, Wiman JS, Sandberg D, Nutley SB (2022). "Longitudinal associations between digital media use and ADHD symptoms in children and adolescents: a systematic literature review". European Child & Adolescent Psychiatry. 33 (8). Springer Science+Business Media: 2503–2526. doi:10.1007/s00787-022-02130-3. PMC 11272698. PMID 36562860.
Liu H, Chen X, Huang M, Yu X, Gan Y, Wang J, et al. (2023). "Screen time and childhood attention deficit hyperactivity disorder: a meta-analysis". Reviews on Environmental Health. De Gruyter. doi:10.1515/reveh-2022-0262. PMID 37163581. S2CID 258591184.
Augner C, Vlasak T, Barth A (2023). "The relationship between problematic internet use and attention deficit, hyperactivity and impulsivity: A meta-analysis". Journal of Psychiatric Research. 168. Elsevier: 1–12. doi:10.1016/j.jpsychires.2023.10.032. PMID 37866293. S2CID 264190691.
Koncz P, Demetrovics Z, Takacs ZK, Griffiths MD, Nagy T, Király O (2023). "The emerging evidence on the association between symptoms of ADHD and gaming disorder: A systematic review and meta-analysis". Clinical Psychology Review. 106. Elsevier: 102343. doi:10.1016/j.cpr.2023.102343. hdl:20.500.11820/91f22260-b579-4f0b-9e81-adc063f27e9e. PMID 37883910.
Balazs J, Kereszteny A (March 2017). "Attention-deficit/hyperactivity disorder and suicide: A systematic review". World Journal of Psychiatry. 7 (1): 44–59. doi:10.5498/wjp.v7.i1.44. PMC 5371172. PMID 28401048.
Garas P, Balazs J (21 December 2020). "Long-Term Suicide Risk of Children and Adolescents With Attention Deficit and Hyperactivity Disorder-A Systematic Review". Frontiers in Psychiatry. 11: 557909. doi:10.3389/fpsyt.2020.557909. PMC 7779592. PMID 33408650. 557909.
Septier M, Stordeur C, Zhang J, Delorme R, Cortese S (August 2019). "Association between suicidal spectrum behaviors and Attention-Deficit/Hyperactivity Disorder: A systematic review and meta-analysis". Neuroscience and Biobehavioral Reviews. 103: 109–118. doi:10.1016/j.neubiorev.2019.05.022. PMID 31129238. S2CID 162184004. Archived from the original on 4 November 2021. Retrieved 7 December 2021.
Beauchaine TP, Ben-David I, Bos M (September 2020). "ADHD, financial distress, and suicide in adulthood: A population study". Science Advances. 6 (40): eaba1551. Bibcode:2020SciA....6.1551B. doi:10.1126/sciadv.aba1551. PMC 7527218. PMID 32998893. eaba1551.
Biederman J (June 2005). "Attention-deficit/hyperactivity disorder: a selective overview". Biological Psychiatry. 57 (11): 1215–1220. doi:10.1016/j.biopsych.2004.10.020. PMID 15949990. S2CID 23671547.
Faraone SV, Larsson H (April 2019). "Genetics of attention deficit hyperactivity disorder". Molecular Psychiatry. 24 (4): 562–575. doi:10.1038/s41380-018-0070-0. PMC 6477889. PMID 29892054. S2CID 47016805.
Nikolas MA, Burt SA (February 2010). "Genetic and environmental influences on ADHD symptom dimensions of inattention and hyperactivity: a meta-analysis". Journal of Abnormal Psychology. 119 (1): 1–17. doi:10.1037/a0018010. PMID 20141238.
Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. (January 2019). "Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder". Nature Genetics. 51 (1): 63–75. doi:10.1038/s41588-018-0269-7. hdl:10023/20827. PMC 6481311. PMID 30478444.
Grimm O, Kranz TM, Reif A (February 2020). "Genetics of ADHD: What Should the Clinician Know?". Current Psychiatry Reports. 22 (4): 18. doi:10.1007/s11920-020-1141-x. PMC 7046577. PMID 32108282.
Cederlöf M, Ohlsson Gotby A, Larsson H, Serlachius E, Boman M, Långström N, et al. (January 2014). "Klinefelter syndrome and risk of psychosis, autism and ADHD". Journal of Psychiatric Research. 48 (1): 128–130. doi:10.1016/j.jpsychires.2013.10.001. PMID 24139812.
Biederman J, Spencer T (November 1999). "Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder". Biological Psychiatry. 46 (9). Elsevier: 1234–1242. doi:10.1016/S0006-3223(99)00192-4. PMID 10560028. S2CID 45497168.
Faraone SV, Larsson H (April 2019). "Genetics of attention deficit hyperactivity disorder". Molecular Psychiatry. 24 (4). Nature Research: 562–575. doi:10.1038/s41380-018-0070-0. PMC 6477889. PMID 29892054.
Baron-Cohen S (June 2002). "The extreme male brain theory of autism". Trends in Cognitive Sciences. 6 (6). Elsevier: 248–254. doi:10.1016/S1364-6613(02)01904-6. PMID 12039606. S2CID 8098723. Archived from the original on 3 July 2013. Retrieved 9 July 2020.
Esteller-Cucala P, Maceda I, Børglum AD, Demontis D, Faraone SV, Cormand B, et al. (May 2020). "Genomic analysis of the natural history of attention-deficit/hyperactivity disorder using Neanderthal and ancient Homo sapiens samples". Scientific Reports. 10 (1): 8622. Bibcode:2020NatSR..10.8622E. doi:10.1038/s41598-020-65322-4. PMC 7248073. PMID 32451437.
Keller MC (December 2008). "The evolutionary persistence of genes that increase mental disorders risk". Current Directions in Psychological Science. 17 (6): 395–399. doi:10.1111/j.1467-8721.2008.006 (inactive 1 November 2024).{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
Faraone SV, Larsson H (April 2019). "Genetics of attention deficit hyperactivity disorder". Molecular Psychiatry. 24 (4). Springer Science and Business Media LLC: 562–575. doi:10.1038/s41380-018-0070-0. PMC 6477889. PMID 29892054.
Skoglund C, Chen Q, D'Onofrio BM, Lichtenstein P, Larsson H (January 2014). "Familial confounding of the association between maternal smoking during pregnancy and ADHD in offspring". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 55 (1): 61–68. doi:10.1111/jcpp.12124. PMC 4217138. PMID 25359172.
Obel C, Zhu JL, Olsen J, Breining S, Li J, Grønborg TK, et al. (April 2016). "The risk of attention deficit hyperactivity disorder in children exposed to maternal smoking during pregnancy - a re-examination using a sibling design". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 57 (4): 532–537. doi:10.1111/jcpp.12478. PMID 26511313.
Biederman J (June 2005). "Attention-deficit/hyperactivity disorder: a selective overview". Biological Psychiatry. 57 (11): 1215–1220. doi:10.1016/j.biopsych.2004.10.020. PMID 15949990.
Hinshaw SP (May 2018). "Attention Deficit Hyperactivity Disorder (ADHD): Controversy, Developmental Mechanisms, and Multiple Levels of Analysis". Annual Review of Clinical Psychology. 14 (1): 291–316. doi:10.1146/annurev-clinpsy-050817-084917. PMID 29220204.
Kebir O, Joober R (December 2011). "Neuropsychological endophenotypes in attention-deficit/hyperactivity disorder: a review of genetic association studies". European Archives of Psychiatry and Clinical Neuroscience. 261 (8): 583–594. doi:10.1007/s00406-011-0207-5. PMID 21409419. S2CID 21383749.
Berry MD (January 2007). "The potential of trace amines and their receptors for treating neurological and psychiatric diseases". Reviews on Recent Clinical Trials. 2 (1): 3–19. CiteSeerX 10.1.1.329.563. doi:10.2174/157488707779318107. PMID 18473983. Although there is little direct evidence, changes in trace amines, in particular PE, have been identified as a possible factor for the onset of attention deficit/hyperactivity disorder (ADHD). ... Further, amphetamines, which have clinical utility in ADHD, are good ligands at trace amine receptors. Of possible relevance in this aspect is modafanil, which has shown beneficial effects in ADHD patients and has been reported to enhance the activity of PE at TAAR1. Conversely, methylphenidate, ...showed poor efficacy at the TAAR1 receptor. In this respect it is worth noting that the enhancement of functioning at TAAR1 seen with modafanil was not a result of a direct interaction with TAAR1.
Sotnikova TD, Caron MG, Gainetdinov RR (August 2009). "Trace amine-associated receptors as emerging therapeutic targets". Molecular Pharmacology. 76 (2): 229–235. doi:10.1124/mol.109.055970. PMC 2713119. PMID 19389919.
Gizer IR, Ficks C, Waldman ID (July 2009). "Candidate gene studies of ADHD: a meta-analytic review". Human Genetics. 126 (1): 51–90. doi:10.1007/s00439-009-0694-x. PMID 19506906. S2CID 166017.
Arcos-Burgos M, Muenke M (November 2010). "Toward a better understanding of ADHD: LPHN3 gene variants and the susceptibility to develop ADHD". Attention Deficit and Hyperactivity Disorders. 2 (3): 139–147. doi:10.1007/s12402-010-0030-2. PMC 3280610. PMID 21432600.
Nikolaidis A, Gray JR (June 2010). "ADHD and the DRD4 exon III 7-repeat polymorphism: an international meta-analysis". Social Cognitive and Affective Neuroscience. 5 (2–3): 188–193. doi:10.1093/scan/nsp049. PMC 2894686. PMID 20019071.
Zayats T, Neale BM (12 February 2020). "Recent advances in understanding of attention deficit hyperactivity disorder (ADHD): how genetics are shaping our conceptualization of this disorder". F1000Research. 8: 2060. doi:10.12688/f1000research.18959.2. PMC 6896240. PMID 31824658.
Sonuga-Barke EJ, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M, et al. (March 2013). "Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments". The American Journal of Psychiatry. 170 (3): 275–289. doi:10.1176/appi.ajp.2012.12070991. eISSN 1535-7228. LCCN 22024537. OCLC 1480183. PMID 23360949. S2CID 434310. Free fatty acid supplementation and artificial food color exclusions appear to have beneficial effects on ADHD symptoms, although the effect of the former are small and those of the latter may be limited to ADHD patients with food sensitivities...
Burger PH, Goecke TW, Fasching PA, Moll G, Heinrich H, Beckmann MW, et al. (September 2011). "[How does maternal alcohol consumption during pregnancy affect the development of attention deficit/hyperactivity syndrome in the child]" [How does maternal alcohol consumption during pregnancy affect the development of attention deficit/hyperactivity syndrome in the child]. Fortschritte der Neurologie-Psychiatrie (Review) (in German). 79 (9): 500–506. doi:10.1055/s-0031-1273360. PMID 21739408. S2CID 140766296.
Eubig PA, Aguiar A, Schantz SL (December 2010). "Lead and PCBs as risk factors for attention deficit/hyperactivity disorder". Environmental Health Perspectives (Review. Research Support, N.I.H., Extramural. Research Support, U.S. Gov't, Non-P.H.S.). 118 (12): 1654–1667. doi:10.1289/ehp.0901852. PMC 3002184. PMID 20829149.
de Cock M, Maas YG, van de Bor M (August 2012). "Does perinatal exposure to endocrine disruptors induce autism spectrum and attention deficit hyperactivity disorders? Review". Acta Paediatrica (Review. Research Support, Non-U.S. Gov't). 101 (8): 811–818. doi:10.1111/j.1651-2227.2012.02693.x. PMID 22458970. S2CID 41748237.
Abbott LC, Winzer-Serhan UH (April 2012). "Smoking during pregnancy: lessons learned from epidemiological studies and experimental studies using animal models". Critical Reviews in Toxicology (Review). 42 (4): 279–303. doi:10.3109/10408444.2012.658506. PMID 22394313. S2CID 38886526.
Tiesler CM, Heinrich J (October 2014). "Prenatal nicotine exposure and child behavioural problems". European Child & Adolescent Psychiatry. 23 (10): 913–929. doi:10.1007/s00787-014-0615-y. PMC 4186967. PMID 25241028.
Botting N, Powls A, Cooke RW, Marlow N (November 1997). "Attention deficit hyperactivity disorders and other psychiatric outcomes in very low birthweight children at 12 years". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 38 (8): 931–941. doi:10.1111/j.1469-7610.1997.tb01612.x. PMID 9413793. Archived from the original on 17 May 2022. Retrieved 22 March 2022.
Thapar A, Cooper M, Jefferies R, Stergiakouli E (March 2012). "What causes attention deficit hyperactivity disorder?". Archives of Disease in Childhood (Review. Research Support, Non-U.S. Gov't). 97 (3): 260–265. doi:10.1136/archdischild-2011-300482. PMC 3927422. PMID 21903599.
Millichap JG (February 2008). "Etiologic classification of attention-deficit/hyperactivity disorder". Pediatrics (Review). 121 (2): e358–e365. doi:10.1542/peds.2007-1332. PMID 18245408. S2CID 24339363.
Eme R (April 2012). "ADHD: an integration with pediatric traumatic brain injury". Expert Review of Neurotherapeutics (Review). 12 (4): 475–483. doi:10.1586/ern.12.15. PMID 22449218. S2CID 35718630.
Millichap JG, Yee MM (February 2012). "The diet factor in attention-deficit/hyperactivity disorder". Pediatrics. 129 (2): 330–337. doi:10.1542/peds.2011-2199. PMID 22232312. S2CID 14925322. Archived from the original on 11 September 2015.
Nigg JT, Holton K (October 2014). "Restriction and elimination diets in ADHD treatment". Child and Adolescent Psychiatric Clinics of North America (Review). 23 (4): 937–953. doi:10.1016/j.chc.2014.05.010. PMC 4322780. PMID 25220094. an elimination diet produces a small aggregate effect but may have greater benefit among some children. Very few studies enable proper evaluation of the likelihood of response in children with ADHD who are not already preselected based on prior diet response.
Chandler DJ, Waterhouse BD, Gao WJ (May 2014). "New perspectives on catecholaminergic regulation of executive circuits: evidence for independent modulation of prefrontal functions by midbrain dopaminergic and noradrenergic neurons". Frontiers in Neural Circuits. 8: 53. doi:10.3389/fncir.2014.00053. PMC 4033238. PMID 24904299.
Castellanos FX, Proal E (January 2012). "Large-scale brain systems in ADHD: beyond the prefrontal-striatal model". Trends in Cognitive Sciences. 16 (1): 17–26. doi:10.1016/j.tics.2011.11.007. PMC 3272832. PMID 22169776. Recent conceptualizations of ADHD have taken seriously the distributed nature of neuronal processing. Most of the candidate networks have focused on prefrontal-striatal-cerebellar circuits, although other posterior regions are also being proposed.
Cortese S, Kelly C, Chabernaud C, Proal E, Di Martino A, Milham MP, et al. (October 2012). "Toward systems neuroscience of ADHD: a meta-analysis of 55 fMRI studies". The American Journal of Psychiatry. 169 (10): 1038–1055. doi:10.1176/appi.ajp.2012.11101521. eISSN 1535-7228. LCCN 22024537. OCLC 1480183. PMC 3879048. PMID 22983386.
Krain AL, Castellanos FX (August 2006). "Brain development and ADHD". Clinical Psychology Review. 26 (4): 433–444. doi:10.1016/j.cpr.2006.01.005. PMID 16480802.
Hoogman M, Bralten J, Hibar DP, Mennes M, Zwiers MP, Schweren LS, et al. (April 2017). "Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: a cross-sectional mega-analysis". The Lancet. Psychiatry. 4 (4): 310–319. doi:10.1016/S2215-0366(17)30049-4. PMC 5933934. PMID 28219628.
Douglas PK, Gutman B, Anderson A, Larios C, Lawrence KE, Narr K, et al. (February 2018). "Hemispheric brain asymmetry differences in youths with attention-deficit/hyperactivity disorder". NeuroImage. Clinical. 18: 744–752. doi:10.1016/j.nicl.2018.02.020. PMC 5988460. PMID 29876263.
Damiani S, Tarchi L, Scalabrini A, Marini S, Provenzani U, Rocchetti M, et al. (April 2021). "Beneath the surface: hyper-connectivity between caudate and salience regions in ADHD fMRI at rest". European Child & Adolescent Psychiatry. 30 (4): 619–631. doi:10.1007/s00787-020-01545-0. hdl:2318/1755224. PMID 32385695. S2CID 218540328.
Tarchi L, Damiani S, Fantoni T, Pisano T, Castellini G, Politi P, et al. (December 2022). "Centrality and interhemispheric coordination are related to different clinical/behavioral factors in attention deficit/hyperactivity disorder: a resting-state fMRI study". Brain Imaging and Behavior. 16 (6): 2526–2542. doi:10.1007/s11682-022-00708-8. PMC 9712307. PMID 35859076.
Mohamed SM, Börger NA, Geuze RH, van der Meere JJ (2015). "Brain lateralization and self-reported symptoms of ADHD in a population sample of adults: a dimensional approach". Frontiers in Psychology. 6: 1418. doi:10.3389/fpsyg.2015.01418. PMC 4585266. PMID 26441789.
Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U (March 2012). "Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis". The American Journal of Psychiatry. 169 (3): 264–272. doi:10.1176/appi.ajp.2011.11060940. eISSN 1535-7228. hdl:11577/2482784. LCCN 22024537. OCLC 1480183. PMID 22294258.
Bidwell LC, McClernon FJ, Kollins SH (August 2011). "Cognitive enhancers for the treatment of ADHD". Pharmacology, Biochemistry, and Behavior. 99 (2): 262–274. doi:10.1016/j.pbb.2011.05.002. PMC 3353150. PMID 21596055.
Cortese S (September 2012). "The neurobiology and genetics of Attention-Deficit/Hyperactivity Disorder (ADHD): what every clinician should know". European Journal of Paediatric Neurology. 16 (5): 422–433. doi:10.1016/j.ejpn.2012.01.009. PMID 22306277.
Lesch KP, Merker S, Reif A, Novak M (June 2013). "Dances with black widow spiders: dysregulation of glutamate signalling enters centre stage in ADHD". European Neuropsychopharmacology. 23 (6): 479–491. doi:10.1016/j.euroneuro.2012.07.013. PMID 22939004. S2CID 14701654.
Skodzik T, Holling H, Pedersen A (February 2017). "Long-Term Memory Performance in Adult ADHD". Journal of Attention Disorders. 21 (4): 267–283. doi:10.1177/1087054713510561. PMID 24232170. S2CID 27070077.
Modesto-Lowe V, Chaplin M, Soovajian V, Meyer A (July 2013). "Are motivation deficits underestimated in patients with ADHD? A review of the literature". Postgraduate Medicine. 125 (4): 47–52. doi:10.3810/pgm.2013.07.2677. PMID 23933893. S2CID 24817804. Behavioral studies show altered processing of reinforcement and incentives in children with ADHD. These children respond more impulsively to rewards and choose small, immediate rewards over larger, delayed incentives. Interestingly, a high intensity of reinforcement is effective in improving task performance in children with ADHD. Pharmacotherapy may also improve task persistence in these children. ... Previous studies suggest that a clinical approach using interventions to improve motivational processes in patients with ADHD may improve outcomes as children with ADHD transition into adolescence and adulthood.
B. Langguth, R. Bär, N. Wodarz, M. Wittmann, R. Laufkötter: Paradoxical reaction in ADHD. In: Deutsches Ärzteblatt international. Band 108, Nummer 31–32, August 2011, S. 541; author reply 541–541; author reply 542, (in German).doi:10.3238/arztebl.2011.0541a, PMID 21886668, PMC 3163785.
Rainer Laufkötter, Berthold Langguth, Monika Johann, Peter Eichhammer, Göran Hajak: ADHS des Erwachsenenalters und Komorbiditäten. In: psychoneuro. 31, 2005, S. 563, (in German).doi:10.1055/s-2005-923370.
Peterson BS, Trampush J, Brown M, Maglione M, Bolshakova M, Rozelle M, et al. (April 2024). "Tools for the Diagnosis of ADHD in Children and Adolescents: A Systematic Review". Pediatrics. 153 (4). doi:10.1542/peds.2024-065854. PMID 38523599.
Peterson BS, Trampush J, Maglione M, Bolshakova M, Brown M, Rozelle M, et al. (2024). "ADHD Diagnosis and Treatment in Children and Adolescents". effectivehealthcare.ahrq.gov. doi:10.23970/ahrqepccer267. PMID 38657097. Retrieved 22 June 2024.
Al Rahbi HA, Al-Sabri RM, Chitme HR (April 2014). "Interventions by pharmacists in out-patient pharmaceutical care". Saudi Pharmaceutical Journal. 22 (2): 101–106. doi:10.1016/j.jsps.2013.04.001. PMC 3950532. PMID 24648820.
Adamou M, Fullen T, Jones SL (25 August 2020). "EEG for Diagnosis of Adult ADHD: A Systematic Review With Narrative Analysis". Frontiers in Psychiatry. 11: 871. doi:10.3389/fpsyt.2020.00871. PMC 7477352. PMID 33192633.
Lenartowicz A, Loo SK (November 2014). "Use of EEG to diagnose ADHD". Current Psychiatry Reports. 16 (11): 498. doi:10.1007/s11920-014-0498-0. PMC 4633088. PMID 25234074.
Singh I (December 2008). "Beyond polemics: science and ethics of ADHD". Nature Reviews. Neuroscience. 9 (12): 957–964. doi:10.1038/nrn2514. PMID 19020513. S2CID 205504587.
Steinau S (2013). "Diagnostic Criteria in Attention Deficit Hyperactivity Disorder - Changes in DSM 5". Frontiers in Psychiatry. 4: 49. doi:10.3389/fpsyt.2013.00049. PMC 3667245. PMID 23755024.
Parens E, Johnston J (January 2009). "Facts, values, and attention-deficit hyperactivity disorder (ADHD): an update on the controversies". Child and Adolescent Psychiatry and Mental Health. 3 (1): 1. doi:10.1186/1753-2000-3-1. PMC 2637252. PMID 19152690.
Song P, Zha M, Yang Q, Zhang Y, Li X, Rudan I (February 2021). "The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis". Journal of Global Health. 11. International Global Health Society: 04009. doi:10.7189/jogh.11.04009. eISSN 2047-2986. OCLC 751737736. PMC 7916320. PMID 33692893.
Culpepper L, Mattingly G (2010). "Challenges in identifying and managing attention-deficit/hyperactivity disorder in adults in the primary care setting: a review of the literature". Primary Care Companion to the Journal of Clinical Psychiatry. 12 (6): PCC.10r00951. doi:10.4088/PCC.10r00951pur. PMC 3067998. PMID 21494335.
Mohr-Jensen C, Steinhausen HC (August 2016). "A meta-analysis and systematic review of the risks associated with childhood attention-deficit hyperactivity disorder on long-term outcome of arrests, convictions, and incarcerations". Clinical Psychology Review. 48: 32–42. doi:10.1016/j.cpr.2016.05.002. PMID 27390061.
Asherson P, Agnew-Blais J (April 2019). "Annual Research Review: Does late-onset attention-deficit/hyperactivity disorder exist?". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 60 (4): 333–352. doi:10.1111/jcpp.13020. PMID 30843223.
Owens JA (October 2008). "Sleep disorders and attention-deficit/hyperactivity disorder". Current Psychiatry Reports. 10 (5): 439–444. doi:10.1007/s11920-008-0070-x. PMID 18803919. S2CID 23624443.
Walters AS, Silvestri R, Zucconi M, Chandrashekariah R, Konofal E (December 2008). "Review of the possible relationship and hypothetical links between attention deficit hyperactivity disorder (ADHD) and the simple sleep related movement disorders, parasomnias, hypersomnias, and circadian rhythm disorders". Journal of Clinical Sleep Medicine. 4 (6): 591–600. doi:10.5664/jcsm.27356. PMC 2603539. PMID 19110891.
Lal C, Strange C, Bachman D (June 2012). "Neurocognitive impairment in obstructive sleep apnea". Chest. 141 (6): 1601–1610. doi:10.1378/chest.11-2214. PMID 22670023.
Peterson BS, Trampush J, Maglione M, Bolshakova M, Rozelle M, Miles J, et al. (April 2024). "Treatments for ADHD in Children and Adolescents: A Systematic Review". Pediatrics. 153 (4). doi:10.1542/peds.2024-065787. PMID 38523592.
Wigal SB (2009). "Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults". CNS Drugs. 23 (Suppl 1): 21–31. doi:10.2165/00023210-200923000-00004. PMID 19621975. S2CID 11340058.
Mayes R, Bagwell C, Erkulwater J (2008). "ADHD and the rise in stimulant use among children". Harvard Review of Psychiatry. 16 (3): 151–166. doi:10.1080/10673220802167782. PMID 18569037. S2CID 18481191.
Coghill DR, Banaschewski T, Soutullo C, Cottingham MG, Zuddas A (November 2017). "Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder". European Child & Adolescent Psychiatry. 26 (11): 1283–1307. doi:10.1007/s00787-017-0986-y. PMC 5656703. PMID 28429134. Text was copied from this source, which is available under a Creative Commons Attribution 4.0 International License "CC BY 4.0 Deed | Attribution 4.0 International | Creative Commons". Archived from the original on 16 October 2017. Retrieved 22 October 2022.{{cite web}}: CS1 maint: bot: original URL status unknown (link).
Luan R, Mu Z, Yue F, He S (2017). "Efficacy and Tolerability of Different Interventions in Children and Adolescents with Attention Deficit Hyperactivity Disorder". Frontiers in Psychiatry. 8: 229. doi:10.3389/fpsyt.2017.00229. PMC 5694170. PMID 29180967.
Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. (September 2018). "Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis". The Lancet. Psychiatry. 5 (9): 727–738. doi:10.1016/S2215-0366(18)30269-4. PMC 6109107. PMID 30097390.
Fabiano GA, Pelham WE, Coles EK, Gnagy EM, Chronis-Tuscano A, O'Connor BC (March 2009). "A meta-analysis of behavioral treatments for attention-deficit/hyperactivity disorder". Clinical Psychology Review. 29 (2): 129–140. doi:10.1016/j.cpr.2008.11.001. PMID 19131150. there is strong and consistent evidence that behavioral treatments are effective for treating ADHD.
Kratochvil CJ, Vaughan BS, Barker A, Corr L, Wheeler A, Madaan V (March 2009). "Review of pediatric attention deficit/hyperactivity disorder for the general psychiatrist". The Psychiatric Clinics of North America. 32 (1): 39–56. doi:10.1016/j.psc.2008.10.001. PMID 19248915.
Lopez PL, Torrente FM, Ciapponi A, Lischinsky AG, Cetkovich-Bakmas M, Rojas JI, et al. (March 2018). "Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults". The Cochrane Database of Systematic Reviews. 2018 (3): CD010840. doi:10.1002/14651858.CD010840.pub2. PMC 6494390. PMID 29566425.
Evans SW, Owens JS, Bunford N (2014). "Evidence-based psychosocial treatments for children and adolescents with attention-deficit/hyperactivity disorder". Journal of Clinical Child and Adolescent Psychology. 43 (4): 527–551. doi:10.1080/15374416.2013.850700. PMC 4025987. PMID 24245813.
Van Doren J, Arns M, Heinrich H, Vollebregt MA, Strehl U, K Loo S (March 2019). "Sustained effects of neurofeedback in ADHD: a systematic review and meta-analysis". European Child & Adolescent Psychiatry. 28 (3). Springer Science and Business Media LLC: 293–305. doi:10.1007/s00787-018-1121-4. PMC 6404655. PMID 29445867.
Enriquez-Geppert S, Smit D, Pimenta MG, Arns M (May 2019). "Neurofeedback as a Treatment Intervention in ADHD: Current Evidence and Practice". Current Psychiatry Reports. 21 (6). Springer Science and Business Media LLC: 46. doi:10.1007/s11920-019-1021-4. PMC 6538574. PMID 31139966.
Daley D, Van Der Oord S, Ferrin M, Cortese S, Danckaerts M, Doepfner M, et al. (September 2018). "Practitioner Review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 59 (9). Wiley: 932–947. doi:10.1111/jcpp.12825. hdl:11343/293788. PMID 29083042. S2CID 31044370. Archived from the original on 25 September 2017. Retrieved 21 November 2018.
Bjornstad G, Montgomery P (April 2005). Bjornstad GJ (ed.). "Family therapy for attention-deficit disorder or attention-deficit/hyperactivity disorder in children and adolescents". The Cochrane Database of Systematic Reviews (2): CD005042. doi:10.1002/14651858.CD005042.pub2. PMID 15846741. S2CID 27339381.
Mikami AY (June 2010). "The importance of friendship for youth with attention-deficit/hyperactivity disorder". Clinical Child and Family Psychology Review. 13 (2): 181–198. doi:10.1007/s10567-010-0067-y. PMC 2921569. PMID 20490677.
Kollins SH, DeLoss DJ, Cañadas E, Lutz J, Findling RL, Keefe RS, et al. (April 2020). "A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial". The Lancet. Digital Health. 2 (4): e168–e178. doi:10.1016/S2589-7500(20)30017-0. PMID 33334505.
Kollins SH, Childress A, Heusser AC, Lutz J (March 2021). "Effectiveness of a digital therapeutic as adjunct to treatment with medication in pediatric ADHD". npj Digital Medicine. 4 (1): 58. doi:10.1038/s41746-021-00429-0. PMC 7997870. PMID 33772095.
Stamatis CA, Mercaldi C, Kollins SH (October 2023). "A Single-Arm Pivotal Trial to Assess the Efficacy of Akl-T01, a Novel Digital Intervention for Attention, in Adults Diagnosed With ADHD". Journal of the American Academy of Child & Adolescent Psychiatry. 62 (10): S318. doi:10.1016/j.jaac.2023.09.510. Retrieved 22 April 2024.
Devilbiss DM, Berridge CW (October 2008). "Cognition-enhancing doses of methylphenidate preferentially increase prefrontal cortex neuronal responsiveness". Biological Psychiatry. 64 (7): 626–635. doi:10.1016/j.biopsych.2008.04.037. PMC 2603602. PMID 18585681.
Schulz KP, Fan J, Bédard AC, Clerkin SM, Ivanov I, Tang CY, et al. (September 2012). "Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder". Archives of General Psychiatry. 69 (9): 952–961. doi:10.1001/archgenpsychiatry.2011.2053. PMID 22945622.
Koda K, Ago Y, Cong Y, Kita Y, Takuma K, Matsuda T (July 2010). "Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice". Journal of Neurochemistry. 114 (1): 259–270. doi:10.1111/j.1471-4159.2010.06750.x. PMID 20403082.
Dodson WW (May 2005). "Pharmacotherapy of adult ADHD". Journal of Clinical Psychology. 61 (5): 589–606. doi:10.1002/jclp.20122. PMID 15723384. For example, pseudoephedrine and ephedrine ... have no detectable effects on the symptoms of ADHD.
Storebø OJ, Storm MR, Pereira Ribeiro J, Skoog M, Groth C, Callesen HE, et al. (March 2023). "Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)". The Cochrane Database of Systematic Reviews. 2023 (3): CD009885. doi:10.1002/14651858.CD009885.pub3. PMC 10042435. PMID 36971690.
Ruiz-Goikoetxea M, Cortese S, Aznarez-Sanado M, Magallón S, Alvarez Zallo N, Luis EO, et al. (January 2018). "Risk of unintentional injuries in children and adolescents with ADHD and the impact of ADHD medications: A systematic review and meta-analysis". Neuroscience and Biobehavioral Reviews. 84: 63–71. doi:10.1016/j.neubiorev.2017.11.007. hdl:10171/45012. PMID 29162520.
Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K (February 2013). "Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects". JAMA Psychiatry. 70 (2): 185–198. doi:10.1001/jamapsychiatry.2013.277. PMID 23247506.
Spencer TJ, Brown A, Seidman LJ, Valera EM, Makris N, Lomedico A, et al. (September 2013). "Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies". The Journal of Clinical Psychiatry. 74 (9): 902–917. doi:10.4088/JCP.12r08287. PMC 3801446. PMID 24107764.
Frodl T, Skokauskas N (February 2012). "Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects". Acta Psychiatrica Scandinavica. 125 (2): 114–126. doi:10.1111/j.1600-0447.2011.01786.x. PMID 22118249. S2CID 25954331. Basal ganglia regions like the right globus pallidus, the right putamen, and the nucleus caudatus are structurally affected in children with ADHD. These changes and alterations in limbic regions like ACC and amygdala are more pronounced in non-treated populations and seem to diminish over time from child to adulthood. Treatment seems to have positive effects on brain structure.
Stuhec M, Lukić P, Locatelli I (February 2019). "Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis". The Annals of Pharmacotherapy. 53 (2): 121–133. doi:10.1177/1060028018795703. PMID 30117329. S2CID 52019992.
Faraone SV, Biederman J, Roe C (October 2002). "Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis". Journal of Clinical Psychopharmacology. 22 (5): 468–473. doi:10.1097/00004714-200210000-00005. PMID 12352269. S2CID 19726926.
Nam SH, Lim MH, Park TW (April 2022). "Stimulant Induced Movement Disorders in Attention Deficit Hyperactivity Disorder". Soa--Ch'ongsonyon Chongsin Uihak = Journal of Child & Adolescent Psychiatry. 33 (2): 27–34. doi:10.5765/jkacap.210034. PMC 8984208. PMID 35418800.
Storebø OJ, Krogh HB, Ramstad E, Moreira-Maia CR, Holmskov M, Skoog M, et al. (November 2015). "Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials". BMJ. 351: h5203. doi:10.1136/bmj.h5203. PMC 4659414. PMID 26608309.
Banaschewski T, Buitelaar J, Chui CS, Coghill D, Cortese S, Simonoff E, et al. (November 2016). "Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater". Evidence-Based Mental Health. 19 (4): 97–99. doi:10.1136/eb-2016-102461. PMC 10699535. PMID 27935807.
Hoekstra PJ, Buitelaar JK (April 2016). "Is the evidence base of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder flawed?". European Child & Adolescent Psychiatry. 25 (4): 339–340. doi:10.1007/s00787-016-0845-2. PMID 27021055.
Banaschewski T, Gerlach M, Becker K, Holtmann M, Döpfner M, Romanos M (July 2016). "Trust, but verify. The errors and misinterpretations in the Cochrane analysis by O. J. Storebo and colleagues on the efficacy and safety of methylphenidate for the treatment of children and adolescents with ADHD". Zeitschrift Fur Kinder- und Jugendpsychiatrie und Psychotherapie. 44 (4): 307–314. doi:10.1024/1422-4917/a000433. PMID 27270192.
Romanos M, Reif A, Banaschewski T (September 2016). "Methylphenidate for Attention-Deficit/Hyperactivity Disorder". JAMA. 316 (9): 994–995. doi:10.1001/jama.2016.10279. PMID 27599342.
Shaw P (May 2016). "Quantifying the Benefits and Risks of Methylphenidate as Treatment for Childhood Attention-Deficit/Hyperactivity Disorder". JAMA. 315 (18): 1953–1955. doi:10.1001/jama.2016.3427. PMID 27163984.
Gerlach M, Banaschewski T, Coghill D, Rohde LA, Romanos M (March 2017). "What are the benefits of methylphenidate as a treatment for children and adolescents with attention-deficit/hyperactivity disorder?". Attention Deficit and Hyperactivity Disorders. 9 (1): 1–3. doi:10.1007/s12402-017-0220-2. PMID 28168407.
Kooij JJ, Bijlenga D, Salerno L, Jaeschke R, Bitter I, Balázs J, et al. (February 2019). "Updated European Consensus Statement on diagnosis and treatment of adult ADHD". European Psychiatry. 56 (1): 14–34. doi:10.1016/j.eurpsy.2018.11.001. hdl:10651/51910. PMID 30453134.
Boesen K, Paludan-Müller AS, Gøtzsche PC, Jørgensen KJ (February 2022). "Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults". The Cochrane Database of Systematic Reviews. 2022 (2): CD012857. doi:10.1002/14651858.CD012857.pub2. PMC 8869321. PMID 35201607.
Jaeschke RR, Sujkowska E, Sowa-Kućma M (October 2021). "Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review". Psychopharmacology. 238 (10): 2667–2691. doi:10.1007/s00213-021-05946-0. PMC 8455398. PMID 34436651.
Carucci S, Balia C, Gagliano A, Lampis A, Buitelaar JK, Danckaerts M, et al. (January 2021). "Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis". Neuroscience and Biobehavioral Reviews. 120: 509–525. doi:10.1016/j.neubiorev.2020.09.031. hdl:11584/301387. PMID 33080250.
Isfandnia F, El Masri S, Radua J, Rubia K (July 2024). "The effects of chronic administration of stimulant and non-stimulant medications on executive functions in ADHD: A systematic review and meta-analysis". Neuroscience and Biobehavioral Reviews. 162 (105703): 105703. doi:10.1016/j.neubiorev.2024.105703. PMID 38718988.
Wynchank D, Bijlenga D, Beekman AT, Kooij JJ, Penninx BW (October 2017). "Adult Attention-Deficit/Hyperactivity Disorder (ADHD) and Insomnia: an Update of the Literature". Current Psychiatry Reports. 19 (12). Springer Science and Business Media LLC: 98. doi:10.1007/s11920-017-0860-0. PMID 29086065. S2CID 38064951. In varying percentages of trial participants, insomnia is a treatment-emergent adverse effect in triple-bead mixed amphetamine salts (40–45%), dasotraline (35–45%), lisdexamfetamine (10–19%), and extended-release methylphenidate (11%).
Shoptaw SJ, Kao U, Ling W (January 2009). Shoptaw SJ, Ali R (eds.). "Treatment for amphetamine psychosis". The Cochrane Database of Systematic Reviews. 2009 (1): CD003026. doi:10.1002/14651858.CD003026.pub3. PMC 7004251. PMID 19160215. A minority of individuals who use amphetamines develop full-blown psychosis requiring care at emergency departments or psychiatric hospitals. In such cases, symptoms of amphetamine psychosis commonly include paranoid and persecutory delusions as well as auditory and visual hallucinations in the presence of extreme agitation. More common (about 18%) is for frequent amphetamine users to report psychotic symptoms that are sub-clinical and that do not require high-intensity intervention ...
About 5–15% of the users who develop an amphetamine psychosis fail to recover completely (Hofmann 1983) ...
Findings from one trial indicate use of antipsychotic medications effectively resolves symptoms of acute amphetamine psychosis.
Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R (February 2009). "Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children". Pediatrics. 123 (2): 611–616. doi:10.1542/peds.2008-0185. PMID 19171629. S2CID 22391693.
Ashton H, Gallagher P, Moore B (September 2006). "The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorder". Journal of Psychopharmacology. 20 (5): 602–610. doi:10.1177/0269881106061710. PMID 16478756. S2CID 32073083.
Parker J, Wales G, Chalhoub N, Harpin V (September 2013). "The long-term outcomes of interventions for the management of attention-deficit hyperactivity disorder in children and adolescents: a systematic review of randomized controlled trials". Psychology Research and Behavior Management. 6: 87–99. doi:10.2147/PRBM.S49114. PMC 3785407. PMID 24082796. Results suggest there is moderate-to-high-level evidence that combined pharmacological and behavioral interventions, and pharmacological interventions alone can be effective in managing the core ADHD symptoms and academic performance at 14 months. However, the effect size may decrease beyond this period. ... Only one paper examining outcomes beyond 36 months met the review criteria. ... There is high level evidence suggesting that pharmacological treatment can have a major beneficial effect on the core symptoms of ADHD (hyperactivity, inattention, and impulsivity) in approximately 80% of cases compared with placebo controls, in the short term.
Castells X, Blanco-Silvente L, Cunill R, et al. (Cochrane Developmental, Psychosocial and Learning Problems Group) (August 2018). "Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults". The Cochrane Database of Systematic Reviews. 2018 (8): CD007813. doi:10.1002/14651858.CD007813.pub3. PMC 6513464. PMID 30091808.
Kiely B, Adesman A (June 2015). "What we do not know about ADHD… yet". Current Opinion in Pediatrics. 27 (3): 395–404. doi:10.1097/MOP.0000000000000229. PMID 25888152. S2CID 39004402. In addition, a consensus has not been reached on the optimal diagnostic criteria for ADHD. Moreover, the benefits and long-term effects of medical and complementary therapies for this disorder continue to be debated. These gaps in knowledge hinder the ability of clinicians to effectively recognise and treat ADHD.
Hazell P (July 2011). "The challenges to demonstrating long-term effects of psychostimulant treatment for attention-deficit/hyperactivity disorder". Current Opinion in Psychiatry. 24 (4): 286–290. doi:10.1097/YCO.0b013e32834742db. PMID 21519262. S2CID 21998152. Archived from the original on 26 July 2020. Retrieved 19 July 2019.
Zhang L, Yao H, Li L, Du Rietz E, Andell P, Garcia-Argibay M, et al. (November 2022). "Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis". JAMA Network Open. 5 (11): e2243597. doi:10.1001/jamanetworkopen.2022.43597. PMC 9685490. PMID 36416824.
Kraemer M, Uekermann J, Wiltfang J, Kis B (July 2010). "Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature". Clinical Neuropharmacology. 33 (4): 204–206. doi:10.1097/WNF.0b013e3181e29174. PMID 20571380. S2CID 34956456.
van de Loo-Neus GH, Rommelse N, Buitelaar JK (August 2011). "To stop or not to stop? How long should medication treatment of attention-deficit hyperactivity disorder be extended?". European Neuropsychopharmacology. 21 (8): 584–599. doi:10.1016/j.euroneuro.2011.03.008. PMID 21530185. S2CID 30068561.
Ibrahim K, Donyai P (July 2015). "Drug Holidays From ADHD Medication: International Experience Over the Past Four Decades". Journal of Attention Disorders. 19 (7): 551–568. doi:10.1177/1087054714548035. PMID 25253684. S2CID 19949563. Archived (PDF) from the original on 30 June 2016.
Potter AS, Schaubhut G, Shipman M (December 2014). "Targeting the nicotinic cholinergic system to treat attention-deficit/hyperactivity disorder: rationale and progress to date". CNS Drugs. 28 (12): 1103–1113. doi:10.1007/s40263-014-0208-9. PMC 4487649. PMID 25349138.
Perrotte G, Moreira MM, de Vargas Junior A, Teixeira Filho A, Castaldelli-Maia JM (September 2023). "Effects of Caffeine on Main Symptoms in Children with ADHD: A Systematic Review and Meta-Analysis of Randomized Trials". Brain Sciences. 13 (9): 1304. doi:10.3390/brainsci13091304. PMC 10526204. PMID 37759905.
Turner D (April 2006). "A review of the use of modafinil for attention-deficit hyperactivity disorder". Expert Review of Neurotherapeutics. 6 (4): 455–468. doi:10.1586/14737175.6.4.455. PMID 16623645. S2CID 24293088.
Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, et al. (July 2005). "A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD". Journal of the American Academy of Child and Adolescent Psychiatry. 44 (7): 647–655. doi:10.1097/01.chi.0000163280.47221.c9. PMID 15968233.
Biederman J, Wigal SB, Spencer TJ, McGough JJ, Mays DA (February 2006). "A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder". Clinical Therapeutics. 28 (2): 280–293. doi:10.1016/j.clinthera.2006.02.008. PMID 16678649.
Bushe C, Day K, Reed V, Karlsdotter K, Berggren L, Pitcher A, et al. (May 2016). "A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients". Journal of Psychopharmacology. 30 (5): 444–458. doi:10.1177/0269881116636105. PMID 27005307. S2CID 104938.
Hazell PL, Kohn MR, Dickson R, Walton RJ, Granger RE, Wyk GW (November 2011). "Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis". Journal of Attention Disorders. 15 (8): 674–683. doi:10.1177/1087054710379737. PMID 20837981. S2CID 43503227.
Hanwella R, Senanayake M, de Silva V (November 2011). "Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis". BMC Psychiatry. 11 (1): 176. doi:10.1186/1471-244X-11-176. PMC 3229459. PMID 22074258.
Faraone SV, Gomeni R, Hull JT, Busse GD, Melyan Z, O'Neal W, et al. (February 2021). "Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials". Psychiatry Research. 296: 113664. doi:10.1016/j.psychres.2020.113664. PMID 33418457. S2CID 230716405.
Mohammadi MR, Kazemi MR, Zia E, Rezazadeh SA, Tabrizi M, Akhondzadeh S (November 2010). "Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial". Human Psychopharmacology. 25 (7–8): 560–565. doi:10.1002/hup.1154. PMID 21312290. S2CID 30677758.
Morrow K, Choi S, Young K, Haidar M, Boduch C, Bourgeois JA (September 2021). "Amantadine for the treatment of childhood and adolescent psychiatric symptoms". Proceedings. 34 (5): 566–570. doi:10.1080/08998280.2021.1925827. PMC 8366930. PMID 34456474.
Stuhec M, Munda B, Svab V, Locatelli I (June 2015). "Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion". Journal of Affective Disorders. 178: 149–159. doi:10.1016/j.jad.2015.03.006. PMID 25813457.
Gurnani T, Ivanov I, Newcorn JH (February 2016). "Pharmacotherapy of Aggression in Child and Adolescent Psychiatric Disorders". Journal of Child and Adolescent Psychopharmacology. 26 (1): 65–73. doi:10.1089/cap.2015.0167. PMID 26881859. Several studies (e.g., Findling et al. 2000; Armenteros et al. 2007) have shown that antipsychotics, especially second generation agents, can be effective when used together with stimulants for aggression in ADHD
Childress AC, Sallee FR (March 2012). "Revisiting clonidine: an innovative add-on option for attention-deficit/hyperactivity disorder". Drugs of Today. 48 (3): 207–217. doi:10.1358/dot.2012.48.3.1750904. PMID 22462040.
Huss M, Chen W, Ludolph AG (January 2016). "Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe". Clinical Drug Investigation. 36 (1). Springer Science and Business Media LLC: 1–25. doi:10.1007/s40261-015-0336-0. PMC 4706844. PMID 26585576.
Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, et al. (SPD503 Study Group) (January 2008). "A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder". Pediatrics. 121 (1): e73–e84. doi:10.1542/peds.2006-3695. PMID 18166547. S2CID 25551406.
Palumbo DR, Sallee FR, Pelham WE, Bukstein OG, Daviss WB, McDERMOTT MP (February 2008). "Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes". Journal of the American Academy of Child and Adolescent Psychiatry. 47 (2): 180–188. doi:10.1097/chi.0b013e31815d9af7. PMID 18182963.
Stevens JR, Wilens TE, Stern TA (2013). "Using stimulants for attention-deficit/hyperactivity disorder: clinical approaches and challenges". The Primary Care Companion for CNS Disorders. 15 (2). doi:10.4088/PCC.12f01472. PMC 3733520. PMID 23930227.
Kessler S (January 1996). "Drug therapy in attention-deficit hyperactivity disorder". Southern Medical Journal. 89 (1): 33–38. doi:10.1097/00007611-199601000-00005. PMID 8545689. S2CID 12798818.
Wolraich ML, Hagan JF, Allan C, Chan E, Davison D, Earls M, et al. (October 2019). "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents". Pediatrics. 144 (4): e20192528. doi:10.1542/peds.2019-2528. PMC 7067282. PMID 31570648.
Ertürk E, Wouters S, Imeraj L, Lampo A (August 2020). "Association of ADHD and Celiac Disease: What Is the Evidence? A Systematic Review of the Literature". Journal of Attention Disorders (Review). 24 (10): 1371–1376. doi:10.1177/1087054715611493. PMID 26825336. S2CID 33989148. Up till now, there is no conclusive evidence for a relationship between ADHD and CD. Therefore, it is not advised to perform routine screening of CD when assessing ADHD (and vice versa) or to implement GFD as a standard treatment in ADHD. Nevertheless, the possibility of untreated CD predisposing to ADHD-like behavior should be kept in mind. ... It is possible that in untreated patients with CD, neurologic symptoms such as chronic fatigue, inattention, pain, and headache could predispose patients to ADHD-like behavior (mainly symptoms of inattentive type), which may be alleviated after GFD treatment.
Pelsser LM, Frankena K, Toorman J, Rodrigues Pereira R (January 2017). "Diet and ADHD, Reviewing the Evidence: A Systematic Review of Meta-Analyses of Double-Blind Placebo-Controlled Trials Evaluating the Efficacy of Diet Interventions on the Behavior of Children with ADHD". PLOS ONE (Systematic Review). 12 (1): e0169277. Bibcode:2017PLoSO..1269277P. doi:10.1371/journal.pone.0169277. PMC 5266211. PMID 28121994.
Arnold LE, DiSilvestro RA (August 2005). "Zinc in attention-deficit/hyperactivity disorder". Journal of Child and Adolescent Psychopharmacology. 15 (4): 619–627. doi:10.1089/cap.2005.15.619. hdl:1811/51593. PMID 16190793.
Bloch MH, Mulqueen J (October 2014). "Nutritional supplements for the treatment of ADHD". Child and Adolescent Psychiatric Clinics of North America. 23 (4): 883–897. doi:10.1016/j.chc.2014.05.002. PMC 4170184. PMID 25220092.
Krause J (April 2008). "SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder". Expert Review of Neurotherapeutics. 8 (4): 611–625. doi:10.1586/14737175.8.4.611. PMID 18416663. S2CID 24589993. Zinc binds at ... extracellular sites of the DAT, serving as a DAT inhibitor. In this context, controlled double-blind studies in children are of interest, which showed positive effects of zinc [supplementation] on symptoms of ADHD. It should be stated that at this time [supplementation] with zinc is not integrated in any ADHD treatment algorithm.
Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-Quiroga JA, et al. (August 2015). "Attention-deficit/hyperactivity disorder". Nature Reviews. Disease Primers (Review). 1: 15020. CiteSeerX 10.1.1.497.1346. doi:10.1038/nrdp.2015.20. PMID 27189265. S2CID 7171541.
McClernon FJ, Kollins SH (October 2008). "ADHD and smoking: from genes to brain to behavior". Annals of the New York Academy of Sciences. 1141 (1): 131–147. Bibcode:2008NYASA1141..131M. doi:10.1196/annals.1441.016. PMC 2758663. PMID 18991955.
Ginsberg Y, Quintero J, Anand E, Casillas M, Upadhyaya HP (2014). "Underdiagnosis of attention-deficit/hyperactivity disorder in adult patients: a review of the literature". The Primary Care Companion for CNS Disorders. 16 (3). doi:10.4088/PCC.13r01600. PMC 4195639. PMID 25317367. Reports indicate that ADHD affects 2.5%–5% of adults in the general population,^5–8 compared with 5%–7% of children.^9,10 ... However, fewer than 20% of adults with ADHD are currently diagnosed and/or treated by psychiatrists.^7,15,16
Baggio S, Fructuoso A, Guimaraes M, Fois E, Golay D, Heller P, et al. (2 August 2018). "Prevalence of Attention Deficit Hyperactivity Disorder in Detention Settings: A Systematic Review and Meta-Analysis". Frontiers in Psychiatry. 9: 331. doi:10.3389/fpsyt.2018.00331. PMC 6084240. PMID 30116206.
Willcutt EG (July 2012). "The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review". Neurotherapeutics. 9 (3): 490–499. doi:10.1007/s13311-012-0135-8. PMC 3441936. PMID 22976615.
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (June 2007). "The worldwide prevalence of ADHD: a systematic review and metaregression analysis". The American Journal of Psychiatry. 164 (6): 942–948. doi:10.1176/appi.ajp.164.6.942. eISSN 1535-7228. LCCN 22024537. OCLC 1480183. PMID 17541055.
Young S, Adamo N, Ásgeirsdóttir BB, Branney P, Beckett M, Colley W, et al. (August 2020). "Females with ADHD: An expert consensus statement taking a lifespan approach providing guidance for the identification and treatment of attention-deficit/ hyperactivity disorder in girls and women". BMC Psychiatry. 20 (1): 404. doi:10.1186/s12888-020-02707-9. PMC 7422602. PMID 32787804.
Emond V, Joyal C, Poissant H (April 2009). "[Structural and functional neuroanatomy of attention-deficit hyperactivity disorder (ADHD)]" [Structural and functional neuroanatomy of attention-deficit hyperactivity disorder (ADHD)]. L'Encephale (in French). 35 (2): 107–114. doi:10.1016/j.encep.2008.01.005. PMID 19393378.
Staller J, Faraone SV (2006). "Attention-deficit hyperactivity disorder in girls: epidemiology and management". CNS Drugs. 20 (2): 107–123. doi:10.2165/00023210-200620020-00003. PMID 16478287. S2CID 25835322.
Whitely M, Raven M, Timimi S, Jureidini J, Phillimore J, Leo J, et al. (April 2019). "Attention deficit hyperactivity disorder late birthdate effect common in both high and low prescribing international jurisdictions: a systematic review". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 60 (4): 380–391. doi:10.1111/jcpp.12991. PMC 7379308. PMID 30317644.
Ford-Jones PC (May 2015). "Misdiagnosis of attention deficit hyperactivity disorder: 'Normal behaviour' and relative maturity". Paediatrics & Child Health. 20 (4): 200–202. doi:10.1093/pch/20.4.200. PMC 4443828. PMID 26038639.
Elder TE (September 2010). "The importance of relative standards in ADHD diagnoses: evidence based on exact birth dates". Journal of Health Economics. 29 (5): 641–656. doi:10.1016/j.jhealeco.2010.06.003. PMC 2933294. PMID 20638739.
Coker TR, Elliott MN, Toomey SL, Schwebel DC, Cuccaro P, Tortolero Emery S, et al. (September 2016). "Racial and Ethnic Disparities in ADHD Diagnosis and Treatment". Pediatrics. 138 (3): e20160407. doi:10.1542/peds.2016-0407. PMC 5684883. PMID 27553219. There are various improvements in care that may help in closing this gap in diagnosis and treatment. These include actively and universally eliciting parental concerns about child behavior and academic performance (at home and school) at well-visits,32,33 providing care that is culturally relevant in families' preferred languages,34 and linking with community resources to provide mental health education, guidance, and services to families (eg, parent training courses for parents of children with ADHD).35–39 Pediatric clinicians also may need to consider universal behavioral health screening tools for children to improve diagnostic capabilities and recognize when a child has ADHD symptoms, even if the problem is not recognized by the parent. Because the rates of diagnosis and treatment are rising in the general population of US children, a significant need remains to identify and treat African-American and Latino children who have ADHD and avoid a widening of these disparities.
Slobodin O, Masalha R (June 2020). "Challenges in ADHD care for ethnic minority children: A review of the current literature". Transcultural Psychiatry. 57 (3): 468–483. doi:10.1177/1363461520902885. PMID 32233772. S2CID 214768588.
Staley BS (2024). "Attention-Deficit/Hyperactivity Disorder Diagnosis, Treatment, and Telehealth Use in Adults — National Center for Health Statistics Rapid Surveys System, United States, October–November 2023". MMWR. Morbidity and Mortality Weekly Report. 73 (40): 890–895. doi:10.15585/mmwr.mm7340a1. ISSN 0149-2195. PMC 11466376. PMID 39388378.
Palmer ED, Finger S (May 2001). "An early description of ADHD (inattentive subtype): Dr Alexander Crichton and 'Mental restlessness' (1798)". Child and Adolescent Mental Health. 6 (2): 66–73. doi:10.1111/1475-3588.00324.
Still G (1902). "Some Abnormal Psychical Conditions in Children: The Goulstonian Lectures". Lancet. 159: 1008–1012. doi:10.1016/s0140-6736(01)74984-7.
Millichap JG (2010). "Definition and History of ADHD". Attention Deficit Hyperactivity Disorder Handbook (2nd ed.). Springer Science. pp. 2–3. doi:10.1007/978-1-4419-1397-5_1. ISBN 978-1-4419-1396-8. LCCN 2009938108. Archived from the original on 14 January 2023. Retrieved 8 May 2022 – via Google Books.
Faraone SV (February 2005). "The scientific foundation for understanding attention-deficit/hyperactivity disorder as a valid psychiatric disorder". European Child & Adolescent Psychiatry. 14 (1): 1–10. doi:10.1007/s00787-005-0429-z. PMID 15756510. S2CID 143646869.
Cormier E (October 2008). "Attention deficit/hyperactivity disorder: a review and update". Journal of Pediatric Nursing. 23 (5): 345–357. doi:10.1016/j.pedn.2008.01.003. PMID 18804015.
Biederman J, Faraone SV, Keenan K, Knee D, Tsuang MT (July 1990). "Family-genetic and psychosocial risk factors in DSM-III attention deficit disorder". Journal of the American Academy of Child and Adolescent Psychiatry. 29 (4): 526–533. doi:10.1097/00004583-199007000-00004. PMID 2387786.
Lahey BB, Applegate B, McBurnett K, Biederman J, Greenhill L, Hynd GW, et al. (November 1994). "DSM-IV field trials for attention deficit hyperactivity disorder in children and adolescents". The American Journal of Psychiatry. 151 (11): 1673–1685. doi:10.1176/ajp.151.11.1673. eISSN 1535-7228. LCCN 22024537. OCLC 1480183. PMID 7943460.
Rasmussen N (July 2006). "Making the first anti-depressant: amphetamine in American medicine, 1929-1950". Journal of the History of Medicine and Allied Sciences. 61 (3): 288–323. doi:10.1093/jhmas/jrj039. PMID 16492800. S2CID 24974454.
Patrick KS, Straughn AB, Perkins JS, González MA (January 2009). "Evolution of stimulants to treat ADHD: transdermal methylphenidate". Human Psychopharmacology. 24 (1): 1–17. doi:10.1002/hup.992. PMC 2629554. PMID 19051222.
Gross MD (February 1995). "Origin of stimulant use for treatment of attention deficit disorder". The American Journal of Psychiatry. 152 (2): 298–299. doi:10.1176/ajp.152.2.298b. eISSN 1535-7228. LCCN 22024537. OCLC 1480183. PMID 7840374.
Brown W (1998). "Charles Bradley, M.D.". American Journal of Psychiatry. 155 (7): 968. doi:10.1176/ajp.155.7.968. eISSN 1535-7228. ISSN 0002-953X. LCCN 22024537. OCLC 1480183.
Hoogman M, Stolte M, Baas M, Kroesbergen E (December 2020). "Creativity and ADHD: A review of behavioral studies, the effect of psychostimulants and neural underpinnings" (PDF). Neuroscience and Biobehavioral Reviews. 119: 66–85. doi:10.1016/j.neubiorev.2020.09.029. hdl:1874/409179. PMID 33035524. S2CID 222142805. Archived (PDF) from the original on 6 September 2023. Retrieved 28 August 2023.
Scassellati C, Bonvicini C, Faraone SV, Gennarelli M (October 2012). "Biomarkers and attention-deficit/hyperactivity disorder: a systematic review and meta-analyses". Journal of the American Academy of Child and Adolescent Psychiatry. 51 (10): 1003–1019.e20. doi:10.1016/j.jaac.2012.08.015. PMID 23021477.

dundee.ac.uk

discovery.dundee.ac.uk

Carucci S, Balia C, Gagliano A, Lampis A, Buitelaar JK, Danckaerts M, et al. (January 2021). "Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis". Neuroscience and Biobehavioral Reviews. 120: 509–525. doi:10.1016/j.neubiorev.2020.09.031. hdl:11584/301387. PMID 33080250.

europepmc.org

"Intergenerational transmission of ADHD behaviors: More evidence for heritability than life history theor". europepmc.org. 2022. Retrieved 1 October 2024.
"Intergenerational transmission of ADHD behaviors: More evidence for heritability than life history theory". europepmc.org. 2022. Retrieved 12 January 2024.

fda.gov

"Background Document for the Food Advisory Committee: Certified Color Additives in Food and Possible Association with Attention Deficit Hyperactivity Disorder in Children" (PDF). U.S. Food and Drug Administration. March 2011. Archived (PDF) from the original on 6 November 2015.
"FDA Permits Marketing of First Game-Based Digital Therapeutic to Improve Attention Function in Children with ADHD". Food and Drug Administration. United States Food and Drug Administration. 17 June 2020. Retrieved 19 April 2024.

accessdata.fda.gov

"Adderall XR Prescribing Information" (PDF). United States Food and Drug Administration. Shire US Inc. December 2013. Archived (PDF) from the original on 30 December 2013. Retrieved 30 December 2013. Treatment-emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without prior history of psychotic illness or mania can be caused by stimulants at usual doses. ... In a pooled analysis of multiple short-term, placebo controlled studies, such symptoms occurred in about 0.1% (4 patients with events out of 3482 exposed to methylphenidate or amphetamine for several weeks at usual doses) of stimulant-treated patients compared to 0 in placebo-treated patients.

guidelines.gov

Dobie C, Donald WB, Hanson M, Heim C, Huxsahl J, Karasov R, et al. (March 2012). "Diagnosis and management of attention deficit hyperactivity disorder in primary care for school-age children and adolescents". National Guideline Clearinghous. p. 79. Archived from the original on 1 March 2013. Retrieved 10 October 2012.

handle.net

hdl.handle.net

Rommelse N, van der Kruijs M, Damhuis J, Hoek I, Smeets S, Antshel KM, et al. (December 2016). "An evidenced-based perspective on the validity of attention-deficit/hyperactivity disorder in the context of high intelligence". Neuroscience and Biobehavioral Reviews. 71: 21–47. doi:10.1016/j.neubiorev.2016.08.032. hdl:2066/163023. PMID 27590827. S2CID 6698847.
Vaa T (January 2014). "ADHD and relative risk of accidents in road traffic: a meta-analysis". Accident Analysis and Prevention. 62. Elsevier: 415–425. doi:10.1016/j.aap.2013.10.003. hdl:11250/2603537. PMID 24238842.
Koncz P, Demetrovics Z, Takacs ZK, Griffiths MD, Nagy T, Király O (2023). "The emerging evidence on the association between symptoms of ADHD and gaming disorder: A systematic review and meta-analysis". Clinical Psychology Review. 106. Elsevier: 102343. doi:10.1016/j.cpr.2023.102343. hdl:20.500.11820/91f22260-b579-4f0b-9e81-adc063f27e9e. PMID 37883910.
Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. (January 2019). "Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder". Nature Genetics. 51 (1): 63–75. doi:10.1038/s41588-018-0269-7. hdl:10023/20827. PMC 6481311. PMID 30478444.
Damiani S, Tarchi L, Scalabrini A, Marini S, Provenzani U, Rocchetti M, et al. (April 2021). "Beneath the surface: hyper-connectivity between caudate and salience regions in ADHD fMRI at rest". European Child & Adolescent Psychiatry. 30 (4): 619–631. doi:10.1007/s00787-020-01545-0. hdl:2318/1755224. PMID 32385695. S2CID 218540328.
Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U (March 2012). "Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis". The American Journal of Psychiatry. 169 (3): 264–272. doi:10.1176/appi.ajp.2011.11060940. eISSN 1535-7228. hdl:11577/2482784. LCCN 22024537. OCLC 1480183. PMID 22294258.
Daley D, Van Der Oord S, Ferrin M, Cortese S, Danckaerts M, Doepfner M, et al. (September 2018). "Practitioner Review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 59 (9). Wiley: 932–947. doi:10.1111/jcpp.12825. hdl:11343/293788. PMID 29083042. S2CID 31044370. Archived from the original on 25 September 2017. Retrieved 21 November 2018.
Ruiz-Goikoetxea M, Cortese S, Aznarez-Sanado M, Magallón S, Alvarez Zallo N, Luis EO, et al. (January 2018). "Risk of unintentional injuries in children and adolescents with ADHD and the impact of ADHD medications: A systematic review and meta-analysis". Neuroscience and Biobehavioral Reviews. 84: 63–71. doi:10.1016/j.neubiorev.2017.11.007. hdl:10171/45012. PMID 29162520.
Kooij JJ, Bijlenga D, Salerno L, Jaeschke R, Bitter I, Balázs J, et al. (February 2019). "Updated European Consensus Statement on diagnosis and treatment of adult ADHD". European Psychiatry. 56 (1): 14–34. doi:10.1016/j.eurpsy.2018.11.001. hdl:10651/51910. PMID 30453134.
Carucci S, Balia C, Gagliano A, Lampis A, Buitelaar JK, Danckaerts M, et al. (January 2021). "Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis". Neuroscience and Biobehavioral Reviews. 120: 509–525. doi:10.1016/j.neubiorev.2020.09.031. hdl:11584/301387. PMID 33080250.
Arnold LE, DiSilvestro RA (August 2005). "Zinc in attention-deficit/hyperactivity disorder". Journal of Child and Adolescent Psychopharmacology. 15 (4): 619–627. doi:10.1089/cap.2005.15.619. hdl:1811/51593. PMID 16190793.
Hoogman M, Stolte M, Baas M, Kroesbergen E (December 2020). "Creativity and ADHD: A review of behavioral studies, the effect of psychostimulants and neural underpinnings" (PDF). Neuroscience and Biobehavioral Reviews. 119: 66–85. doi:10.1016/j.neubiorev.2020.09.029. hdl:1874/409179. PMID 33035524. S2CID 222142805. Archived (PDF) from the original on 6 September 2023. Retrieved 28 August 2023.

harvard.edu

ui.adsabs.harvard.edu

Beyens I, Valkenburg PM, Piotrowski JT (2 October 2018). "Screen media use and ADHD-related behaviors: Four decades of research". PNAS USA. 115 (40). National Academy of Sciences: 9875–9881. Bibcode:2018PNAS..115.9875B. doi:10.1073/pnas.1611611114. PMC 6176582. PMID 30275318.
Beauchaine TP, Ben-David I, Bos M (September 2020). "ADHD, financial distress, and suicide in adulthood: A population study". Science Advances. 6 (40): eaba1551. Bibcode:2020SciA....6.1551B. doi:10.1126/sciadv.aba1551. PMC 7527218. PMID 32998893. eaba1551.
Esteller-Cucala P, Maceda I, Børglum AD, Demontis D, Faraone SV, Cormand B, et al. (May 2020). "Genomic analysis of the natural history of attention-deficit/hyperactivity disorder using Neanderthal and ancient Homo sapiens samples". Scientific Reports. 10 (1): 8622. Bibcode:2020NatSR..10.8622E. doi:10.1038/s41598-020-65322-4. PMC 7248073. PMID 32451437.
Pelsser LM, Frankena K, Toorman J, Rodrigues Pereira R (January 2017). "Diet and ADHD, Reviewing the Evidence: A Systematic Review of Meta-Analyses of Double-Blind Placebo-Controlled Trials Evaluating the Efficacy of Diet Interventions on the Behavior of Children with ADHD". PLOS ONE (Systematic Review). 12 (1): e0169277. Bibcode:2017PLoSO..1269277P. doi:10.1371/journal.pone.0169277. PMC 5266211. PMID 28121994.
McClernon FJ, Kollins SH (October 2008). "ADHD and smoking: from genes to brain to behavior". Annals of the New York Academy of Sciences. 1141 (1): 131–147. Bibcode:2008NYASA1141..131M. doi:10.1196/annals.1441.016. PMC 2758663. PMID 18991955.

healthcentral.com

Bailey E (5 September 2007). "ADHD and Learning Disabilities: How can you help your child cope with ADHD and subsequent Learning Difficulties? There is a way". Remedy Health Media, LLC. Archived from the original on 3 December 2013. Retrieved 15 November 2013.

heysigmund.com

Young K (9 February 2017). "Anxiety or ADHD? Why They Sometimes Look the Same and How to Tell the Difference". Hey Sigmund. Archived from the original on 26 January 2023. Retrieved 27 January 2023.

ima.org.il

Berger I (September 2011). "Diagnosis of attention deficit hyperactivity disorder: much ado about something" (PDF). The Israel Medical Association Journal. 13 (9): 571–574. PMID 21991721. Archived (PDF) from the original on 28 July 2020. Retrieved 23 May 2013.

jaacap.org

Stamatis CA, Mercaldi C, Kollins SH (October 2023). "A Single-Arm Pivotal Trial to Assess the Efficacy of Akl-T01, a Novel Digital Intervention for Attention, in Adults Diagnosed With ADHD". Journal of the American Academy of Child & Adolescent Psychiatry. 62 (10): S318. doi:10.1016/j.jaac.2023.09.510. Retrieved 22 April 2024.

kcl.ac.uk

kclpure.kcl.ac.uk

Nazar BP, Bernardes C, Peachey G, Sergeant J, Mattos P, Treasure J (December 2016). "The risk of eating disorders comorbid with attention-deficit/hyperactivity disorder: A systematic review and meta-analysis". The International Journal of Eating Disorders. 49 (12): 1045–1057. doi:10.1002/eat.22643. PMID 27859581. S2CID 38002526. Archived from the original on 8 December 2022. Retrieved 26 October 2022.
Obel C, Zhu JL, Olsen J, Breining S, Li J, Grønborg TK, et al. (April 2016). "The risk of attention deficit hyperactivity disorder in children exposed to maternal smoking during pregnancy - a re-examination using a sibling design". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 57 (4): 532–537. doi:10.1111/jcpp.12478. PMID 26511313.
Isfandnia F, El Masri S, Radua J, Rubia K (July 2024). "The effects of chronic administration of stimulant and non-stimulant medications on executive functions in ADHD: A systematic review and meta-analysis". Neuroscience and Biobehavioral Reviews. 162 (105703): 105703. doi:10.1016/j.neubiorev.2024.105703. PMID 38718988.

loc.gov

lccn.loc.gov

Sonuga-Barke EJ, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M, et al. (March 2013). "Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments". The American Journal of Psychiatry. 170 (3): 275–289. doi:10.1176/appi.ajp.2012.12070991. eISSN 1535-7228. LCCN 22024537. OCLC 1480183. PMID 23360949. S2CID 434310. Free fatty acid supplementation and artificial food color exclusions appear to have beneficial effects on ADHD symptoms, although the effect of the former are small and those of the latter may be limited to ADHD patients with food sensitivities...
Cortese S, Kelly C, Chabernaud C, Proal E, Di Martino A, Milham MP, et al. (October 2012). "Toward systems neuroscience of ADHD: a meta-analysis of 55 fMRI studies". The American Journal of Psychiatry. 169 (10): 1038–1055. doi:10.1176/appi.ajp.2012.11101521. eISSN 1535-7228. LCCN 22024537. OCLC 1480183. PMC 3879048. PMID 22983386.
Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U (March 2012). "Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis". The American Journal of Psychiatry. 169 (3): 264–272. doi:10.1176/appi.ajp.2011.11060940. eISSN 1535-7228. hdl:11577/2482784. LCCN 22024537. OCLC 1480183. PMID 22294258.
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (June 2007). "The worldwide prevalence of ADHD: a systematic review and metaregression analysis". The American Journal of Psychiatry. 164 (6): 942–948. doi:10.1176/appi.ajp.164.6.942. eISSN 1535-7228. LCCN 22024537. OCLC 1480183. PMID 17541055.
Millichap JG (2010). "Definition and History of ADHD". Attention Deficit Hyperactivity Disorder Handbook (2nd ed.). Springer Science. pp. 2–3. doi:10.1007/978-1-4419-1397-5_1. ISBN 978-1-4419-1396-8. LCCN 2009938108. Archived from the original on 14 January 2023. Retrieved 8 May 2022 – via Google Books.
Lahey BB, Applegate B, McBurnett K, Biederman J, Greenhill L, Hynd GW, et al. (November 1994). "DSM-IV field trials for attention deficit hyperactivity disorder in children and adolescents". The American Journal of Psychiatry. 151 (11): 1673–1685. doi:10.1176/ajp.151.11.1673. eISSN 1535-7228. LCCN 22024537. OCLC 1480183. PMID 7943460.
Gross MD (February 1995). "Origin of stimulant use for treatment of attention deficit disorder". The American Journal of Psychiatry. 152 (2): 298–299. doi:10.1176/ajp.152.2.298b. eISSN 1535-7228. LCCN 22024537. OCLC 1480183. PMID 7840374.
Brown W (1998). "Charles Bradley, M.D.". American Journal of Psychiatry. 155 (7): 968. doi:10.1176/ajp.155.7.968. eISSN 1535-7228. ISSN 0002-953X. LCCN 22024537. OCLC 1480183.

lu.se

lup.lub.lu.se

Hofvander B, Ossowski D, Lundström S, Anckarsäter H (2009). "Continuity of aggressive antisocial behavior from childhood to adulthood: The question of phenotype definition". International Journal of Law and Psychiatry. 32 (4): 224–234. doi:10.1016/j.ijlp.2009.04.004. PMID 19428109. Archived from the original on 17 May 2022. Retrieved 22 November 2021.

medscape.com

Biederman J (21 November 2003). "New-Generation Long-Acting Stimulants for the Treatment of Attention-Deficit/Hyperactivity Disorder". Medscape. Archived from the original on 8 May 2022. Retrieved 8 May 2022. As most treatment guidelines and prescribing information for stimulant medications relate to experience in school-aged children, prescribed doses for older patients are lacking. Emerging evidence for both methylphenidate and Adderall indicate that when weight-corrected daily doses, equipotent with those used in the treatment of younger patients, are used to treat adults with ADHD, these patients show a very robust clinical response consistent with that observed in pediatric studies. These data suggest that older patients may require a more aggressive approach in terms of dosing, based on the same target dosage ranges that have already been established – for methylphenidate, 1–1.5–2 mg/kg/day, and for D,L-amphetamine, 0.5–0.75–1 mg/kg/day....
In particular, adolescents and adults are vulnerable to underdosing, and are thus at potential risk of failing to receive adequate dosage levels. As with all therapeutic agents, the efficacy and safety of stimulant medications should always guide prescribing behavior: careful dosage titration of the selected stimulant product should help to ensure that each patient with ADHD receives an adequate dose, so that the clinical benefits of therapy can be fully attained.

medscape.org

Young JL (20 December 2010). "Individualizing Treatment for Adult ADHD: An Evidence-Based Guideline". Medscape. Archived from the original on 8 May 2022. Retrieved 8 May 2022.

merckmedicus.com

"ADHD –Pathophysiology". MerckMedicus Modules. Whitehouse Station, NJ, USA: Merck & Co., Inc. August 2002. Archived from the original on 1 May 2010.

nature.com

Faraone SV, Bellgrove MA, Brikell I, Cortese S, Hartman CA, Hollis C, et al. (22 February 2024). "Attention-deficit/hyperactivity disorder". Nature Reviews Disease Primers. 10 (1): 1–21. doi:10.1038/s41572-024-00495-0. ISSN 2056-676X.
Faraone SV, Bellgrove MA, Brikell I, Cortese S, Hartman CA, Hollis C, et al. (22 February 2024). "Attention-deficit/hyperactivity disorder". Nature Reviews Disease Primers. 10 (1): 1–21. doi:10.1038/s41572-024-00495-0. ISSN 2056-676X.

nhs.uk

"ADHD Symptoms". nhs.uk. 20 October 2017. Archived from the original on 1 February 2021. Retrieved 15 May 2018.
"Attention deficit hyperactivity disorder (ADHD)". nhs.uk. 1 June 2018. Retrieved 16 February 2024.

nice.org.uk

National Institute for Health and Care Excellence (2019). Attention deficit hyperactivity disorder: diagnosis and management. NICE Guideline, No. 87. London: National Guideline Centre (UK). ISBN 978-1-4731-2830-9. OCLC 1126668845. Archived from the original on 12 January 2021. Retrieved 9 January 2021.

nih.gov

pubmed.ncbi.nlm.nih.gov

Foreman DM (February 2006). "Attention deficit hyperactivity disorder: legal and ethical aspects". Archives of Disease in Childhood. 91 (2): 192–194. doi:10.1136/adc.2004.064576. PMC 2082674. PMID 16428370.
Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, et al. (September 2021). "The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder". Neuroscience and Biobehavioral Reviews. 128. Elsevier BV: 789–818. doi:10.1016/j.neubiorev.2021.01.022. ISSN 0149-7634. PMC 8328933. PMID 33549739.
Pievsky MA, McGrath RE (March 2018). "The Neurocognitive Profile of Attention-Deficit/Hyperactivity Disorder: A Review of Meta-Analyses". Archives of Clinical Neuropsychology. 33 (2): 143–157. doi:10.1093/arclin/acx055. PMID 29106438.
Schoechlin C, Engel RR (August 2005). "Neuropsychological performance in adult attention-deficit hyperactivity disorder: meta-analysis of empirical data". Archives of Clinical Neuropsychology. 20 (6): 727–744. doi:10.1016/j.acn.2005.04.005. PMID 15953706.
Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K (February 2013). "Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects". JAMA Psychiatry. 70 (2): 185–198. doi:10.1001/jamapsychiatry.2013.277. PMID 23247506.
Hoogman M, Muetzel R, Guimaraes JP, Shumskaya E, Mennes M, Zwiers MP, et al. (July 2019). "Brain Imaging of the Cortex in ADHD: A Coordinated Analysis of Large-Scale Clinical and Population-Based Samples". The American Journal of Psychiatry. 176 (7): 531–542. doi:10.1176/appi.ajp.2019.18091033. PMC 6879185. PMID 31014101.
Brown TE (October 2008). "ADD/ADHD and Impaired Executive Function in Clinical Practice". Current Psychiatry Reports. 10 (5): 407–411. doi:10.1007/s11920-008-0065-7. PMID 18803914. S2CID 146463279.
Diamond A (2013). "Executive functions". Annual Review of Psychology. 64: 135–168. doi:10.1146/annurev-psych-113011-143750. PMC 4084861. PMID 23020641. EFs and prefrontal cortex are the first to suffer, and suffer disproportionately, if something is not right in your life. They suffer first, and most, if you are stressed (Arnsten 1998, Liston et al. 2009, Oaten & Cheng 2005), sad (Hirt et al. 2008, von Hecker & Meiser 2005), lonely (Baumeister et al. 2002, Cacioppo & Patrick 2008, Campbell et al. 2006, Tun et al. 2012), sleep deprived (Barnes et al. 2012, Huang et al. 2007), or not physically fit (Best 2010, Chaddock et al. 2011, Hillman et al. 2008). Any of these can cause you to appear to have a disorder of EFs, such as ADHD, when you do not.
Retz W, Stieglitz RD, Corbisiero S, Retz-Junginger P, Rösler M (October 2012). "Emotional dysregulation in adult ADHD: What is the empirical evidence?". Expert Review of Neurotherapeutics. 12 (10): 1241–1251. doi:10.1586/ern.12.109. PMID 23082740. S2CID 207221320.
Faraone SV, Rostain AL, Blader J, Busch B, Childress AC, Connor DF, et al. (February 2019). "Practitioner Review: Emotional dysregulation in attention-deficit/hyperactivity disorder - implications for clinical recognition and intervention". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 60 (2): 133–150. doi:10.1111/jcpp.12899. PMID 29624671.
Shaw P, Stringaris A, Nigg J, Leibenluft E (March 2014). "Emotion dysregulation in attention deficit hyperactivity disorder". The American Journal of Psychiatry. 171 (3): 276–293. doi:10.1176/appi.ajp.2013.13070966. PMC 4282137. PMID 24480998.
Barkley RA (December 2002). "International Consensus Statement on ADHD". Journal of the American Academy of Child and Adolescent Psychiatry. 41 (12): 1389. doi:10.1097/00004583-200212000-00001. ISSN 0890-8567. PMID 12447019.
Fleming M, Fitton CA, Steiner MF, McLay JS, Clark D, King A, et al. (July 2017). "Educational and Health Outcomes of Children Treated for Attention-Deficit/Hyperactivity Disorder". JAMA Pediatrics. 171 (7): e170691. doi:10.1001/jamapediatrics.2017.0691. PMC 6583483. PMID 28459927.
Lee YC, Yang HJ, Chen VC, Lee WT, Teng MJ, Lin CH, et al. (1 April 2016). "Meta-analysis of quality of life in children and adolescents with ADHD: By both parent proxy-report and child self-report using PedsQL™". Research in Developmental Disabilities. 51–52: 160–172. doi:10.1016/j.ridd.2015.11.009. PMID 26829402.
Barkley RA, Fischer M (July 2019). "Hyperactive Child Syndrome and Estimated Life Expectancy at Young Adult Follow-Up: The Role of ADHD Persistence and Other Potential Predictors". Journal of Attention Disorders. 23 (9): 907–923. doi:10.1177/1087054718816164. PMID 30526189. S2CID 54472439.
Cattoi B, Alpern I, Katz JS, Keepnews D, Solanto MV (April 2022). "The Adverse Health Outcomes, Economic Burden, and Public Health Implications of Unmanaged Attention Deficit Hyperactivity Disorder (ADHD): A Call to Action Resulting from CHADD Summit, Washington, DC, October 17, 2019". Journal of Attention Disorders. 26 (6): 807–808. doi:10.1177/10870547211036754. PMID 34585995. S2CID 238218526.
Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, et al. (1 September 2021). "The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder". Neuroscience & Biobehavioral Reviews. 128: 789–818. doi:10.1016/j.neubiorev.2021.01.022. ISSN 0149-7634. PMC 8328933. PMID 33549739.
Groen Y, Priegnitz U, Fuermaier AB, Tucha L, Tucha O, Aschenbrenner S, et al. (December 2020). "Testing the relation between ADHD and hyperfocus experiences". Research in Developmental Disabilities. 107: 103789. doi:10.1016/j.ridd.2020.103789. PMID 33126147.
Ashinoff BK, Abu-Akel A (February 2021). "Hyperfocus: the forgotten frontier of attention". Psychological Research. 85 (1): 1–19. doi:10.1007/s00426-019-01245-8. PMC 7851038. PMID 31541305.
Ishii S, Takagi S, Kobayashi N, Jitoku D, Sugihara G, Takahashi H (16 March 2023). "Hyperfocus symptom and internet addiction in individuals with attention-deficit/hyperactivity disorder trait". Frontiers in Psychiatry. 14: 1127777. doi:10.3389/fpsyt.2023.1127777. PMC 10061009. PMID 37009127.
Larsson H, Anckarsater H, Råstam M, Chang Z, Lichtenstein P (January 2012). "Childhood attention-deficit hyperactivity disorder as an extreme of a continuous trait: a quantitative genetic study of 8,500 twin pairs". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 53 (1): 73–80. doi:10.1111/j.1469-7610.2011.02467.x. PMID 21923806.
Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM, Perlis RH, et al. (September 2013). "Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs". Nature Genetics. 45 (9): 984–994. doi:10.1038/ng.2711. PMC 3800159. PMID 23933821.
Cecil CA, Nigg JT (November 2022). "Epigenetics and ADHD: Reflections on Current Knowledge, Research Priorities and Translational Potential". Molecular Diagnosis & Therapy. 26 (6): 581–606. doi:10.1007/s40291-022-00609-y. PMC 7613776. PMID 35933504.
Nigg JT, Sibley MH, Thapar A, Karalunas SL (December 2020). "Development of ADHD: Etiology, Heterogeneity, and Early Life Course". Annual Review of Developmental Psychology. 2 (1): 559–583. doi:10.1146/annurev-devpsych-060320-093413. PMC 8336725. PMID 34368774.
Franke B, Michelini G, Asherson P, Banaschewski T, Bilbow A, Buitelaar JK, et al. (October 2018). "Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan". European Neuropsychopharmacology. 28 (10): 1059–1088. doi:10.1016/j.euroneuro.2018.08.001. PMC 6379245. PMID 30195575.
Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-Quiroga JA, et al. (August 2015). "Attention-deficit/hyperactivity disorder" (PDF). Nature Reviews. Disease Primers. 1: 15020. doi:10.1038/nrdp.2015.20. PMID 27189265. S2CID 7171541.
Larsson H, Chang Z, D'Onofrio BM, Lichtenstein P (July 2014). "The heritability of clinically diagnosed Attention-Deficit/Hyperactivity Disorder across the life span". Psychological Medicine. 44 (10): 2223–2229. doi:10.1017/S0033291713002493. ISSN 0033-2917. PMC 4071160. PMID 24107258.
Sinopoli KJ, Schachar R, Dennis M (August 2011). "Traumatic brain injury and secondary attention-deficit/hyperactivity disorder in children and adolescents: the effect of reward on inhibitory control". Journal of Clinical and Experimental Neuropsychology. 33 (7): 805–819. doi:10.1080/13803395.2011.562864. PMC 3184364. PMID 21598155.
Eme R (April 2012). "ADHD: an integration with pediatric traumatic brain injury". Expert Review of Neurotherapeutics. 12 (4): 475–483. doi:10.1586/ern.12.15. PMID 22449218. S2CID 35718630.
Gerring JP, Brady KD, Chen A, Vasa R, Grados M, Bandeen-Roche KJ, et al. (1998). "Premorbid Prevalence of ADHD and Development of Secondary ADHD After Closed Head Injury". Journal of the American Academy of Child & Adolescent Psychiatry. 37 (6): 647–654. doi:10.1097/00004583-199806000-00015. PMID 9628085.
Faraone SV, Larsson H (April 2019). "Genetics of attention deficit hyperactivity disorder". Molecular Psychiatry. 24 (4): 562–575. doi:10.1038/s41380-018-0070-0. PMC 6477889. PMID 29892054.
Faraone SV, Biederman J (July 2016). "Can Attention-Deficit/Hyperactivity Disorder Onset Occur in Adulthood?". JAMA Psychiatry. 73 (7): 655–656. doi:10.1001/jamapsychiatry.2016.0400. PMID 27191055.
Epstein JN, Loren RE (October 2013). "Changes in the Definition of ADHD in DSM-5: Subtle but Important". Neuropsychiatry. 3 (5): 455–458. doi:10.2217/npy.13.59 (inactive 20 November 2024). PMC 3955126. PMID 24644516.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
Gershon J (January 2002). "A meta-analytic review of gender differences in ADHD". Journal of Attention Disorders. 5 (3): 143–154. doi:10.1177/108705470200500302. PMID 11911007. S2CID 8076914.
Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugué M, Carpentier PJ, et al. (September 2010). "European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD". BMC Psychiatry. 10 (67): 67. doi:10.1186/1471-244X-10-67. PMC 2942810. PMID 20815868.
Carpenter Rich E, Loo SK, Yang M, Dang J, Smalley SL (July 2009). "Social functioning difficulties in ADHD: association with PDD risk". Clinical Child Psychology and Psychiatry. 14 (3): 329–344. doi:10.1177/1359104508100890. PMC 2827258. PMID 19515751.
Coleman WL (August 2008). "Social competence and friendship formation in adolescents with attention-deficit/hyperactivity disorder". Adolescent Medicine. 19 (2): 278–99, x. PMID 18822833.
Bellani M, Moretti A, Perlini C, Brambilla P (December 2011). "Language disturbances in ADHD". Epidemiology and Psychiatric Sciences. 20 (4): 311–315. doi:10.1017/S2045796011000527. PMID 22201208.
Racine MB, Majnemer A, Shevell M, Snider L (April 2008). "Handwriting performance in children with attention deficit hyperactivity disorder (ADHD)". Journal of Child Neurology. 23 (4): 399–406. doi:10.1177/0883073807309244. PMID 18401033. S2CID 206546871.
Peterson RL, Pennington BF (May 2012). "Developmental dyslexia". Lancet. 379 (9830): 1997–2007. doi:10.1016/S0140-6736(12)60198-6. PMC 3465717. PMID 22513218.
Sexton CC, Gelhorn HL, Bell JA, Classi PM (November 2012). "The co-occurrence of reading disorder and ADHD: epidemiology, treatment, psychosocial impact, and economic burden". Journal of Learning Disabilities. 45 (6): 538–564. doi:10.1177/0022219411407772. PMID 21757683. S2CID 385238.
Nicolson RI, Fawcett AJ (January 2011). "Dyslexia, dysgraphia, procedural learning and the cerebellum". Cortex; A Journal Devoted to the Study of the Nervous System and Behavior. 47 (1): 117–127. doi:10.1016/j.cortex.2009.08.016. PMID 19818437. S2CID 32228208.
Walitza S, Drechsler R, Ball J (August 2012). "[The school child with ADHD]" [The school child with ADHD]. Therapeutische Umschau (in German). 69 (8): 467–473. doi:10.1024/0040-5930/a000316. PMID 22851461.
Frazier TW, Demaree HA, Youngstrom EA (July 2004). "Meta-analysis of intellectual and neuropsychological test performance in attention-deficit/hyperactivity disorder". Neuropsychology. 18 (3): 543–555. doi:10.1037/0894-4105.18.3.543. PMID 15291732. S2CID 17628705.
Mackenzie GB, Wonders E (2016). "Rethinking Intelligence Quotient Exclusion Criteria Practices in the Study of Attention Deficit Hyperactivity Disorder". Frontiers in Psychology. 7: 794. doi:10.3389/fpsyg.2016.00794. PMC 4886698. PMID 27303350.
Rommelse N, van der Kruijs M, Damhuis J, Hoek I, Smeets S, Antshel KM, et al. (December 2016). "An evidenced-based perspective on the validity of attention-deficit/hyperactivity disorder in the context of high intelligence". Neuroscience and Biobehavioral Reviews. 71: 21–47. doi:10.1016/j.neubiorev.2016.08.032. hdl:2066/163023. PMID 27590827. S2CID 6698847.
Bridgett DJ, Walker ME (March 2006). "Intellectual functioning in adults with ADHD: a meta-analytic examination of full scale IQ differences between adults with and without ADHD". Psychological Assessment. 18 (1): 1–14. doi:10.1037/1040-3590.18.1.1. PMID 16594807.
Young S, Hollingdale J, Absoud M, Bolton P, Branney P, Colley W, et al. (May 2020). "Guidance for identification and treatment of individuals with attention deficit/hyperactivity disorder and autism spectrum disorder based upon expert consensus". BMC Medicine. 18 (1). Springer Science and Business Media LLC: 146. doi:10.1186/s12916-020-01585-y. PMC 7247165. PMID 32448170.
Hofvander B, Ossowski D, Lundström S, Anckarsäter H (2009). "Continuity of aggressive antisocial behavior from childhood to adulthood: The question of phenotype definition". International Journal of Law and Psychiatry. 32 (4): 224–234. doi:10.1016/j.ijlp.2009.04.004. PMID 19428109. Archived from the original on 17 May 2022. Retrieved 22 November 2021.
Rubia K (June 2011). ""Cool" inferior frontostriatal dysfunction in attention-deficit/hyperactivity disorder versus "hot" ventromedial orbitofrontal-limbic dysfunction in conduct disorder: a review". Biological Psychiatry. 69 (12). Elsevier BV/The Society of Biological Psychiatry: e69–e87. doi:10.1016/j.biopsych.2010.09.023. PMID 21094938. S2CID 14987165.
Wilens TE, Spencer TJ (September 2010). "Understanding attention-deficit/hyperactivity disorder from childhood to adulthood". Postgraduate Medicine. 122 (5): 97–109. doi:10.3810/pgm.2010.09.2206. PMC 3724232. PMID 20861593.
Baud P, Perroud N, Aubry JM (June 2011). "[Bipolar disorder and attention deficit/hyperactivity disorder in adults: differential diagnosis or comorbidity]". Revue Médicale Suisse (in French). 7 (297): 1219–1222. doi:10.53738/REVMED.2011.7.297.1219. PMID 21717696.
Wilens TE, Morrison NR (July 2011). "The intersection of attention-deficit/hyperactivity disorder and substance abuse". Current Opinion in Psychiatry. 24 (4): 280–285. doi:10.1097/YCO.0b013e328345c956. PMC 3435098. PMID 21483267.
Corkum P, Davidson F, Macpherson M (June 2011). "A framework for the assessment and treatment of sleep problems in children with attention-deficit/hyperactivity disorder". Pediatric Clinics of North America. 58 (3): 667–683. doi:10.1016/j.pcl.2011.03.004. PMID 21600348.
Tsai MH, Huang YS (May 2010). "Attention-deficit/hyperactivity disorder and sleep disorders in children". The Medical Clinics of North America. 94 (3): 615–632. doi:10.1016/j.mcna.2010.03.008. PMID 20451036.
Bendz LM, Scates AC (January 2010). "Melatonin treatment for insomnia in pediatric patients with attention-deficit/hyperactivity disorder". The Annals of Pharmacotherapy. 44 (1): 185–191. doi:10.1345/aph.1M365. PMID 20028959. S2CID 207263711.
Merino-Andreu M (March 2011). "[Attention deficit hyperactivity disorder and restless legs syndrome in children]" [Attention deficit hyperactivity disorder and restless legs syndrome in children]. Revista de Neurologia (in Spanish). 52 (Suppl 1): S85–S95. doi:10.33588/rn.52S01.2011037. PMID 21365608.
Picchietti MA, Picchietti DL (August 2010). "Advances in pediatric restless legs syndrome: Iron, genetics, diagnosis and treatment". Sleep Medicine. 11 (7): 643–651. doi:10.1016/j.sleep.2009.11.014. PMID 20620105.
Karroum E, Konofal E, Arnulf I (2008). "[Restless-legs syndrome]". Revue Neurologique (in French). 164 (8–9): 701–721. doi:10.1016/j.neurol.2008.06.006. PMID 18656214.
Wajszilber D, Santiseban JA, Gruber R (December 2018). "Sleep disorders in patients with ADHD: impact and management challenges". Nature and Science of Sleep. 10: 453–480. doi:10.2147/NSS.S163074. PMC 6299464. PMID 30588139.
Long Y, Pan N, Ji S, Qin K, Chen Y, Zhang X, et al. (September 2022). "Distinct brain structural abnormalities in attention-deficit/hyperactivity disorder and substance use disorders: A comparative meta-analysis". Translational Psychiatry. 12 (1): 368. doi:10.1038/s41398-022-02130-6. PMC 9448791. PMID 36068207.
Storebø OJ, Rasmussen PD, Simonsen E (February 2016). "Association Between Insecure Attachment and ADHD: Environmental Mediating Factors" (PDF). Journal of Attention Disorders. 20 (2): 187–196. doi:10.1177/1087054713501079. PMID 24062279. S2CID 23564305. Archived (PDF) from the original on 9 December 2021. Retrieved 22 November 2021.
Becker SP, Willcutt EG, Leopold DR, Fredrick JW, Smith ZR, Jacobson LA, et al. (June 2023). "Report of a Work Group on Sluggish Cognitive Tempo: Key Research Directions and a Consensus Change in Terminology to Cognitive Disengagement Syndrome". Journal of the American Academy of Child and Adolescent Psychiatry. 62 (6): 629–645. doi:10.1016/j.jaac.2022.07.821. PMC 9943858. PMID 36007816.
Barkley RA (January 2014). "Sluggish cognitive tempo (concentration deficit disorder?): current status, future directions, and a plea to change the name" (PDF). Journal of Abnormal Child Psychology. 42 (1): 117–125. doi:10.1007/s10802-013-9824-y. PMID 24234590. S2CID 8287560. Archived (PDF) from the original on 9 August 2017.
Nazar BP, Bernardes C, Peachey G, Sergeant J, Mattos P, Treasure J (December 2016). "The risk of eating disorders comorbid with attention-deficit/hyperactivity disorder: A systematic review and meta-analysis". The International Journal of Eating Disorders. 49 (12): 1045–1057. doi:10.1002/eat.22643. PMID 27859581. S2CID 38002526. Archived from the original on 8 December 2022. Retrieved 26 October 2022.
Schneider M, VanOrmer J, Zlomke K (2019). "Adverse Childhood Experiences and Family Resilience Among Children with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder". Journal of Developmental and Behavioral Pediatrics. 40 (8): 573–580. doi:10.1097/DBP.0000000000000703. PMID 31335581. S2CID 198193637.
Moon DS, Bong SJ, Kim BN, Kang NR (January 2021). "Association between Maternal Adverse Childhood Experiences and Attention-Deficit/Hyperactivity Disorder in the Offspring: The Mediating Role of Antepartum Health Risks". Soa--Ch'ongsonyon Chongsin Uihak = Journal of Child & Adolescent Psychiatry. 32 (1): 28–34. doi:10.5765/jkacap.200041. PMC 7788667. PMID 33424239.
Harrington KM, Miller MW, Wolf EJ, Reardon AF, Ryabchenko KA, Ofrat S (August 2012). "Attention-deficit/hyperactivity disorder comorbidity in a sample of veterans with posttraumatic stress disorder". Comprehensive Psychiatry. 53 (6): 679–690. doi:10.1016/j.comppsych.2011.12.001. PMC 6519447. PMID 22305866.
Zhang N, Gao M, Yu J, Zhang Q, Wang W, Zhou C, et al. (October 2022). "Understanding the association between adverse childhood experiences and subsequent attention deficit hyperactivity disorder: A systematic review and meta-analysis of observational studies". Brain and Behavior. 12 (10): e32748. doi:10.1002/brb3.2748. PMC 9575611. PMID 36068993.
Nguyen MN, Watanabe-Galloway S, Hill JL, Siahpush M, Tibbits MK, Wichman C (June 2019). "Ecological model of school engagement and attention-deficit/hyperactivity disorder in school-aged children". European Child & Adolescent Psychiatry. 28 (6): 795–805. doi:10.1007/s00787-018-1248-3. PMID 30390147. S2CID 53263217.
Williams AE, Giust JM, Kronenberger WG, Dunn DW (2016). "Epilepsy and attention-deficit hyperactivity disorder: links, risks, and challenges". Neuropsychiatric Disease and Treatment. 12: 287–296. doi:10.2147/NDT.S81549. PMC 4755462. PMID 26929624.
Silva RR, Munoz DM, Alpert M (March 1996). "Carbamazepine use in children and adolescents with features of attention-deficit hyperactivity disorder: a meta-analysis". Journal of the American Academy of Child and Adolescent Psychiatry. 35 (3): 352–358. doi:10.1097/00004583-199603000-00017. PMID 8714324.
Instanes JT, Klungsøyr K, Halmøy A, Fasmer OB, Haavik J (February 2018). "Adult ADHD and Comorbid Somatic Disease: A Systematic Literature Review". Journal of Attention Disorders (Systematic Review). 22 (3): 203–228. doi:10.1177/1087054716669589. PMC 5987989. PMID 27664125.
Gaur S (May 2022). "The Association between ADHD and Celiac Disease in Children". Children. 9 (6). MDPI: 781. doi:10.3390/children9060781. PMC 9221618. PMID 35740718.
Hsu TW, Chen MH, Chu CS, Tsai SJ, Bai YM, Su TP, et al. (May 2022). "Attention deficit hyperactivity disorder and risk of migraine: A nationwide longitudinal study". Headache. 62 (5): 634–641. doi:10.1111/head.14306. PMID 35524451. S2CID 248553863.
Salem H, Vivas D, Cao F, Kazimi IF, Teixeira AL, Zeni CP (March 2018). "ADHD is associated with migraine: a systematic review and meta-analysis". European Child & Adolescent Psychiatry. 27 (3). Springer Science and Business Media LLC: 267–277. doi:10.1007/s00787-017-1045-4. PMID 28905127. S2CID 3949012.
Pan PY, Jonsson U, Şahpazoğlu Çakmak SS, Häge A, Hohmann S, Nobel Norrman H, et al. (January 2022). "Headache in ADHD as comorbidity and a side effect of medications: a systematic review and meta-analysis". Psychological Medicine. 52 (1). Cambridge University Press: 14–25. doi:10.1017/s0033291721004141. PMC 8711104. PMID 34635194.
Cannon Homaei S, Barone H, Kleppe R, Betari N, Reif A, Haavik J (January 2022). "ADHD symptoms in neurometabolic diseases: Underlying mechanisms and clinical implications". Neuroscience and Biobehavioral Reviews. 132: 838–856. doi:10.1016/j.neubiorev.2021.11.012. PMID 34774900. S2CID 243983688.
Brunkhorst-Kanaan N, Libutzki B, Reif A, Larsson H, McNeill RV, Kittel-Schneider S (June 2021). "ADHD and accidents over the life span - A systematic review". Neuroscience and Biobehavioral Reviews. 125. Elsevier: 582–591. doi:10.1016/j.neubiorev.2021.02.002. PMID 33582234. S2CID 231885131.
Vaa T (January 2014). "ADHD and relative risk of accidents in road traffic: a meta-analysis". Accident Analysis and Prevention. 62. Elsevier: 415–425. doi:10.1016/j.aap.2013.10.003. hdl:11250/2603537. PMID 24238842.
González-Bueso V, Santamaría JJ, Fernández D, Merino L, Montero E, Ribas J (2018). "Association between Internet Gaming Disorder or Pathological Video-Game Use and Comorbid Psychopathology: A Comprehensive Review". International Journal of Environmental Research and Public Health. 15 (4). MDPI: 668. doi:10.3390/ijerph15040668. PMC 5923710. PMID 29614059.
Beyens I, Valkenburg PM, Piotrowski JT (2 October 2018). "Screen media use and ADHD-related behaviors: Four decades of research". PNAS USA. 115 (40). National Academy of Sciences: 9875–9881. Bibcode:2018PNAS..115.9875B. doi:10.1073/pnas.1611611114. PMC 6176582. PMID 30275318.
Li Y, Li G, Liu L, Wu H (2020). "Correlations between mobile phone addiction and anxiety, depression, impulsivity, and poor sleep quality among college students: A systematic review and meta-analysis". Journal of Behavioral Addictions. 9 (3). Akadémiai Kiadó: 551–571. doi:10.1556/2006.2020.00057. PMC 8943681. PMID 32903205.
Dullur P, Krishnan V, Diaz AM (2021). "A systematic review on the intersection of attention-deficit hyperactivity disorder and gaming disorder". Journal of Psychiatric Research. 133. Elsevier: 212–222. doi:10.1016/j.jpsychires.2020.12.026. PMID 33360866. S2CID 229687229.
Gao X, Zhang M, Yang Z, Wen M, Huang H, Zheng R, et al. (2021). "Structural and Functional Brain Abnormalities in Internet Gaming Disorder and Attention-Deficit/Hyperactivity Disorder: A Comparative Meta-Analysis". Frontiers in Psychiatry. 12. Frontiers Media: 679437. doi:10.3389/fpsyt.2021.679437. PMC 8281314. PMID 34276447.
Eirich R, McArthur BA, Anhorn C, McGuinness C, Christakis DA, Madigan S (2022). "Association of Screen Time With Internalizing and Externalizing Behavior Problems in Children 12 Years or Younger: A Systematic Review and Meta-analysis". JAMA Psychiatry. 79 (5). American Medical Association: 393–405. doi:10.1001/jamapsychiatry.2022.0155. PMC 8928099. PMID 35293954.
Santos RM, Mendes CG, Miranda DM, Romano-Silva MA (2022). "The Association between Screen Time and Attention in Children: A Systematic Review". Developmental Neuropsychology. 47 (4). Routledge: 175–192. doi:10.1080/87565641.2022.2064863. PMID 35430923. S2CID 248228233.
Werling AM, Kuzhippallil S, Emery S, Walitza S, Drechsler R (2022). "Problematic use of digital media in children and adolescents with a diagnosis of attention-deficit/hyperactivity disorder compared to controls. A meta-analysis". Journal of Behavioral Addictions. 11 (2). Akadémiai Kiadó: 305–325. doi:10.1556/2006.2022.00007. PMC 9295226. PMID 35567763.
Thorell LB, Burén J, Wiman JS, Sandberg D, Nutley SB (2022). "Longitudinal associations between digital media use and ADHD symptoms in children and adolescents: a systematic literature review". European Child & Adolescent Psychiatry. 33 (8). Springer Science+Business Media: 2503–2526. doi:10.1007/s00787-022-02130-3. PMC 11272698. PMID 36562860.
Liu H, Chen X, Huang M, Yu X, Gan Y, Wang J, et al. (2023). "Screen time and childhood attention deficit hyperactivity disorder: a meta-analysis". Reviews on Environmental Health. De Gruyter. doi:10.1515/reveh-2022-0262. PMID 37163581. S2CID 258591184.
Augner C, Vlasak T, Barth A (2023). "The relationship between problematic internet use and attention deficit, hyperactivity and impulsivity: A meta-analysis". Journal of Psychiatric Research. 168. Elsevier: 1–12. doi:10.1016/j.jpsychires.2023.10.032. PMID 37866293. S2CID 264190691.
Koncz P, Demetrovics Z, Takacs ZK, Griffiths MD, Nagy T, Király O (2023). "The emerging evidence on the association between symptoms of ADHD and gaming disorder: A systematic review and meta-analysis". Clinical Psychology Review. 106. Elsevier: 102343. doi:10.1016/j.cpr.2023.102343. hdl:20.500.11820/91f22260-b579-4f0b-9e81-adc063f27e9e. PMID 37883910.
Balazs J, Kereszteny A (March 2017). "Attention-deficit/hyperactivity disorder and suicide: A systematic review". World Journal of Psychiatry. 7 (1): 44–59. doi:10.5498/wjp.v7.i1.44. PMC 5371172. PMID 28401048.
Garas P, Balazs J (21 December 2020). "Long-Term Suicide Risk of Children and Adolescents With Attention Deficit and Hyperactivity Disorder-A Systematic Review". Frontiers in Psychiatry. 11: 557909. doi:10.3389/fpsyt.2020.557909. PMC 7779592. PMID 33408650. 557909.
Septier M, Stordeur C, Zhang J, Delorme R, Cortese S (August 2019). "Association between suicidal spectrum behaviors and Attention-Deficit/Hyperactivity Disorder: A systematic review and meta-analysis". Neuroscience and Biobehavioral Reviews. 103: 109–118. doi:10.1016/j.neubiorev.2019.05.022. PMID 31129238. S2CID 162184004. Archived from the original on 4 November 2021. Retrieved 7 December 2021.
Beauchaine TP, Ben-David I, Bos M (September 2020). "ADHD, financial distress, and suicide in adulthood: A population study". Science Advances. 6 (40): eaba1551. Bibcode:2020SciA....6.1551B. doi:10.1126/sciadv.aba1551. PMC 7527218. PMID 32998893. eaba1551.
Biederman J (June 2005). "Attention-deficit/hyperactivity disorder: a selective overview". Biological Psychiatry. 57 (11): 1215–1220. doi:10.1016/j.biopsych.2004.10.020. PMID 15949990. S2CID 23671547.
Faraone SV, Larsson H (April 2019). "Genetics of attention deficit hyperactivity disorder". Molecular Psychiatry. 24 (4): 562–575. doi:10.1038/s41380-018-0070-0. PMC 6477889. PMID 29892054. S2CID 47016805.
Nikolas MA, Burt SA (February 2010). "Genetic and environmental influences on ADHD symptom dimensions of inattention and hyperactivity: a meta-analysis". Journal of Abnormal Psychology. 119 (1): 1–17. doi:10.1037/a0018010. PMID 20141238.
Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. (January 2019). "Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder". Nature Genetics. 51 (1): 63–75. doi:10.1038/s41588-018-0269-7. hdl:10023/20827. PMC 6481311. PMID 30478444.
Grimm O, Kranz TM, Reif A (February 2020). "Genetics of ADHD: What Should the Clinician Know?". Current Psychiatry Reports. 22 (4): 18. doi:10.1007/s11920-020-1141-x. PMC 7046577. PMID 32108282.
Cederlöf M, Ohlsson Gotby A, Larsson H, Serlachius E, Boman M, Långström N, et al. (January 2014). "Klinefelter syndrome and risk of psychosis, autism and ADHD". Journal of Psychiatric Research. 48 (1): 128–130. doi:10.1016/j.jpsychires.2013.10.001. PMID 24139812.
Biederman J, Spencer T (November 1999). "Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder". Biological Psychiatry. 46 (9). Elsevier: 1234–1242. doi:10.1016/S0006-3223(99)00192-4. PMID 10560028. S2CID 45497168.
Faraone SV, Larsson H (April 2019). "Genetics of attention deficit hyperactivity disorder". Molecular Psychiatry. 24 (4). Nature Research: 562–575. doi:10.1038/s41380-018-0070-0. PMC 6477889. PMID 29892054.
Baron-Cohen S (June 2002). "The extreme male brain theory of autism". Trends in Cognitive Sciences. 6 (6). Elsevier: 248–254. doi:10.1016/S1364-6613(02)01904-6. PMID 12039606. S2CID 8098723. Archived from the original on 3 July 2013. Retrieved 9 July 2020.
Esteller-Cucala P, Maceda I, Børglum AD, Demontis D, Faraone SV, Cormand B, et al. (May 2020). "Genomic analysis of the natural history of attention-deficit/hyperactivity disorder using Neanderthal and ancient Homo sapiens samples". Scientific Reports. 10 (1): 8622. Bibcode:2020NatSR..10.8622E. doi:10.1038/s41598-020-65322-4. PMC 7248073. PMID 32451437.
Faraone SV, Larsson H (April 2019). "Genetics of attention deficit hyperactivity disorder". Molecular Psychiatry. 24 (4). Springer Science and Business Media LLC: 562–575. doi:10.1038/s41380-018-0070-0. PMC 6477889. PMID 29892054.
Skoglund C, Chen Q, D'Onofrio BM, Lichtenstein P, Larsson H (January 2014). "Familial confounding of the association between maternal smoking during pregnancy and ADHD in offspring". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 55 (1): 61–68. doi:10.1111/jcpp.12124. PMC 4217138. PMID 25359172.
Obel C, Zhu JL, Olsen J, Breining S, Li J, Grønborg TK, et al. (April 2016). "The risk of attention deficit hyperactivity disorder in children exposed to maternal smoking during pregnancy - a re-examination using a sibling design". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 57 (4): 532–537. doi:10.1111/jcpp.12478. PMID 26511313.
Biederman J (June 2005). "Attention-deficit/hyperactivity disorder: a selective overview". Biological Psychiatry. 57 (11): 1215–1220. doi:10.1016/j.biopsych.2004.10.020. PMID 15949990.
Hinshaw SP (May 2018). "Attention Deficit Hyperactivity Disorder (ADHD): Controversy, Developmental Mechanisms, and Multiple Levels of Analysis". Annual Review of Clinical Psychology. 14 (1): 291–316. doi:10.1146/annurev-clinpsy-050817-084917. PMID 29220204.
Kebir O, Joober R (December 2011). "Neuropsychological endophenotypes in attention-deficit/hyperactivity disorder: a review of genetic association studies". European Archives of Psychiatry and Clinical Neuroscience. 261 (8): 583–594. doi:10.1007/s00406-011-0207-5. PMID 21409419. S2CID 21383749.
Berry MD (January 2007). "The potential of trace amines and their receptors for treating neurological and psychiatric diseases". Reviews on Recent Clinical Trials. 2 (1): 3–19. CiteSeerX 10.1.1.329.563. doi:10.2174/157488707779318107. PMID 18473983. Although there is little direct evidence, changes in trace amines, in particular PE, have been identified as a possible factor for the onset of attention deficit/hyperactivity disorder (ADHD). ... Further, amphetamines, which have clinical utility in ADHD, are good ligands at trace amine receptors. Of possible relevance in this aspect is modafanil, which has shown beneficial effects in ADHD patients and has been reported to enhance the activity of PE at TAAR1. Conversely, methylphenidate, ...showed poor efficacy at the TAAR1 receptor. In this respect it is worth noting that the enhancement of functioning at TAAR1 seen with modafanil was not a result of a direct interaction with TAAR1.
Sotnikova TD, Caron MG, Gainetdinov RR (August 2009). "Trace amine-associated receptors as emerging therapeutic targets". Molecular Pharmacology. 76 (2): 229–235. doi:10.1124/mol.109.055970. PMC 2713119. PMID 19389919.
Gizer IR, Ficks C, Waldman ID (July 2009). "Candidate gene studies of ADHD: a meta-analytic review". Human Genetics. 126 (1): 51–90. doi:10.1007/s00439-009-0694-x. PMID 19506906. S2CID 166017.
Arcos-Burgos M, Muenke M (November 2010). "Toward a better understanding of ADHD: LPHN3 gene variants and the susceptibility to develop ADHD". Attention Deficit and Hyperactivity Disorders. 2 (3): 139–147. doi:10.1007/s12402-010-0030-2. PMC 3280610. PMID 21432600.
Nikolaidis A, Gray JR (June 2010). "ADHD and the DRD4 exon III 7-repeat polymorphism: an international meta-analysis". Social Cognitive and Affective Neuroscience. 5 (2–3): 188–193. doi:10.1093/scan/nsp049. PMC 2894686. PMID 20019071.
Zayats T, Neale BM (12 February 2020). "Recent advances in understanding of attention deficit hyperactivity disorder (ADHD): how genetics are shaping our conceptualization of this disorder". F1000Research. 8: 2060. doi:10.12688/f1000research.18959.2. PMC 6896240. PMID 31824658.
Sonuga-Barke EJ, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M, et al. (March 2013). "Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments". The American Journal of Psychiatry. 170 (3): 275–289. doi:10.1176/appi.ajp.2012.12070991. eISSN 1535-7228. LCCN 22024537. OCLC 1480183. PMID 23360949. S2CID 434310. Free fatty acid supplementation and artificial food color exclusions appear to have beneficial effects on ADHD symptoms, although the effect of the former are small and those of the latter may be limited to ADHD patients with food sensitivities...
Burger PH, Goecke TW, Fasching PA, Moll G, Heinrich H, Beckmann MW, et al. (September 2011). "[How does maternal alcohol consumption during pregnancy affect the development of attention deficit/hyperactivity syndrome in the child]" [How does maternal alcohol consumption during pregnancy affect the development of attention deficit/hyperactivity syndrome in the child]. Fortschritte der Neurologie-Psychiatrie (Review) (in German). 79 (9): 500–506. doi:10.1055/s-0031-1273360. PMID 21739408. S2CID 140766296.
Eubig PA, Aguiar A, Schantz SL (December 2010). "Lead and PCBs as risk factors for attention deficit/hyperactivity disorder". Environmental Health Perspectives (Review. Research Support, N.I.H., Extramural. Research Support, U.S. Gov't, Non-P.H.S.). 118 (12): 1654–1667. doi:10.1289/ehp.0901852. PMC 3002184. PMID 20829149.
de Cock M, Maas YG, van de Bor M (August 2012). "Does perinatal exposure to endocrine disruptors induce autism spectrum and attention deficit hyperactivity disorders? Review". Acta Paediatrica (Review. Research Support, Non-U.S. Gov't). 101 (8): 811–818. doi:10.1111/j.1651-2227.2012.02693.x. PMID 22458970. S2CID 41748237.
Abbott LC, Winzer-Serhan UH (April 2012). "Smoking during pregnancy: lessons learned from epidemiological studies and experimental studies using animal models". Critical Reviews in Toxicology (Review). 42 (4): 279–303. doi:10.3109/10408444.2012.658506. PMID 22394313. S2CID 38886526.
Tiesler CM, Heinrich J (October 2014). "Prenatal nicotine exposure and child behavioural problems". European Child & Adolescent Psychiatry. 23 (10): 913–929. doi:10.1007/s00787-014-0615-y. PMC 4186967. PMID 25241028.
Botting N, Powls A, Cooke RW, Marlow N (November 1997). "Attention deficit hyperactivity disorders and other psychiatric outcomes in very low birthweight children at 12 years". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 38 (8): 931–941. doi:10.1111/j.1469-7610.1997.tb01612.x. PMID 9413793. Archived from the original on 17 May 2022. Retrieved 22 March 2022.
Thapar A, Cooper M, Jefferies R, Stergiakouli E (March 2012). "What causes attention deficit hyperactivity disorder?". Archives of Disease in Childhood (Review. Research Support, Non-U.S. Gov't). 97 (3): 260–265. doi:10.1136/archdischild-2011-300482. PMC 3927422. PMID 21903599.
Millichap JG (February 2008). "Etiologic classification of attention-deficit/hyperactivity disorder". Pediatrics (Review). 121 (2): e358–e365. doi:10.1542/peds.2007-1332. PMID 18245408. S2CID 24339363.
Eme R (April 2012). "ADHD: an integration with pediatric traumatic brain injury". Expert Review of Neurotherapeutics (Review). 12 (4): 475–483. doi:10.1586/ern.12.15. PMID 22449218. S2CID 35718630.
Millichap JG, Yee MM (February 2012). "The diet factor in attention-deficit/hyperactivity disorder". Pediatrics. 129 (2): 330–337. doi:10.1542/peds.2011-2199. PMID 22232312. S2CID 14925322. Archived from the original on 11 September 2015.
Nigg JT, Holton K (October 2014). "Restriction and elimination diets in ADHD treatment". Child and Adolescent Psychiatric Clinics of North America (Review). 23 (4): 937–953. doi:10.1016/j.chc.2014.05.010. PMC 4322780. PMID 25220094. an elimination diet produces a small aggregate effect but may have greater benefit among some children. Very few studies enable proper evaluation of the likelihood of response in children with ADHD who are not already preselected based on prior diet response.
Chandler DJ, Waterhouse BD, Gao WJ (May 2014). "New perspectives on catecholaminergic regulation of executive circuits: evidence for independent modulation of prefrontal functions by midbrain dopaminergic and noradrenergic neurons". Frontiers in Neural Circuits. 8: 53. doi:10.3389/fncir.2014.00053. PMC 4033238. PMID 24904299.
Castellanos FX, Proal E (January 2012). "Large-scale brain systems in ADHD: beyond the prefrontal-striatal model". Trends in Cognitive Sciences. 16 (1): 17–26. doi:10.1016/j.tics.2011.11.007. PMC 3272832. PMID 22169776. Recent conceptualizations of ADHD have taken seriously the distributed nature of neuronal processing. Most of the candidate networks have focused on prefrontal-striatal-cerebellar circuits, although other posterior regions are also being proposed.
Cortese S, Kelly C, Chabernaud C, Proal E, Di Martino A, Milham MP, et al. (October 2012). "Toward systems neuroscience of ADHD: a meta-analysis of 55 fMRI studies". The American Journal of Psychiatry. 169 (10): 1038–1055. doi:10.1176/appi.ajp.2012.11101521. eISSN 1535-7228. LCCN 22024537. OCLC 1480183. PMC 3879048. PMID 22983386.
Krain AL, Castellanos FX (August 2006). "Brain development and ADHD". Clinical Psychology Review. 26 (4): 433–444. doi:10.1016/j.cpr.2006.01.005. PMID 16480802.
Hoogman M, Bralten J, Hibar DP, Mennes M, Zwiers MP, Schweren LS, et al. (April 2017). "Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: a cross-sectional mega-analysis". The Lancet. Psychiatry. 4 (4): 310–319. doi:10.1016/S2215-0366(17)30049-4. PMC 5933934. PMID 28219628.
Douglas PK, Gutman B, Anderson A, Larios C, Lawrence KE, Narr K, et al. (February 2018). "Hemispheric brain asymmetry differences in youths with attention-deficit/hyperactivity disorder". NeuroImage. Clinical. 18: 744–752. doi:10.1016/j.nicl.2018.02.020. PMC 5988460. PMID 29876263.
Damiani S, Tarchi L, Scalabrini A, Marini S, Provenzani U, Rocchetti M, et al. (April 2021). "Beneath the surface: hyper-connectivity between caudate and salience regions in ADHD fMRI at rest". European Child & Adolescent Psychiatry. 30 (4): 619–631. doi:10.1007/s00787-020-01545-0. hdl:2318/1755224. PMID 32385695. S2CID 218540328.
Tarchi L, Damiani S, Fantoni T, Pisano T, Castellini G, Politi P, et al. (December 2022). "Centrality and interhemispheric coordination are related to different clinical/behavioral factors in attention deficit/hyperactivity disorder: a resting-state fMRI study". Brain Imaging and Behavior. 16 (6): 2526–2542. doi:10.1007/s11682-022-00708-8. PMC 9712307. PMID 35859076.
Mohamed SM, Börger NA, Geuze RH, van der Meere JJ (2015). "Brain lateralization and self-reported symptoms of ADHD in a population sample of adults: a dimensional approach". Frontiers in Psychology. 6: 1418. doi:10.3389/fpsyg.2015.01418. PMC 4585266. PMID 26441789.
Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U (March 2012). "Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis". The American Journal of Psychiatry. 169 (3): 264–272. doi:10.1176/appi.ajp.2011.11060940. eISSN 1535-7228. hdl:11577/2482784. LCCN 22024537. OCLC 1480183. PMID 22294258.
Bidwell LC, McClernon FJ, Kollins SH (August 2011). "Cognitive enhancers for the treatment of ADHD". Pharmacology, Biochemistry, and Behavior. 99 (2): 262–274. doi:10.1016/j.pbb.2011.05.002. PMC 3353150. PMID 21596055.
Cortese S (September 2012). "The neurobiology and genetics of Attention-Deficit/Hyperactivity Disorder (ADHD): what every clinician should know". European Journal of Paediatric Neurology. 16 (5): 422–433. doi:10.1016/j.ejpn.2012.01.009. PMID 22306277.
Lesch KP, Merker S, Reif A, Novak M (June 2013). "Dances with black widow spiders: dysregulation of glutamate signalling enters centre stage in ADHD". European Neuropsychopharmacology. 23 (6): 479–491. doi:10.1016/j.euroneuro.2012.07.013. PMID 22939004. S2CID 14701654.
Skodzik T, Holling H, Pedersen A (February 2017). "Long-Term Memory Performance in Adult ADHD". Journal of Attention Disorders. 21 (4): 267–283. doi:10.1177/1087054713510561. PMID 24232170. S2CID 27070077.
Modesto-Lowe V, Chaplin M, Soovajian V, Meyer A (July 2013). "Are motivation deficits underestimated in patients with ADHD? A review of the literature". Postgraduate Medicine. 125 (4): 47–52. doi:10.3810/pgm.2013.07.2677. PMID 23933893. S2CID 24817804. Behavioral studies show altered processing of reinforcement and incentives in children with ADHD. These children respond more impulsively to rewards and choose small, immediate rewards over larger, delayed incentives. Interestingly, a high intensity of reinforcement is effective in improving task performance in children with ADHD. Pharmacotherapy may also improve task persistence in these children. ... Previous studies suggest that a clinical approach using interventions to improve motivational processes in patients with ADHD may improve outcomes as children with ADHD transition into adolescence and adulthood.
Peterson BS, Trampush J, Brown M, Maglione M, Bolshakova M, Rozelle M, et al. (April 2024). "Tools for the Diagnosis of ADHD in Children and Adolescents: A Systematic Review". Pediatrics. 153 (4). doi:10.1542/peds.2024-065854. PMID 38523599.
Peterson BS, Trampush J, Maglione M, Bolshakova M, Brown M, Rozelle M, et al. (2024). "ADHD Diagnosis and Treatment in Children and Adolescents". effectivehealthcare.ahrq.gov. doi:10.23970/ahrqepccer267. PMID 38657097. Retrieved 22 June 2024.
Al Rahbi HA, Al-Sabri RM, Chitme HR (April 2014). "Interventions by pharmacists in out-patient pharmaceutical care". Saudi Pharmaceutical Journal. 22 (2): 101–106. doi:10.1016/j.jsps.2013.04.001. PMC 3950532. PMID 24648820.
Adamou M, Fullen T, Jones SL (25 August 2020). "EEG for Diagnosis of Adult ADHD: A Systematic Review With Narrative Analysis". Frontiers in Psychiatry. 11: 871. doi:10.3389/fpsyt.2020.00871. PMC 7477352. PMID 33192633.
Lenartowicz A, Loo SK (November 2014). "Use of EEG to diagnose ADHD". Current Psychiatry Reports. 16 (11): 498. doi:10.1007/s11920-014-0498-0. PMC 4633088. PMID 25234074.
Singh I (December 2008). "Beyond polemics: science and ethics of ADHD". Nature Reviews. Neuroscience. 9 (12): 957–964. doi:10.1038/nrn2514. PMID 19020513. S2CID 205504587.
Berger I (September 2011). "Diagnosis of attention deficit hyperactivity disorder: much ado about something" (PDF). The Israel Medical Association Journal. 13 (9): 571–574. PMID 21991721. Archived (PDF) from the original on 28 July 2020. Retrieved 23 May 2013.
Steinau S (2013). "Diagnostic Criteria in Attention Deficit Hyperactivity Disorder - Changes in DSM 5". Frontiers in Psychiatry. 4: 49. doi:10.3389/fpsyt.2013.00049. PMC 3667245. PMID 23755024.
Parens E, Johnston J (January 2009). "Facts, values, and attention-deficit hyperactivity disorder (ADHD): an update on the controversies". Child and Adolescent Psychiatry and Mental Health. 3 (1): 1. doi:10.1186/1753-2000-3-1. PMC 2637252. PMID 19152690.
Song P, Zha M, Yang Q, Zhang Y, Li X, Rudan I (February 2021). "The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis". Journal of Global Health. 11. International Global Health Society: 04009. doi:10.7189/jogh.11.04009. eISSN 2047-2986. OCLC 751737736. PMC 7916320. PMID 33692893.
Culpepper L, Mattingly G (2010). "Challenges in identifying and managing attention-deficit/hyperactivity disorder in adults in the primary care setting: a review of the literature". Primary Care Companion to the Journal of Clinical Psychiatry. 12 (6): PCC.10r00951. doi:10.4088/PCC.10r00951pur. PMC 3067998. PMID 21494335.
Gentile JP, Atiq R, Gillig PM (August 2006). "Adult ADHD: Diagnosis, Differential Diagnosis, and Medication Management". Psychiatry. 3 (8): 25–30. PMC 2957278. PMID 20963192. likelihood that the adult with ADHD has developed coping mechanisms to compensate for his or her impairment
Mohr-Jensen C, Steinhausen HC (August 2016). "A meta-analysis and systematic review of the risks associated with childhood attention-deficit hyperactivity disorder on long-term outcome of arrests, convictions, and incarcerations". Clinical Psychology Review. 48: 32–42. doi:10.1016/j.cpr.2016.05.002. PMID 27390061.
Asherson P, Agnew-Blais J (April 2019). "Annual Research Review: Does late-onset attention-deficit/hyperactivity disorder exist?". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 60 (4): 333–352. doi:10.1111/jcpp.13020. PMID 30843223.
Owens JA (October 2008). "Sleep disorders and attention-deficit/hyperactivity disorder". Current Psychiatry Reports. 10 (5): 439–444. doi:10.1007/s11920-008-0070-x. PMID 18803919. S2CID 23624443.
Walters AS, Silvestri R, Zucconi M, Chandrashekariah R, Konofal E (December 2008). "Review of the possible relationship and hypothetical links between attention deficit hyperactivity disorder (ADHD) and the simple sleep related movement disorders, parasomnias, hypersomnias, and circadian rhythm disorders". Journal of Clinical Sleep Medicine. 4 (6): 591–600. doi:10.5664/jcsm.27356. PMC 2603539. PMID 19110891.
Lal C, Strange C, Bachman D (June 2012). "Neurocognitive impairment in obstructive sleep apnea". Chest. 141 (6): 1601–1610. doi:10.1378/chest.11-2214. PMID 22670023.
Peterson BS, Trampush J, Maglione M, Bolshakova M, Rozelle M, Miles J, et al. (April 2024). "Treatments for ADHD in Children and Adolescents: A Systematic Review". Pediatrics. 153 (4). doi:10.1542/peds.2024-065787. PMID 38523592.
Wigal SB (2009). "Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults". CNS Drugs. 23 (Suppl 1): 21–31. doi:10.2165/00023210-200923000-00004. PMID 19621975. S2CID 11340058.
Mayes R, Bagwell C, Erkulwater J (2008). "ADHD and the rise in stimulant use among children". Harvard Review of Psychiatry. 16 (3): 151–166. doi:10.1080/10673220802167782. PMID 18569037. S2CID 18481191.
Coghill DR, Banaschewski T, Soutullo C, Cottingham MG, Zuddas A (November 2017). "Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder". European Child & Adolescent Psychiatry. 26 (11): 1283–1307. doi:10.1007/s00787-017-0986-y. PMC 5656703. PMID 28429134. Text was copied from this source, which is available under a Creative Commons Attribution 4.0 International License "CC BY 4.0 Deed | Attribution 4.0 International | Creative Commons". Archived from the original on 16 October 2017. Retrieved 22 October 2022.{{cite web}}: CS1 maint: bot: original URL status unknown (link).
Luan R, Mu Z, Yue F, He S (2017). "Efficacy and Tolerability of Different Interventions in Children and Adolescents with Attention Deficit Hyperactivity Disorder". Frontiers in Psychiatry. 8: 229. doi:10.3389/fpsyt.2017.00229. PMC 5694170. PMID 29180967.
Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. (September 2018). "Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis". The Lancet. Psychiatry. 5 (9): 727–738. doi:10.1016/S2215-0366(18)30269-4. PMC 6109107. PMID 30097390.
Fabiano GA, Pelham WE, Coles EK, Gnagy EM, Chronis-Tuscano A, O'Connor BC (March 2009). "A meta-analysis of behavioral treatments for attention-deficit/hyperactivity disorder". Clinical Psychology Review. 29 (2): 129–140. doi:10.1016/j.cpr.2008.11.001. PMID 19131150. there is strong and consistent evidence that behavioral treatments are effective for treating ADHD.
Kratochvil CJ, Vaughan BS, Barker A, Corr L, Wheeler A, Madaan V (March 2009). "Review of pediatric attention deficit/hyperactivity disorder for the general psychiatrist". The Psychiatric Clinics of North America. 32 (1): 39–56. doi:10.1016/j.psc.2008.10.001. PMID 19248915.
Lopez PL, Torrente FM, Ciapponi A, Lischinsky AG, Cetkovich-Bakmas M, Rojas JI, et al. (March 2018). "Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults". The Cochrane Database of Systematic Reviews. 2018 (3): CD010840. doi:10.1002/14651858.CD010840.pub2. PMC 6494390. PMID 29566425.
Evans SW, Owens JS, Bunford N (2014). "Evidence-based psychosocial treatments for children and adolescents with attention-deficit/hyperactivity disorder". Journal of Clinical Child and Adolescent Psychology. 43 (4): 527–551. doi:10.1080/15374416.2013.850700. PMC 4025987. PMID 24245813.
Van Doren J, Arns M, Heinrich H, Vollebregt MA, Strehl U, K Loo S (March 2019). "Sustained effects of neurofeedback in ADHD: a systematic review and meta-analysis". European Child & Adolescent Psychiatry. 28 (3). Springer Science and Business Media LLC: 293–305. doi:10.1007/s00787-018-1121-4. PMC 6404655. PMID 29445867.
Enriquez-Geppert S, Smit D, Pimenta MG, Arns M (May 2019). "Neurofeedback as a Treatment Intervention in ADHD: Current Evidence and Practice". Current Psychiatry Reports. 21 (6). Springer Science and Business Media LLC: 46. doi:10.1007/s11920-019-1021-4. PMC 6538574. PMID 31139966.
Daley D, Van Der Oord S, Ferrin M, Cortese S, Danckaerts M, Doepfner M, et al. (September 2018). "Practitioner Review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 59 (9). Wiley: 932–947. doi:10.1111/jcpp.12825. hdl:11343/293788. PMID 29083042. S2CID 31044370. Archived from the original on 25 September 2017. Retrieved 21 November 2018.
Bjornstad G, Montgomery P (April 2005). Bjornstad GJ (ed.). "Family therapy for attention-deficit disorder or attention-deficit/hyperactivity disorder in children and adolescents". The Cochrane Database of Systematic Reviews (2): CD005042. doi:10.1002/14651858.CD005042.pub2. PMID 15846741. S2CID 27339381.
Mikami AY (June 2010). "The importance of friendship for youth with attention-deficit/hyperactivity disorder". Clinical Child and Family Psychology Review. 13 (2): 181–198. doi:10.1007/s10567-010-0067-y. PMC 2921569. PMID 20490677.
Kollins SH, DeLoss DJ, Cañadas E, Lutz J, Findling RL, Keefe RS, et al. (April 2020). "A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial". The Lancet. Digital Health. 2 (4): e168–e178. doi:10.1016/S2589-7500(20)30017-0. PMID 33334505.
Kollins SH, Childress A, Heusser AC, Lutz J (March 2021). "Effectiveness of a digital therapeutic as adjunct to treatment with medication in pediatric ADHD". npj Digital Medicine. 4 (1): 58. doi:10.1038/s41746-021-00429-0. PMC 7997870. PMID 33772095.
Devilbiss DM, Berridge CW (October 2008). "Cognition-enhancing doses of methylphenidate preferentially increase prefrontal cortex neuronal responsiveness". Biological Psychiatry. 64 (7): 626–635. doi:10.1016/j.biopsych.2008.04.037. PMC 2603602. PMID 18585681.
Schulz KP, Fan J, Bédard AC, Clerkin SM, Ivanov I, Tang CY, et al. (September 2012). "Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder". Archives of General Psychiatry. 69 (9): 952–961. doi:10.1001/archgenpsychiatry.2011.2053. PMID 22945622.
Koda K, Ago Y, Cong Y, Kita Y, Takuma K, Matsuda T (July 2010). "Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice". Journal of Neurochemistry. 114 (1): 259–270. doi:10.1111/j.1471-4159.2010.06750.x. PMID 20403082.
Dodson WW (May 2005). "Pharmacotherapy of adult ADHD". Journal of Clinical Psychology. 61 (5): 589–606. doi:10.1002/jclp.20122. PMID 15723384. For example, pseudoephedrine and ephedrine ... have no detectable effects on the symptoms of ADHD.
Storebø OJ, Storm MR, Pereira Ribeiro J, Skoog M, Groth C, Callesen HE, et al. (March 2023). "Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)". The Cochrane Database of Systematic Reviews. 2023 (3): CD009885. doi:10.1002/14651858.CD009885.pub3. PMC 10042435. PMID 36971690.
Ruiz-Goikoetxea M, Cortese S, Aznarez-Sanado M, Magallón S, Alvarez Zallo N, Luis EO, et al. (January 2018). "Risk of unintentional injuries in children and adolescents with ADHD and the impact of ADHD medications: A systematic review and meta-analysis". Neuroscience and Biobehavioral Reviews. 84: 63–71. doi:10.1016/j.neubiorev.2017.11.007. hdl:10171/45012. PMID 29162520.
Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K (February 2013). "Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects". JAMA Psychiatry. 70 (2): 185–198. doi:10.1001/jamapsychiatry.2013.277. PMID 23247506.
Spencer TJ, Brown A, Seidman LJ, Valera EM, Makris N, Lomedico A, et al. (September 2013). "Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies". The Journal of Clinical Psychiatry. 74 (9): 902–917. doi:10.4088/JCP.12r08287. PMC 3801446. PMID 24107764.
Frodl T, Skokauskas N (February 2012). "Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects". Acta Psychiatrica Scandinavica. 125 (2): 114–126. doi:10.1111/j.1600-0447.2011.01786.x. PMID 22118249. S2CID 25954331. Basal ganglia regions like the right globus pallidus, the right putamen, and the nucleus caudatus are structurally affected in children with ADHD. These changes and alterations in limbic regions like ACC and amygdala are more pronounced in non-treated populations and seem to diminish over time from child to adulthood. Treatment seems to have positive effects on brain structure.
Stuhec M, Lukić P, Locatelli I (February 2019). "Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis". The Annals of Pharmacotherapy. 53 (2): 121–133. doi:10.1177/1060028018795703. PMID 30117329. S2CID 52019992.
Faraone SV, Biederman J, Roe C (October 2002). "Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis". Journal of Clinical Psychopharmacology. 22 (5): 468–473. doi:10.1097/00004714-200210000-00005. PMID 12352269. S2CID 19726926.
Nam SH, Lim MH, Park TW (April 2022). "Stimulant Induced Movement Disorders in Attention Deficit Hyperactivity Disorder". Soa--Ch'ongsonyon Chongsin Uihak = Journal of Child & Adolescent Psychiatry. 33 (2): 27–34. doi:10.5765/jkacap.210034. PMC 8984208. PMID 35418800.
Storebø OJ, Krogh HB, Ramstad E, Moreira-Maia CR, Holmskov M, Skoog M, et al. (November 2015). "Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials". BMJ. 351: h5203. doi:10.1136/bmj.h5203. PMC 4659414. PMID 26608309.
Banaschewski T, Buitelaar J, Chui CS, Coghill D, Cortese S, Simonoff E, et al. (November 2016). "Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater". Evidence-Based Mental Health. 19 (4): 97–99. doi:10.1136/eb-2016-102461. PMC 10699535. PMID 27935807.
Hoekstra PJ, Buitelaar JK (April 2016). "Is the evidence base of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder flawed?". European Child & Adolescent Psychiatry. 25 (4): 339–340. doi:10.1007/s00787-016-0845-2. PMID 27021055.
Banaschewski T, Gerlach M, Becker K, Holtmann M, Döpfner M, Romanos M (July 2016). "Trust, but verify. The errors and misinterpretations in the Cochrane analysis by O. J. Storebo and colleagues on the efficacy and safety of methylphenidate for the treatment of children and adolescents with ADHD". Zeitschrift Fur Kinder- und Jugendpsychiatrie und Psychotherapie. 44 (4): 307–314. doi:10.1024/1422-4917/a000433. PMID 27270192.
Romanos M, Reif A, Banaschewski T (September 2016). "Methylphenidate for Attention-Deficit/Hyperactivity Disorder". JAMA. 316 (9): 994–995. doi:10.1001/jama.2016.10279. PMID 27599342.
Shaw P (May 2016). "Quantifying the Benefits and Risks of Methylphenidate as Treatment for Childhood Attention-Deficit/Hyperactivity Disorder". JAMA. 315 (18): 1953–1955. doi:10.1001/jama.2016.3427. PMID 27163984.
Gerlach M, Banaschewski T, Coghill D, Rohde LA, Romanos M (March 2017). "What are the benefits of methylphenidate as a treatment for children and adolescents with attention-deficit/hyperactivity disorder?". Attention Deficit and Hyperactivity Disorders. 9 (1): 1–3. doi:10.1007/s12402-017-0220-2. PMID 28168407.
Kooij JJ, Bijlenga D, Salerno L, Jaeschke R, Bitter I, Balázs J, et al. (February 2019). "Updated European Consensus Statement on diagnosis and treatment of adult ADHD". European Psychiatry. 56 (1): 14–34. doi:10.1016/j.eurpsy.2018.11.001. hdl:10651/51910. PMID 30453134.
Boesen K, Paludan-Müller AS, Gøtzsche PC, Jørgensen KJ (February 2022). "Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults". The Cochrane Database of Systematic Reviews. 2022 (2): CD012857. doi:10.1002/14651858.CD012857.pub2. PMC 8869321. PMID 35201607.
Jaeschke RR, Sujkowska E, Sowa-Kućma M (October 2021). "Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review". Psychopharmacology. 238 (10): 2667–2691. doi:10.1007/s00213-021-05946-0. PMC 8455398. PMID 34436651.
Carucci S, Balia C, Gagliano A, Lampis A, Buitelaar JK, Danckaerts M, et al. (January 2021). "Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis". Neuroscience and Biobehavioral Reviews. 120: 509–525. doi:10.1016/j.neubiorev.2020.09.031. hdl:11584/301387. PMID 33080250.
Isfandnia F, El Masri S, Radua J, Rubia K (July 2024). "The effects of chronic administration of stimulant and non-stimulant medications on executive functions in ADHD: A systematic review and meta-analysis". Neuroscience and Biobehavioral Reviews. 162 (105703): 105703. doi:10.1016/j.neubiorev.2024.105703. PMID 38718988.
Wynchank D, Bijlenga D, Beekman AT, Kooij JJ, Penninx BW (October 2017). "Adult Attention-Deficit/Hyperactivity Disorder (ADHD) and Insomnia: an Update of the Literature". Current Psychiatry Reports. 19 (12). Springer Science and Business Media LLC: 98. doi:10.1007/s11920-017-0860-0. PMID 29086065. S2CID 38064951. In varying percentages of trial participants, insomnia is a treatment-emergent adverse effect in triple-bead mixed amphetamine salts (40–45%), dasotraline (35–45%), lisdexamfetamine (10–19%), and extended-release methylphenidate (11%).
Shoptaw SJ, Kao U, Ling W (January 2009). Shoptaw SJ, Ali R (eds.). "Treatment for amphetamine psychosis". The Cochrane Database of Systematic Reviews. 2009 (1): CD003026. doi:10.1002/14651858.CD003026.pub3. PMC 7004251. PMID 19160215. A minority of individuals who use amphetamines develop full-blown psychosis requiring care at emergency departments or psychiatric hospitals. In such cases, symptoms of amphetamine psychosis commonly include paranoid and persecutory delusions as well as auditory and visual hallucinations in the presence of extreme agitation. More common (about 18%) is for frequent amphetamine users to report psychotic symptoms that are sub-clinical and that do not require high-intensity intervention ...
About 5–15% of the users who develop an amphetamine psychosis fail to recover completely (Hofmann 1983) ...
Findings from one trial indicate use of antipsychotic medications effectively resolves symptoms of acute amphetamine psychosis.
Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R (February 2009). "Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children". Pediatrics. 123 (2): 611–616. doi:10.1542/peds.2008-0185. PMID 19171629. S2CID 22391693.
Ashton H, Gallagher P, Moore B (September 2006). "The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorder". Journal of Psychopharmacology. 20 (5): 602–610. doi:10.1177/0269881106061710. PMID 16478756. S2CID 32073083.
Parker J, Wales G, Chalhoub N, Harpin V (September 2013). "The long-term outcomes of interventions for the management of attention-deficit hyperactivity disorder in children and adolescents: a systematic review of randomized controlled trials". Psychology Research and Behavior Management. 6: 87–99. doi:10.2147/PRBM.S49114. PMC 3785407. PMID 24082796. Results suggest there is moderate-to-high-level evidence that combined pharmacological and behavioral interventions, and pharmacological interventions alone can be effective in managing the core ADHD symptoms and academic performance at 14 months. However, the effect size may decrease beyond this period. ... Only one paper examining outcomes beyond 36 months met the review criteria. ... There is high level evidence suggesting that pharmacological treatment can have a major beneficial effect on the core symptoms of ADHD (hyperactivity, inattention, and impulsivity) in approximately 80% of cases compared with placebo controls, in the short term.
Castells X, Blanco-Silvente L, Cunill R, et al. (Cochrane Developmental, Psychosocial and Learning Problems Group) (August 2018). "Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults". The Cochrane Database of Systematic Reviews. 2018 (8): CD007813. doi:10.1002/14651858.CD007813.pub3. PMC 6513464. PMID 30091808.
Kiely B, Adesman A (June 2015). "What we do not know about ADHD… yet". Current Opinion in Pediatrics. 27 (3): 395–404. doi:10.1097/MOP.0000000000000229. PMID 25888152. S2CID 39004402. In addition, a consensus has not been reached on the optimal diagnostic criteria for ADHD. Moreover, the benefits and long-term effects of medical and complementary therapies for this disorder continue to be debated. These gaps in knowledge hinder the ability of clinicians to effectively recognise and treat ADHD.
Hazell P (July 2011). "The challenges to demonstrating long-term effects of psychostimulant treatment for attention-deficit/hyperactivity disorder". Current Opinion in Psychiatry. 24 (4): 286–290. doi:10.1097/YCO.0b013e32834742db. PMID 21519262. S2CID 21998152. Archived from the original on 26 July 2020. Retrieved 19 July 2019.
Kemper AR, Maslow GR, Hill S, Namdari B, Allen Lapointe NM, Goode AP, et al. (January 2018). "Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment in Children and Adolescents". Comparative Effectiveness Reviews (203). Rockville (MD): Agency for Healthcare Research and Quality (US). PMID 29558081. Archived from the original on 17 May 2022. Retrieved 7 November 2021.
Zhang L, Yao H, Li L, Du Rietz E, Andell P, Garcia-Argibay M, et al. (November 2022). "Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis". JAMA Network Open. 5 (11): e2243597. doi:10.1001/jamanetworkopen.2022.43597. PMC 9685490. PMID 36416824.
Kraemer M, Uekermann J, Wiltfang J, Kis B (July 2010). "Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature". Clinical Neuropharmacology. 33 (4): 204–206. doi:10.1097/WNF.0b013e3181e29174. PMID 20571380. S2CID 34956456.
van de Loo-Neus GH, Rommelse N, Buitelaar JK (August 2011). "To stop or not to stop? How long should medication treatment of attention-deficit hyperactivity disorder be extended?". European Neuropsychopharmacology. 21 (8): 584–599. doi:10.1016/j.euroneuro.2011.03.008. PMID 21530185. S2CID 30068561.
Ibrahim K, Donyai P (July 2015). "Drug Holidays From ADHD Medication: International Experience Over the Past Four Decades". Journal of Attention Disorders. 19 (7): 551–568. doi:10.1177/1087054714548035. PMID 25253684. S2CID 19949563. Archived (PDF) from the original on 30 June 2016.
Potter AS, Schaubhut G, Shipman M (December 2014). "Targeting the nicotinic cholinergic system to treat attention-deficit/hyperactivity disorder: rationale and progress to date". CNS Drugs. 28 (12): 1103–1113. doi:10.1007/s40263-014-0208-9. PMC 4487649. PMID 25349138.
Perrotte G, Moreira MM, de Vargas Junior A, Teixeira Filho A, Castaldelli-Maia JM (September 2023). "Effects of Caffeine on Main Symptoms in Children with ADHD: A Systematic Review and Meta-Analysis of Randomized Trials". Brain Sciences. 13 (9): 1304. doi:10.3390/brainsci13091304. PMC 10526204. PMID 37759905.
Turner D (April 2006). "A review of the use of modafinil for attention-deficit hyperactivity disorder". Expert Review of Neurotherapeutics. 6 (4): 455–468. doi:10.1586/14737175.6.4.455. PMID 16623645. S2CID 24293088.
Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, et al. (July 2005). "A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD". Journal of the American Academy of Child and Adolescent Psychiatry. 44 (7): 647–655. doi:10.1097/01.chi.0000163280.47221.c9. PMID 15968233.
Biederman J, Wigal SB, Spencer TJ, McGough JJ, Mays DA (February 2006). "A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder". Clinical Therapeutics. 28 (2): 280–293. doi:10.1016/j.clinthera.2006.02.008. PMID 16678649.
Bushe C, Day K, Reed V, Karlsdotter K, Berggren L, Pitcher A, et al. (May 2016). "A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients". Journal of Psychopharmacology. 30 (5): 444–458. doi:10.1177/0269881116636105. PMID 27005307. S2CID 104938.
Hazell PL, Kohn MR, Dickson R, Walton RJ, Granger RE, Wyk GW (November 2011). "Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis". Journal of Attention Disorders. 15 (8): 674–683. doi:10.1177/1087054710379737. PMID 20837981. S2CID 43503227.
Hanwella R, Senanayake M, de Silva V (November 2011). "Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis". BMC Psychiatry. 11 (1): 176. doi:10.1186/1471-244X-11-176. PMC 3229459. PMID 22074258.
Rezaei G, Hosseini SA, Akbari Sari A, Olyaeemanesh A, Lotfi MH, Yassini M, et al. (10 February 2016). "Comparative efficacy of methylphenidate and atomoxetine in the treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review and meta-analysis". Medical Journal of the Islamic Republic of Iran. 30: 325. PMC 4898838. PMID 27390695.
Faraone SV, Gomeni R, Hull JT, Busse GD, Melyan Z, O'Neal W, et al. (February 2021). "Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials". Psychiatry Research. 296: 113664. doi:10.1016/j.psychres.2020.113664. PMID 33418457. S2CID 230716405.
Mohammadi MR, Kazemi MR, Zia E, Rezazadeh SA, Tabrizi M, Akhondzadeh S (November 2010). "Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial". Human Psychopharmacology. 25 (7–8): 560–565. doi:10.1002/hup.1154. PMID 21312290. S2CID 30677758.
Morrow K, Choi S, Young K, Haidar M, Boduch C, Bourgeois JA (September 2021). "Amantadine for the treatment of childhood and adolescent psychiatric symptoms". Proceedings. 34 (5): 566–570. doi:10.1080/08998280.2021.1925827. PMC 8366930. PMID 34456474.
Stuhec M, Munda B, Svab V, Locatelli I (June 2015). "Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion". Journal of Affective Disorders. 178: 149–159. doi:10.1016/j.jad.2015.03.006. PMID 25813457.
McDonagh MS, Peterson K, Thakurta S, Low A (December 2011). Drug Class Review: Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder (Report). Drug Class Reviews. United States Library of Medicine. PMID 22420008. Archived from the original on 31 August 2016.
Gurnani T, Ivanov I, Newcorn JH (February 2016). "Pharmacotherapy of Aggression in Child and Adolescent Psychiatric Disorders". Journal of Child and Adolescent Psychopharmacology. 26 (1): 65–73. doi:10.1089/cap.2015.0167. PMID 26881859. Several studies (e.g., Findling et al. 2000; Armenteros et al. 2007) have shown that antipsychotics, especially second generation agents, can be effective when used together with stimulants for aggression in ADHD
Childress AC, Sallee FR (March 2012). "Revisiting clonidine: an innovative add-on option for attention-deficit/hyperactivity disorder". Drugs of Today. 48 (3): 207–217. doi:10.1358/dot.2012.48.3.1750904. PMID 22462040.
Huss M, Chen W, Ludolph AG (January 2016). "Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe". Clinical Drug Investigation. 36 (1). Springer Science and Business Media LLC: 1–25. doi:10.1007/s40261-015-0336-0. PMC 4706844. PMID 26585576.
Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, et al. (SPD503 Study Group) (January 2008). "A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder". Pediatrics. 121 (1): e73–e84. doi:10.1542/peds.2006-3695. PMID 18166547. S2CID 25551406.
Palumbo DR, Sallee FR, Pelham WE, Bukstein OG, Daviss WB, McDERMOTT MP (February 2008). "Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes". Journal of the American Academy of Child and Adolescent Psychiatry. 47 (2): 180–188. doi:10.1097/chi.0b013e31815d9af7. PMID 18182963.
Arnsten AF, Jin LE (2012). "Focus: Translational Medicine: Guanfacine for the Treatment of Cognitive Disorders: A Century of Discoveries at Yale". The Yale Journal of Biology and Medicine. 85 (1): 45–58. PMC 3313539. PMID 22461743.
Stevens JR, Wilens TE, Stern TA (2013). "Using stimulants for attention-deficit/hyperactivity disorder: clinical approaches and challenges". The Primary Care Companion for CNS Disorders. 15 (2). doi:10.4088/PCC.12f01472. PMC 3733520. PMID 23930227.
Kessler S (January 1996). "Drug therapy in attention-deficit hyperactivity disorder". Southern Medical Journal. 89 (1): 33–38. doi:10.1097/00007611-199601000-00005. PMID 8545689. S2CID 12798818.
Wolraich ML, Hagan JF, Allan C, Chan E, Davison D, Earls M, et al. (October 2019). "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents". Pediatrics. 144 (4): e20192528. doi:10.1542/peds.2019-2528. PMC 7067282. PMID 31570648.
Ertürk E, Wouters S, Imeraj L, Lampo A (August 2020). "Association of ADHD and Celiac Disease: What Is the Evidence? A Systematic Review of the Literature". Journal of Attention Disorders (Review). 24 (10): 1371–1376. doi:10.1177/1087054715611493. PMID 26825336. S2CID 33989148. Up till now, there is no conclusive evidence for a relationship between ADHD and CD. Therefore, it is not advised to perform routine screening of CD when assessing ADHD (and vice versa) or to implement GFD as a standard treatment in ADHD. Nevertheless, the possibility of untreated CD predisposing to ADHD-like behavior should be kept in mind. ... It is possible that in untreated patients with CD, neurologic symptoms such as chronic fatigue, inattention, pain, and headache could predispose patients to ADHD-like behavior (mainly symptoms of inattentive type), which may be alleviated after GFD treatment.
Pelsser LM, Frankena K, Toorman J, Rodrigues Pereira R (January 2017). "Diet and ADHD, Reviewing the Evidence: A Systematic Review of Meta-Analyses of Double-Blind Placebo-Controlled Trials Evaluating the Efficacy of Diet Interventions on the Behavior of Children with ADHD". PLOS ONE (Systematic Review). 12 (1): e0169277. Bibcode:2017PLoSO..1269277P. doi:10.1371/journal.pone.0169277. PMC 5266211. PMID 28121994.
Konikowska K, Regulska-Ilow B, Rózańska D (2012). "The influence of components of diet on the symptoms of ADHD in children". Roczniki Panstwowego Zakladu Higieny. 63 (2): 127–134. PMID 22928358.
Arnold LE, DiSilvestro RA (August 2005). "Zinc in attention-deficit/hyperactivity disorder". Journal of Child and Adolescent Psychopharmacology. 15 (4): 619–627. doi:10.1089/cap.2005.15.619. hdl:1811/51593. PMID 16190793.
Bloch MH, Mulqueen J (October 2014). "Nutritional supplements for the treatment of ADHD". Child and Adolescent Psychiatric Clinics of North America. 23 (4): 883–897. doi:10.1016/j.chc.2014.05.002. PMC 4170184. PMID 25220092.
Krause J (April 2008). "SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder". Expert Review of Neurotherapeutics. 8 (4): 611–625. doi:10.1586/14737175.8.4.611. PMID 18416663. S2CID 24589993. Zinc binds at ... extracellular sites of the DAT, serving as a DAT inhibitor. In this context, controlled double-blind studies in children are of interest, which showed positive effects of zinc [supplementation] on symptoms of ADHD. It should be stated that at this time [supplementation] with zinc is not integrated in any ADHD treatment algorithm.
Bálint S, Czobor P, Mészáros A, Simon V, Bitter I (2008). "[Neuropsychological impairments in adult attention deficit hyperactivity disorder: a literature review]" [Neuropsychological impairments in adult attention deficit hyperactivity disorder: A literature review]. Psychiatria Hungarica (in Hungarian). 23 (5). Magyar Pszichiátriai Társaság: 324–335. PMID 19129549. PsycNET 2008-18348-001.
Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-Quiroga JA, et al. (August 2015). "Attention-deficit/hyperactivity disorder". Nature Reviews. Disease Primers (Review). 1: 15020. CiteSeerX 10.1.1.497.1346. doi:10.1038/nrdp.2015.20. PMID 27189265. S2CID 7171541.
McClernon FJ, Kollins SH (October 2008). "ADHD and smoking: from genes to brain to behavior". Annals of the New York Academy of Sciences. 1141 (1): 131–147. Bibcode:2008NYASA1141..131M. doi:10.1196/annals.1441.016. PMC 2758663. PMID 18991955.
Ginsberg Y, Quintero J, Anand E, Casillas M, Upadhyaya HP (2014). "Underdiagnosis of attention-deficit/hyperactivity disorder in adult patients: a review of the literature". The Primary Care Companion for CNS Disorders. 16 (3). doi:10.4088/PCC.13r01600. PMC 4195639. PMID 25317367. Reports indicate that ADHD affects 2.5%–5% of adults in the general population,^5–8 compared with 5%–7% of children.^9,10 ... However, fewer than 20% of adults with ADHD are currently diagnosed and/or treated by psychiatrists.^7,15,16
Baggio S, Fructuoso A, Guimaraes M, Fois E, Golay D, Heller P, et al. (2 August 2018). "Prevalence of Attention Deficit Hyperactivity Disorder in Detention Settings: A Systematic Review and Meta-Analysis". Frontiers in Psychiatry. 9: 331. doi:10.3389/fpsyt.2018.00331. PMC 6084240. PMID 30116206.
Willcutt EG (July 2012). "The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review". Neurotherapeutics. 9 (3): 490–499. doi:10.1007/s13311-012-0135-8. PMC 3441936. PMID 22976615.
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (June 2007). "The worldwide prevalence of ADHD: a systematic review and metaregression analysis". The American Journal of Psychiatry. 164 (6): 942–948. doi:10.1176/appi.ajp.164.6.942. eISSN 1535-7228. LCCN 22024537. OCLC 1480183. PMID 17541055.
Young S, Adamo N, Ásgeirsdóttir BB, Branney P, Beckett M, Colley W, et al. (August 2020). "Females with ADHD: An expert consensus statement taking a lifespan approach providing guidance for the identification and treatment of attention-deficit/ hyperactivity disorder in girls and women". BMC Psychiatry. 20 (1): 404. doi:10.1186/s12888-020-02707-9. PMC 7422602. PMID 32787804.
Emond V, Joyal C, Poissant H (April 2009). "[Structural and functional neuroanatomy of attention-deficit hyperactivity disorder (ADHD)]" [Structural and functional neuroanatomy of attention-deficit hyperactivity disorder (ADHD)]. L'Encephale (in French). 35 (2): 107–114. doi:10.1016/j.encep.2008.01.005. PMID 19393378.
Staller J, Faraone SV (2006). "Attention-deficit hyperactivity disorder in girls: epidemiology and management". CNS Drugs. 20 (2): 107–123. doi:10.2165/00023210-200620020-00003. PMID 16478287. S2CID 25835322.
Whitely M, Raven M, Timimi S, Jureidini J, Phillimore J, Leo J, et al. (April 2019). "Attention deficit hyperactivity disorder late birthdate effect common in both high and low prescribing international jurisdictions: a systematic review". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 60 (4): 380–391. doi:10.1111/jcpp.12991. PMC 7379308. PMID 30317644.
Ford-Jones PC (May 2015). "Misdiagnosis of attention deficit hyperactivity disorder: 'Normal behaviour' and relative maturity". Paediatrics & Child Health. 20 (4): 200–202. doi:10.1093/pch/20.4.200. PMC 4443828. PMID 26038639.
Elder TE (September 2010). "The importance of relative standards in ADHD diagnoses: evidence based on exact birth dates". Journal of Health Economics. 29 (5): 641–656. doi:10.1016/j.jhealeco.2010.06.003. PMC 2933294. PMID 20638739.
Coker TR, Elliott MN, Toomey SL, Schwebel DC, Cuccaro P, Tortolero Emery S, et al. (September 2016). "Racial and Ethnic Disparities in ADHD Diagnosis and Treatment". Pediatrics. 138 (3): e20160407. doi:10.1542/peds.2016-0407. PMC 5684883. PMID 27553219. There are various improvements in care that may help in closing this gap in diagnosis and treatment. These include actively and universally eliciting parental concerns about child behavior and academic performance (at home and school) at well-visits,32,33 providing care that is culturally relevant in families' preferred languages,34 and linking with community resources to provide mental health education, guidance, and services to families (eg, parent training courses for parents of children with ADHD).35–39 Pediatric clinicians also may need to consider universal behavioral health screening tools for children to improve diagnostic capabilities and recognize when a child has ADHD symptoms, even if the problem is not recognized by the parent. Because the rates of diagnosis and treatment are rising in the general population of US children, a significant need remains to identify and treat African-American and Latino children who have ADHD and avoid a widening of these disparities.
Slobodin O, Masalha R (June 2020). "Challenges in ADHD care for ethnic minority children: A review of the current literature". Transcultural Psychiatry. 57 (3): 468–483. doi:10.1177/1363461520902885. PMID 32233772. S2CID 214768588.
Staley BS (2024). "Attention-Deficit/Hyperactivity Disorder Diagnosis, Treatment, and Telehealth Use in Adults — National Center for Health Statistics Rapid Surveys System, United States, October–November 2023". MMWR. Morbidity and Mortality Weekly Report. 73 (40): 890–895. doi:10.15585/mmwr.mm7340a1. ISSN 0149-2195. PMC 11466376. PMID 39388378.
Faraone SV (February 2005). "The scientific foundation for understanding attention-deficit/hyperactivity disorder as a valid psychiatric disorder". European Child & Adolescent Psychiatry. 14 (1): 1–10. doi:10.1007/s00787-005-0429-z. PMID 15756510. S2CID 143646869.
Cormier E (October 2008). "Attention deficit/hyperactivity disorder: a review and update". Journal of Pediatric Nursing. 23 (5): 345–357. doi:10.1016/j.pedn.2008.01.003. PMID 18804015.
Biederman J, Faraone SV, Keenan K, Knee D, Tsuang MT (July 1990). "Family-genetic and psychosocial risk factors in DSM-III attention deficit disorder". Journal of the American Academy of Child and Adolescent Psychiatry. 29 (4): 526–533. doi:10.1097/00004583-199007000-00004. PMID 2387786.
Lahey BB, Applegate B, McBurnett K, Biederman J, Greenhill L, Hynd GW, et al. (November 1994). "DSM-IV field trials for attention deficit hyperactivity disorder in children and adolescents". The American Journal of Psychiatry. 151 (11): 1673–1685. doi:10.1176/ajp.151.11.1673. eISSN 1535-7228. LCCN 22024537. OCLC 1480183. PMID 7943460.
Rasmussen N (July 2006). "Making the first anti-depressant: amphetamine in American medicine, 1929-1950". Journal of the History of Medicine and Allied Sciences. 61 (3): 288–323. doi:10.1093/jhmas/jrj039. PMID 16492800. S2CID 24974454.
Patrick KS, Straughn AB, Perkins JS, González MA (January 2009). "Evolution of stimulants to treat ADHD: transdermal methylphenidate". Human Psychopharmacology. 24 (1): 1–17. doi:10.1002/hup.992. PMC 2629554. PMID 19051222.
Gross MD (February 1995). "Origin of stimulant use for treatment of attention deficit disorder". The American Journal of Psychiatry. 152 (2): 298–299. doi:10.1176/ajp.152.2.298b. eISSN 1535-7228. LCCN 22024537. OCLC 1480183. PMID 7840374.
Hoogman M, Stolte M, Baas M, Kroesbergen E (December 2020). "Creativity and ADHD: A review of behavioral studies, the effect of psychostimulants and neural underpinnings" (PDF). Neuroscience and Biobehavioral Reviews. 119: 66–85. doi:10.1016/j.neubiorev.2020.09.029. hdl:1874/409179. PMID 33035524. S2CID 222142805. Archived (PDF) from the original on 6 September 2023. Retrieved 28 August 2023.
Scassellati C, Bonvicini C, Faraone SV, Gennarelli M (October 2012). "Biomarkers and attention-deficit/hyperactivity disorder: a systematic review and meta-analyses". Journal of the American Academy of Child and Adolescent Psychiatry. 51 (10): 1003–1019.e20. doi:10.1016/j.jaac.2012.08.015. PMID 23021477.

ncbi.nlm.nih.gov

Foreman DM (February 2006). "Attention deficit hyperactivity disorder: legal and ethical aspects". Archives of Disease in Childhood. 91 (2): 192–194. doi:10.1136/adc.2004.064576. PMC 2082674. PMID 16428370.
Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, et al. (September 2021). "The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder". Neuroscience and Biobehavioral Reviews. 128. Elsevier BV: 789–818. doi:10.1016/j.neubiorev.2021.01.022. ISSN 0149-7634. PMC 8328933. PMID 33549739.
Hoogman M, Muetzel R, Guimaraes JP, Shumskaya E, Mennes M, Zwiers MP, et al. (July 2019). "Brain Imaging of the Cortex in ADHD: A Coordinated Analysis of Large-Scale Clinical and Population-Based Samples". The American Journal of Psychiatry. 176 (7): 531–542. doi:10.1176/appi.ajp.2019.18091033. PMC 6879185. PMID 31014101.
Diamond A (2013). "Executive functions". Annual Review of Psychology. 64: 135–168. doi:10.1146/annurev-psych-113011-143750. PMC 4084861. PMID 23020641. EFs and prefrontal cortex are the first to suffer, and suffer disproportionately, if something is not right in your life. They suffer first, and most, if you are stressed (Arnsten 1998, Liston et al. 2009, Oaten & Cheng 2005), sad (Hirt et al. 2008, von Hecker & Meiser 2005), lonely (Baumeister et al. 2002, Cacioppo & Patrick 2008, Campbell et al. 2006, Tun et al. 2012), sleep deprived (Barnes et al. 2012, Huang et al. 2007), or not physically fit (Best 2010, Chaddock et al. 2011, Hillman et al. 2008). Any of these can cause you to appear to have a disorder of EFs, such as ADHD, when you do not.
Shaw P, Stringaris A, Nigg J, Leibenluft E (March 2014). "Emotion dysregulation in attention deficit hyperactivity disorder". The American Journal of Psychiatry. 171 (3): 276–293. doi:10.1176/appi.ajp.2013.13070966. PMC 4282137. PMID 24480998.
Fleming M, Fitton CA, Steiner MF, McLay JS, Clark D, King A, et al. (July 2017). "Educational and Health Outcomes of Children Treated for Attention-Deficit/Hyperactivity Disorder". JAMA Pediatrics. 171 (7): e170691. doi:10.1001/jamapediatrics.2017.0691. PMC 6583483. PMID 28459927.
Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, et al. (1 September 2021). "The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder". Neuroscience & Biobehavioral Reviews. 128: 789–818. doi:10.1016/j.neubiorev.2021.01.022. ISSN 0149-7634. PMC 8328933. PMID 33549739.
Ashinoff BK, Abu-Akel A (February 2021). "Hyperfocus: the forgotten frontier of attention". Psychological Research. 85 (1): 1–19. doi:10.1007/s00426-019-01245-8. PMC 7851038. PMID 31541305.
Ishii S, Takagi S, Kobayashi N, Jitoku D, Sugihara G, Takahashi H (16 March 2023). "Hyperfocus symptom and internet addiction in individuals with attention-deficit/hyperactivity disorder trait". Frontiers in Psychiatry. 14: 1127777. doi:10.3389/fpsyt.2023.1127777. PMC 10061009. PMID 37009127.
Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM, Perlis RH, et al. (September 2013). "Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs". Nature Genetics. 45 (9): 984–994. doi:10.1038/ng.2711. PMC 3800159. PMID 23933821.
Cecil CA, Nigg JT (November 2022). "Epigenetics and ADHD: Reflections on Current Knowledge, Research Priorities and Translational Potential". Molecular Diagnosis & Therapy. 26 (6): 581–606. doi:10.1007/s40291-022-00609-y. PMC 7613776. PMID 35933504.
Nigg JT, Sibley MH, Thapar A, Karalunas SL (December 2020). "Development of ADHD: Etiology, Heterogeneity, and Early Life Course". Annual Review of Developmental Psychology. 2 (1): 559–583. doi:10.1146/annurev-devpsych-060320-093413. PMC 8336725. PMID 34368774.
Franke B, Michelini G, Asherson P, Banaschewski T, Bilbow A, Buitelaar JK, et al. (October 2018). "Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan". European Neuropsychopharmacology. 28 (10): 1059–1088. doi:10.1016/j.euroneuro.2018.08.001. PMC 6379245. PMID 30195575.
Larsson H, Chang Z, D'Onofrio BM, Lichtenstein P (July 2014). "The heritability of clinically diagnosed Attention-Deficit/Hyperactivity Disorder across the life span". Psychological Medicine. 44 (10): 2223–2229. doi:10.1017/S0033291713002493. ISSN 0033-2917. PMC 4071160. PMID 24107258.
Sinopoli KJ, Schachar R, Dennis M (August 2011). "Traumatic brain injury and secondary attention-deficit/hyperactivity disorder in children and adolescents: the effect of reward on inhibitory control". Journal of Clinical and Experimental Neuropsychology. 33 (7): 805–819. doi:10.1080/13803395.2011.562864. PMC 3184364. PMID 21598155.
Faraone SV, Larsson H (April 2019). "Genetics of attention deficit hyperactivity disorder". Molecular Psychiatry. 24 (4): 562–575. doi:10.1038/s41380-018-0070-0. PMC 6477889. PMID 29892054.
Epstein JN, Loren RE (October 2013). "Changes in the Definition of ADHD in DSM-5: Subtle but Important". Neuropsychiatry. 3 (5): 455–458. doi:10.2217/npy.13.59 (inactive 20 November 2024). PMC 3955126. PMID 24644516.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugué M, Carpentier PJ, et al. (September 2010). "European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD". BMC Psychiatry. 10 (67): 67. doi:10.1186/1471-244X-10-67. PMC 2942810. PMID 20815868.
Carpenter Rich E, Loo SK, Yang M, Dang J, Smalley SL (July 2009). "Social functioning difficulties in ADHD: association with PDD risk". Clinical Child Psychology and Psychiatry. 14 (3): 329–344. doi:10.1177/1359104508100890. PMC 2827258. PMID 19515751.
Peterson RL, Pennington BF (May 2012). "Developmental dyslexia". Lancet. 379 (9830): 1997–2007. doi:10.1016/S0140-6736(12)60198-6. PMC 3465717. PMID 22513218.
Mackenzie GB, Wonders E (2016). "Rethinking Intelligence Quotient Exclusion Criteria Practices in the Study of Attention Deficit Hyperactivity Disorder". Frontiers in Psychology. 7: 794. doi:10.3389/fpsyg.2016.00794. PMC 4886698. PMID 27303350.
Young S, Hollingdale J, Absoud M, Bolton P, Branney P, Colley W, et al. (May 2020). "Guidance for identification and treatment of individuals with attention deficit/hyperactivity disorder and autism spectrum disorder based upon expert consensus". BMC Medicine. 18 (1). Springer Science and Business Media LLC: 146. doi:10.1186/s12916-020-01585-y. PMC 7247165. PMID 32448170.
Wilens TE, Spencer TJ (September 2010). "Understanding attention-deficit/hyperactivity disorder from childhood to adulthood". Postgraduate Medicine. 122 (5): 97–109. doi:10.3810/pgm.2010.09.2206. PMC 3724232. PMID 20861593.
Wilens TE, Morrison NR (July 2011). "The intersection of attention-deficit/hyperactivity disorder and substance abuse". Current Opinion in Psychiatry. 24 (4): 280–285. doi:10.1097/YCO.0b013e328345c956. PMC 3435098. PMID 21483267.
Wajszilber D, Santiseban JA, Gruber R (December 2018). "Sleep disorders in patients with ADHD: impact and management challenges". Nature and Science of Sleep. 10: 453–480. doi:10.2147/NSS.S163074. PMC 6299464. PMID 30588139.
Long Y, Pan N, Ji S, Qin K, Chen Y, Zhang X, et al. (September 2022). "Distinct brain structural abnormalities in attention-deficit/hyperactivity disorder and substance use disorders: A comparative meta-analysis". Translational Psychiatry. 12 (1): 368. doi:10.1038/s41398-022-02130-6. PMC 9448791. PMID 36068207.
National Collaborating Centre for Mental Health (2009). "Attention Deficit Hyperactivity Disorder". Attention Deficit Hyperactivity Disorder: Diagnosis and Management of ADHD in Children, Young People and Adults. NICE Clinical Guidelines. Vol. 72. Leicester: British Psychological Society. pp. 18–26, 38. ISBN 978-1-85433-471-8. Archived from the original on 13 January 2016 – via NCBI Bookshelf.
Becker SP, Willcutt EG, Leopold DR, Fredrick JW, Smith ZR, Jacobson LA, et al. (June 2023). "Report of a Work Group on Sluggish Cognitive Tempo: Key Research Directions and a Consensus Change in Terminology to Cognitive Disengagement Syndrome". Journal of the American Academy of Child and Adolescent Psychiatry. 62 (6): 629–645. doi:10.1016/j.jaac.2022.07.821. PMC 9943858. PMID 36007816.
Moon DS, Bong SJ, Kim BN, Kang NR (January 2021). "Association between Maternal Adverse Childhood Experiences and Attention-Deficit/Hyperactivity Disorder in the Offspring: The Mediating Role of Antepartum Health Risks". Soa--Ch'ongsonyon Chongsin Uihak = Journal of Child & Adolescent Psychiatry. 32 (1): 28–34. doi:10.5765/jkacap.200041. PMC 7788667. PMID 33424239.
Harrington KM, Miller MW, Wolf EJ, Reardon AF, Ryabchenko KA, Ofrat S (August 2012). "Attention-deficit/hyperactivity disorder comorbidity in a sample of veterans with posttraumatic stress disorder". Comprehensive Psychiatry. 53 (6): 679–690. doi:10.1016/j.comppsych.2011.12.001. PMC 6519447. PMID 22305866.
Zhang N, Gao M, Yu J, Zhang Q, Wang W, Zhou C, et al. (October 2022). "Understanding the association between adverse childhood experiences and subsequent attention deficit hyperactivity disorder: A systematic review and meta-analysis of observational studies". Brain and Behavior. 12 (10): e32748. doi:10.1002/brb3.2748. PMC 9575611. PMID 36068993.
Williams AE, Giust JM, Kronenberger WG, Dunn DW (2016). "Epilepsy and attention-deficit hyperactivity disorder: links, risks, and challenges". Neuropsychiatric Disease and Treatment. 12: 287–296. doi:10.2147/NDT.S81549. PMC 4755462. PMID 26929624.
Instanes JT, Klungsøyr K, Halmøy A, Fasmer OB, Haavik J (February 2018). "Adult ADHD and Comorbid Somatic Disease: A Systematic Literature Review". Journal of Attention Disorders (Systematic Review). 22 (3): 203–228. doi:10.1177/1087054716669589. PMC 5987989. PMID 27664125.
Gaur S (May 2022). "The Association between ADHD and Celiac Disease in Children". Children. 9 (6). MDPI: 781. doi:10.3390/children9060781. PMC 9221618. PMID 35740718.
Pan PY, Jonsson U, Şahpazoğlu Çakmak SS, Häge A, Hohmann S, Nobel Norrman H, et al. (January 2022). "Headache in ADHD as comorbidity and a side effect of medications: a systematic review and meta-analysis". Psychological Medicine. 52 (1). Cambridge University Press: 14–25. doi:10.1017/s0033291721004141. PMC 8711104. PMID 34635194.
González-Bueso V, Santamaría JJ, Fernández D, Merino L, Montero E, Ribas J (2018). "Association between Internet Gaming Disorder or Pathological Video-Game Use and Comorbid Psychopathology: A Comprehensive Review". International Journal of Environmental Research and Public Health. 15 (4). MDPI: 668. doi:10.3390/ijerph15040668. PMC 5923710. PMID 29614059.
Beyens I, Valkenburg PM, Piotrowski JT (2 October 2018). "Screen media use and ADHD-related behaviors: Four decades of research". PNAS USA. 115 (40). National Academy of Sciences: 9875–9881. Bibcode:2018PNAS..115.9875B. doi:10.1073/pnas.1611611114. PMC 6176582. PMID 30275318.
Li Y, Li G, Liu L, Wu H (2020). "Correlations between mobile phone addiction and anxiety, depression, impulsivity, and poor sleep quality among college students: A systematic review and meta-analysis". Journal of Behavioral Addictions. 9 (3). Akadémiai Kiadó: 551–571. doi:10.1556/2006.2020.00057. PMC 8943681. PMID 32903205.
Gao X, Zhang M, Yang Z, Wen M, Huang H, Zheng R, et al. (2021). "Structural and Functional Brain Abnormalities in Internet Gaming Disorder and Attention-Deficit/Hyperactivity Disorder: A Comparative Meta-Analysis". Frontiers in Psychiatry. 12. Frontiers Media: 679437. doi:10.3389/fpsyt.2021.679437. PMC 8281314. PMID 34276447.
Eirich R, McArthur BA, Anhorn C, McGuinness C, Christakis DA, Madigan S (2022). "Association of Screen Time With Internalizing and Externalizing Behavior Problems in Children 12 Years or Younger: A Systematic Review and Meta-analysis". JAMA Psychiatry. 79 (5). American Medical Association: 393–405. doi:10.1001/jamapsychiatry.2022.0155. PMC 8928099. PMID 35293954.
Werling AM, Kuzhippallil S, Emery S, Walitza S, Drechsler R (2022). "Problematic use of digital media in children and adolescents with a diagnosis of attention-deficit/hyperactivity disorder compared to controls. A meta-analysis". Journal of Behavioral Addictions. 11 (2). Akadémiai Kiadó: 305–325. doi:10.1556/2006.2022.00007. PMC 9295226. PMID 35567763.
Thorell LB, Burén J, Wiman JS, Sandberg D, Nutley SB (2022). "Longitudinal associations between digital media use and ADHD symptoms in children and adolescents: a systematic literature review". European Child & Adolescent Psychiatry. 33 (8). Springer Science+Business Media: 2503–2526. doi:10.1007/s00787-022-02130-3. PMC 11272698. PMID 36562860.
Balazs J, Kereszteny A (March 2017). "Attention-deficit/hyperactivity disorder and suicide: A systematic review". World Journal of Psychiatry. 7 (1): 44–59. doi:10.5498/wjp.v7.i1.44. PMC 5371172. PMID 28401048.
Garas P, Balazs J (21 December 2020). "Long-Term Suicide Risk of Children and Adolescents With Attention Deficit and Hyperactivity Disorder-A Systematic Review". Frontiers in Psychiatry. 11: 557909. doi:10.3389/fpsyt.2020.557909. PMC 7779592. PMID 33408650. 557909.
Beauchaine TP, Ben-David I, Bos M (September 2020). "ADHD, financial distress, and suicide in adulthood: A population study". Science Advances. 6 (40): eaba1551. Bibcode:2020SciA....6.1551B. doi:10.1126/sciadv.aba1551. PMC 7527218. PMID 32998893. eaba1551.
Faraone SV, Larsson H (April 2019). "Genetics of attention deficit hyperactivity disorder". Molecular Psychiatry. 24 (4): 562–575. doi:10.1038/s41380-018-0070-0. PMC 6477889. PMID 29892054. S2CID 47016805.
Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. (January 2019). "Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder". Nature Genetics. 51 (1): 63–75. doi:10.1038/s41588-018-0269-7. hdl:10023/20827. PMC 6481311. PMID 30478444.
Grimm O, Kranz TM, Reif A (February 2020). "Genetics of ADHD: What Should the Clinician Know?". Current Psychiatry Reports. 22 (4): 18. doi:10.1007/s11920-020-1141-x. PMC 7046577. PMID 32108282.
Faraone SV, Larsson H (April 2019). "Genetics of attention deficit hyperactivity disorder". Molecular Psychiatry. 24 (4). Nature Research: 562–575. doi:10.1038/s41380-018-0070-0. PMC 6477889. PMID 29892054.
Esteller-Cucala P, Maceda I, Børglum AD, Demontis D, Faraone SV, Cormand B, et al. (May 2020). "Genomic analysis of the natural history of attention-deficit/hyperactivity disorder using Neanderthal and ancient Homo sapiens samples". Scientific Reports. 10 (1): 8622. Bibcode:2020NatSR..10.8622E. doi:10.1038/s41598-020-65322-4. PMC 7248073. PMID 32451437.
Faraone SV, Larsson H (April 2019). "Genetics of attention deficit hyperactivity disorder". Molecular Psychiatry. 24 (4). Springer Science and Business Media LLC: 562–575. doi:10.1038/s41380-018-0070-0. PMC 6477889. PMID 29892054.
Skoglund C, Chen Q, D'Onofrio BM, Lichtenstein P, Larsson H (January 2014). "Familial confounding of the association between maternal smoking during pregnancy and ADHD in offspring". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 55 (1): 61–68. doi:10.1111/jcpp.12124. PMC 4217138. PMID 25359172.
Sotnikova TD, Caron MG, Gainetdinov RR (August 2009). "Trace amine-associated receptors as emerging therapeutic targets". Molecular Pharmacology. 76 (2): 229–235. doi:10.1124/mol.109.055970. PMC 2713119. PMID 19389919.
Arcos-Burgos M, Muenke M (November 2010). "Toward a better understanding of ADHD: LPHN3 gene variants and the susceptibility to develop ADHD". Attention Deficit and Hyperactivity Disorders. 2 (3): 139–147. doi:10.1007/s12402-010-0030-2. PMC 3280610. PMID 21432600.
Nikolaidis A, Gray JR (June 2010). "ADHD and the DRD4 exon III 7-repeat polymorphism: an international meta-analysis". Social Cognitive and Affective Neuroscience. 5 (2–3): 188–193. doi:10.1093/scan/nsp049. PMC 2894686. PMID 20019071.
Zayats T, Neale BM (12 February 2020). "Recent advances in understanding of attention deficit hyperactivity disorder (ADHD): how genetics are shaping our conceptualization of this disorder". F1000Research. 8: 2060. doi:10.12688/f1000research.18959.2. PMC 6896240. PMID 31824658.
Eubig PA, Aguiar A, Schantz SL (December 2010). "Lead and PCBs as risk factors for attention deficit/hyperactivity disorder". Environmental Health Perspectives (Review. Research Support, N.I.H., Extramural. Research Support, U.S. Gov't, Non-P.H.S.). 118 (12): 1654–1667. doi:10.1289/ehp.0901852. PMC 3002184. PMID 20829149.
Tiesler CM, Heinrich J (October 2014). "Prenatal nicotine exposure and child behavioural problems". European Child & Adolescent Psychiatry. 23 (10): 913–929. doi:10.1007/s00787-014-0615-y. PMC 4186967. PMID 25241028.
Thapar A, Cooper M, Jefferies R, Stergiakouli E (March 2012). "What causes attention deficit hyperactivity disorder?". Archives of Disease in Childhood (Review. Research Support, Non-U.S. Gov't). 97 (3): 260–265. doi:10.1136/archdischild-2011-300482. PMC 3927422. PMID 21903599.
Nigg JT, Holton K (October 2014). "Restriction and elimination diets in ADHD treatment". Child and Adolescent Psychiatric Clinics of North America (Review). 23 (4): 937–953. doi:10.1016/j.chc.2014.05.010. PMC 4322780. PMID 25220094. an elimination diet produces a small aggregate effect but may have greater benefit among some children. Very few studies enable proper evaluation of the likelihood of response in children with ADHD who are not already preselected based on prior diet response.
National Collaborating Centre for Mental Health (2009). Attention Deficit Hyperactivity Disorder: Diagnosis and Management of ADHD in Children, Young People and Adults. NICE Clinical Guidelines. Vol. 72. Leicester: British Psychological Society. ISBN 978-1-85433-471-8. Archived from the original on 13 January 2016 – via NCBI Bookshelf.
Chandler DJ, Waterhouse BD, Gao WJ (May 2014). "New perspectives on catecholaminergic regulation of executive circuits: evidence for independent modulation of prefrontal functions by midbrain dopaminergic and noradrenergic neurons". Frontiers in Neural Circuits. 8: 53. doi:10.3389/fncir.2014.00053. PMC 4033238. PMID 24904299.
Castellanos FX, Proal E (January 2012). "Large-scale brain systems in ADHD: beyond the prefrontal-striatal model". Trends in Cognitive Sciences. 16 (1): 17–26. doi:10.1016/j.tics.2011.11.007. PMC 3272832. PMID 22169776. Recent conceptualizations of ADHD have taken seriously the distributed nature of neuronal processing. Most of the candidate networks have focused on prefrontal-striatal-cerebellar circuits, although other posterior regions are also being proposed.
Cortese S, Kelly C, Chabernaud C, Proal E, Di Martino A, Milham MP, et al. (October 2012). "Toward systems neuroscience of ADHD: a meta-analysis of 55 fMRI studies". The American Journal of Psychiatry. 169 (10): 1038–1055. doi:10.1176/appi.ajp.2012.11101521. eISSN 1535-7228. LCCN 22024537. OCLC 1480183. PMC 3879048. PMID 22983386.
Hoogman M, Bralten J, Hibar DP, Mennes M, Zwiers MP, Schweren LS, et al. (April 2017). "Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: a cross-sectional mega-analysis". The Lancet. Psychiatry. 4 (4): 310–319. doi:10.1016/S2215-0366(17)30049-4. PMC 5933934. PMID 28219628.
Douglas PK, Gutman B, Anderson A, Larios C, Lawrence KE, Narr K, et al. (February 2018). "Hemispheric brain asymmetry differences in youths with attention-deficit/hyperactivity disorder". NeuroImage. Clinical. 18: 744–752. doi:10.1016/j.nicl.2018.02.020. PMC 5988460. PMID 29876263.
Tarchi L, Damiani S, Fantoni T, Pisano T, Castellini G, Politi P, et al. (December 2022). "Centrality and interhemispheric coordination are related to different clinical/behavioral factors in attention deficit/hyperactivity disorder: a resting-state fMRI study". Brain Imaging and Behavior. 16 (6): 2526–2542. doi:10.1007/s11682-022-00708-8. PMC 9712307. PMID 35859076.
Mohamed SM, Börger NA, Geuze RH, van der Meere JJ (2015). "Brain lateralization and self-reported symptoms of ADHD in a population sample of adults: a dimensional approach". Frontiers in Psychology. 6: 1418. doi:10.3389/fpsyg.2015.01418. PMC 4585266. PMID 26441789.
Bidwell LC, McClernon FJ, Kollins SH (August 2011). "Cognitive enhancers for the treatment of ADHD". Pharmacology, Biochemistry, and Behavior. 99 (2): 262–274. doi:10.1016/j.pbb.2011.05.002. PMC 3353150. PMID 21596055.
B. Langguth, R. Bär, N. Wodarz, M. Wittmann, R. Laufkötter: Paradoxical reaction in ADHD. In: Deutsches Ärzteblatt international. Band 108, Nummer 31–32, August 2011, S. 541; author reply 541–541; author reply 542, (in German).doi:10.3238/arztebl.2011.0541a, PMID 21886668, PMC 3163785.
Al Rahbi HA, Al-Sabri RM, Chitme HR (April 2014). "Interventions by pharmacists in out-patient pharmaceutical care". Saudi Pharmaceutical Journal. 22 (2): 101–106. doi:10.1016/j.jsps.2013.04.001. PMC 3950532. PMID 24648820.
Adamou M, Fullen T, Jones SL (25 August 2020). "EEG for Diagnosis of Adult ADHD: A Systematic Review With Narrative Analysis". Frontiers in Psychiatry. 11: 871. doi:10.3389/fpsyt.2020.00871. PMC 7477352. PMID 33192633.
Lenartowicz A, Loo SK (November 2014). "Use of EEG to diagnose ADHD". Current Psychiatry Reports. 16 (11): 498. doi:10.1007/s11920-014-0498-0. PMC 4633088. PMID 25234074.
Steinau S (2013). "Diagnostic Criteria in Attention Deficit Hyperactivity Disorder - Changes in DSM 5". Frontiers in Psychiatry. 4: 49. doi:10.3389/fpsyt.2013.00049. PMC 3667245. PMID 23755024.
Parens E, Johnston J (January 2009). "Facts, values, and attention-deficit hyperactivity disorder (ADHD): an update on the controversies". Child and Adolescent Psychiatry and Mental Health. 3 (1): 1. doi:10.1186/1753-2000-3-1. PMC 2637252. PMID 19152690.
Song P, Zha M, Yang Q, Zhang Y, Li X, Rudan I (February 2021). "The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis". Journal of Global Health. 11. International Global Health Society: 04009. doi:10.7189/jogh.11.04009. eISSN 2047-2986. OCLC 751737736. PMC 7916320. PMID 33692893.
Culpepper L, Mattingly G (2010). "Challenges in identifying and managing attention-deficit/hyperactivity disorder in adults in the primary care setting: a review of the literature". Primary Care Companion to the Journal of Clinical Psychiatry. 12 (6): PCC.10r00951. doi:10.4088/PCC.10r00951pur. PMC 3067998. PMID 21494335.
Gentile JP, Atiq R, Gillig PM (August 2006). "Adult ADHD: Diagnosis, Differential Diagnosis, and Medication Management". Psychiatry. 3 (8): 25–30. PMC 2957278. PMID 20963192. likelihood that the adult with ADHD has developed coping mechanisms to compensate for his or her impairment
Walters AS, Silvestri R, Zucconi M, Chandrashekariah R, Konofal E (December 2008). "Review of the possible relationship and hypothetical links between attention deficit hyperactivity disorder (ADHD) and the simple sleep related movement disorders, parasomnias, hypersomnias, and circadian rhythm disorders". Journal of Clinical Sleep Medicine. 4 (6): 591–600. doi:10.5664/jcsm.27356. PMC 2603539. PMID 19110891.
Coghill DR, Banaschewski T, Soutullo C, Cottingham MG, Zuddas A (November 2017). "Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder". European Child & Adolescent Psychiatry. 26 (11): 1283–1307. doi:10.1007/s00787-017-0986-y. PMC 5656703. PMID 28429134. Text was copied from this source, which is available under a Creative Commons Attribution 4.0 International License "CC BY 4.0 Deed | Attribution 4.0 International | Creative Commons". Archived from the original on 16 October 2017. Retrieved 22 October 2022.{{cite web}}: CS1 maint: bot: original URL status unknown (link).
Luan R, Mu Z, Yue F, He S (2017). "Efficacy and Tolerability of Different Interventions in Children and Adolescents with Attention Deficit Hyperactivity Disorder". Frontiers in Psychiatry. 8: 229. doi:10.3389/fpsyt.2017.00229. PMC 5694170. PMID 29180967.
Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. (September 2018). "Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis". The Lancet. Psychiatry. 5 (9): 727–738. doi:10.1016/S2215-0366(18)30269-4. PMC 6109107. PMID 30097390.
Lopez PL, Torrente FM, Ciapponi A, Lischinsky AG, Cetkovich-Bakmas M, Rojas JI, et al. (March 2018). "Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults". The Cochrane Database of Systematic Reviews. 2018 (3): CD010840. doi:10.1002/14651858.CD010840.pub2. PMC 6494390. PMID 29566425.
Evans SW, Owens JS, Bunford N (2014). "Evidence-based psychosocial treatments for children and adolescents with attention-deficit/hyperactivity disorder". Journal of Clinical Child and Adolescent Psychology. 43 (4): 527–551. doi:10.1080/15374416.2013.850700. PMC 4025987. PMID 24245813.
Van Doren J, Arns M, Heinrich H, Vollebregt MA, Strehl U, K Loo S (March 2019). "Sustained effects of neurofeedback in ADHD: a systematic review and meta-analysis". European Child & Adolescent Psychiatry. 28 (3). Springer Science and Business Media LLC: 293–305. doi:10.1007/s00787-018-1121-4. PMC 6404655. PMID 29445867.
Enriquez-Geppert S, Smit D, Pimenta MG, Arns M (May 2019). "Neurofeedback as a Treatment Intervention in ADHD: Current Evidence and Practice". Current Psychiatry Reports. 21 (6). Springer Science and Business Media LLC: 46. doi:10.1007/s11920-019-1021-4. PMC 6538574. PMID 31139966.
Mikami AY (June 2010). "The importance of friendship for youth with attention-deficit/hyperactivity disorder". Clinical Child and Family Psychology Review. 13 (2): 181–198. doi:10.1007/s10567-010-0067-y. PMC 2921569. PMID 20490677.
Kollins SH, Childress A, Heusser AC, Lutz J (March 2021). "Effectiveness of a digital therapeutic as adjunct to treatment with medication in pediatric ADHD". npj Digital Medicine. 4 (1): 58. doi:10.1038/s41746-021-00429-0. PMC 7997870. PMID 33772095.
Devilbiss DM, Berridge CW (October 2008). "Cognition-enhancing doses of methylphenidate preferentially increase prefrontal cortex neuronal responsiveness". Biological Psychiatry. 64 (7): 626–635. doi:10.1016/j.biopsych.2008.04.037. PMC 2603602. PMID 18585681.
Storebø OJ, Storm MR, Pereira Ribeiro J, Skoog M, Groth C, Callesen HE, et al. (March 2023). "Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)". The Cochrane Database of Systematic Reviews. 2023 (3): CD009885. doi:10.1002/14651858.CD009885.pub3. PMC 10042435. PMID 36971690.
Spencer TJ, Brown A, Seidman LJ, Valera EM, Makris N, Lomedico A, et al. (September 2013). "Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies". The Journal of Clinical Psychiatry. 74 (9): 902–917. doi:10.4088/JCP.12r08287. PMC 3801446. PMID 24107764.
Nam SH, Lim MH, Park TW (April 2022). "Stimulant Induced Movement Disorders in Attention Deficit Hyperactivity Disorder". Soa--Ch'ongsonyon Chongsin Uihak = Journal of Child & Adolescent Psychiatry. 33 (2): 27–34. doi:10.5765/jkacap.210034. PMC 8984208. PMID 35418800.
Storebø OJ, Krogh HB, Ramstad E, Moreira-Maia CR, Holmskov M, Skoog M, et al. (November 2015). "Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials". BMJ. 351: h5203. doi:10.1136/bmj.h5203. PMC 4659414. PMID 26608309.
Banaschewski T, Buitelaar J, Chui CS, Coghill D, Cortese S, Simonoff E, et al. (November 2016). "Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater". Evidence-Based Mental Health. 19 (4): 97–99. doi:10.1136/eb-2016-102461. PMC 10699535. PMID 27935807.
Boesen K, Paludan-Müller AS, Gøtzsche PC, Jørgensen KJ (February 2022). "Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults". The Cochrane Database of Systematic Reviews. 2022 (2): CD012857. doi:10.1002/14651858.CD012857.pub2. PMC 8869321. PMID 35201607.
Jaeschke RR, Sujkowska E, Sowa-Kućma M (October 2021). "Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review". Psychopharmacology. 238 (10): 2667–2691. doi:10.1007/s00213-021-05946-0. PMC 8455398. PMID 34436651.
Shoptaw SJ, Kao U, Ling W (January 2009). Shoptaw SJ, Ali R (eds.). "Treatment for amphetamine psychosis". The Cochrane Database of Systematic Reviews. 2009 (1): CD003026. doi:10.1002/14651858.CD003026.pub3. PMC 7004251. PMID 19160215. A minority of individuals who use amphetamines develop full-blown psychosis requiring care at emergency departments or psychiatric hospitals. In such cases, symptoms of amphetamine psychosis commonly include paranoid and persecutory delusions as well as auditory and visual hallucinations in the presence of extreme agitation. More common (about 18%) is for frequent amphetamine users to report psychotic symptoms that are sub-clinical and that do not require high-intensity intervention ...
About 5–15% of the users who develop an amphetamine psychosis fail to recover completely (Hofmann 1983) ...
Findings from one trial indicate use of antipsychotic medications effectively resolves symptoms of acute amphetamine psychosis.
Parker J, Wales G, Chalhoub N, Harpin V (September 2013). "The long-term outcomes of interventions for the management of attention-deficit hyperactivity disorder in children and adolescents: a systematic review of randomized controlled trials". Psychology Research and Behavior Management. 6: 87–99. doi:10.2147/PRBM.S49114. PMC 3785407. PMID 24082796. Results suggest there is moderate-to-high-level evidence that combined pharmacological and behavioral interventions, and pharmacological interventions alone can be effective in managing the core ADHD symptoms and academic performance at 14 months. However, the effect size may decrease beyond this period. ... Only one paper examining outcomes beyond 36 months met the review criteria. ... There is high level evidence suggesting that pharmacological treatment can have a major beneficial effect on the core symptoms of ADHD (hyperactivity, inattention, and impulsivity) in approximately 80% of cases compared with placebo controls, in the short term.
Castells X, Blanco-Silvente L, Cunill R, et al. (Cochrane Developmental, Psychosocial and Learning Problems Group) (August 2018). "Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults". The Cochrane Database of Systematic Reviews. 2018 (8): CD007813. doi:10.1002/14651858.CD007813.pub3. PMC 6513464. PMID 30091808.
Kemper AR, Maslow GR, Hill S, Namdari B, Allen Lapointe NM, Goode AP, et al. (January 2018). "Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment in Children and Adolescents". Comparative Effectiveness Reviews (203). Rockville (MD): Agency for Healthcare Research and Quality (US). PMID 29558081. Archived from the original on 17 May 2022. Retrieved 7 November 2021.
Zhang L, Yao H, Li L, Du Rietz E, Andell P, Garcia-Argibay M, et al. (November 2022). "Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis". JAMA Network Open. 5 (11): e2243597. doi:10.1001/jamanetworkopen.2022.43597. PMC 9685490. PMID 36416824.
McDonagh MS, Christensen V, Peterson K, Thakurta S (October 2009). "Black box warnings of ADHD drugs approved by the US Food and Drug Administration". Drug Class Review: Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder: Final Report Update 3 [Internet]. Portland, Oregon: Oregon Health & Science University. Appendix G: Black box warnings of ADHD drugs approved by the US Food and Drug Administration. Archived from the original on 8 September 2017. Retrieved 17 January 2014 – via United States National Library of Medicine.
Potter AS, Schaubhut G, Shipman M (December 2014). "Targeting the nicotinic cholinergic system to treat attention-deficit/hyperactivity disorder: rationale and progress to date". CNS Drugs. 28 (12): 1103–1113. doi:10.1007/s40263-014-0208-9. PMC 4487649. PMID 25349138.
Perrotte G, Moreira MM, de Vargas Junior A, Teixeira Filho A, Castaldelli-Maia JM (September 2023). "Effects of Caffeine on Main Symptoms in Children with ADHD: A Systematic Review and Meta-Analysis of Randomized Trials". Brain Sciences. 13 (9): 1304. doi:10.3390/brainsci13091304. PMC 10526204. PMID 37759905.
Hanwella R, Senanayake M, de Silva V (November 2011). "Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis". BMC Psychiatry. 11 (1): 176. doi:10.1186/1471-244X-11-176. PMC 3229459. PMID 22074258.
Rezaei G, Hosseini SA, Akbari Sari A, Olyaeemanesh A, Lotfi MH, Yassini M, et al. (10 February 2016). "Comparative efficacy of methylphenidate and atomoxetine in the treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review and meta-analysis". Medical Journal of the Islamic Republic of Iran. 30: 325. PMC 4898838. PMID 27390695.
Morrow K, Choi S, Young K, Haidar M, Boduch C, Bourgeois JA (September 2021). "Amantadine for the treatment of childhood and adolescent psychiatric symptoms". Proceedings. 34 (5): 566–570. doi:10.1080/08998280.2021.1925827. PMC 8366930. PMID 34456474.
McDonagh MS, Peterson K, Thakurta S, Low A (December 2011). Drug Class Review: Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder (Report). Drug Class Reviews. United States Library of Medicine. PMID 22420008. Archived from the original on 31 August 2016.
Huss M, Chen W, Ludolph AG (January 2016). "Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe". Clinical Drug Investigation. 36 (1). Springer Science and Business Media LLC: 1–25. doi:10.1007/s40261-015-0336-0. PMC 4706844. PMID 26585576.
Arnsten AF, Jin LE (2012). "Focus: Translational Medicine: Guanfacine for the Treatment of Cognitive Disorders: A Century of Discoveries at Yale". The Yale Journal of Biology and Medicine. 85 (1): 45–58. PMC 3313539. PMID 22461743.
Stevens JR, Wilens TE, Stern TA (2013). "Using stimulants for attention-deficit/hyperactivity disorder: clinical approaches and challenges". The Primary Care Companion for CNS Disorders. 15 (2). doi:10.4088/PCC.12f01472. PMC 3733520. PMID 23930227.
Wolraich ML, Hagan JF, Allan C, Chan E, Davison D, Earls M, et al. (October 2019). "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents". Pediatrics. 144 (4): e20192528. doi:10.1542/peds.2019-2528. PMC 7067282. PMID 31570648.
Pelsser LM, Frankena K, Toorman J, Rodrigues Pereira R (January 2017). "Diet and ADHD, Reviewing the Evidence: A Systematic Review of Meta-Analyses of Double-Blind Placebo-Controlled Trials Evaluating the Efficacy of Diet Interventions on the Behavior of Children with ADHD". PLOS ONE (Systematic Review). 12 (1): e0169277. Bibcode:2017PLoSO..1269277P. doi:10.1371/journal.pone.0169277. PMC 5266211. PMID 28121994.
Bloch MH, Mulqueen J (October 2014). "Nutritional supplements for the treatment of ADHD". Child and Adolescent Psychiatric Clinics of North America. 23 (4): 883–897. doi:10.1016/j.chc.2014.05.002. PMC 4170184. PMID 25220092.
McClernon FJ, Kollins SH (October 2008). "ADHD and smoking: from genes to brain to behavior". Annals of the New York Academy of Sciences. 1141 (1): 131–147. Bibcode:2008NYASA1141..131M. doi:10.1196/annals.1441.016. PMC 2758663. PMID 18991955.
Ginsberg Y, Quintero J, Anand E, Casillas M, Upadhyaya HP (2014). "Underdiagnosis of attention-deficit/hyperactivity disorder in adult patients: a review of the literature". The Primary Care Companion for CNS Disorders. 16 (3). doi:10.4088/PCC.13r01600. PMC 4195639. PMID 25317367. Reports indicate that ADHD affects 2.5%–5% of adults in the general population,^5–8 compared with 5%–7% of children.^9,10 ... However, fewer than 20% of adults with ADHD are currently diagnosed and/or treated by psychiatrists.^7,15,16
Baggio S, Fructuoso A, Guimaraes M, Fois E, Golay D, Heller P, et al. (2 August 2018). "Prevalence of Attention Deficit Hyperactivity Disorder in Detention Settings: A Systematic Review and Meta-Analysis". Frontiers in Psychiatry. 9: 331. doi:10.3389/fpsyt.2018.00331. PMC 6084240. PMID 30116206.
Willcutt EG (July 2012). "The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review". Neurotherapeutics. 9 (3): 490–499. doi:10.1007/s13311-012-0135-8. PMC 3441936. PMID 22976615.
Young S, Adamo N, Ásgeirsdóttir BB, Branney P, Beckett M, Colley W, et al. (August 2020). "Females with ADHD: An expert consensus statement taking a lifespan approach providing guidance for the identification and treatment of attention-deficit/ hyperactivity disorder in girls and women". BMC Psychiatry. 20 (1): 404. doi:10.1186/s12888-020-02707-9. PMC 7422602. PMID 32787804.
Whitely M, Raven M, Timimi S, Jureidini J, Phillimore J, Leo J, et al. (April 2019). "Attention deficit hyperactivity disorder late birthdate effect common in both high and low prescribing international jurisdictions: a systematic review". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 60 (4): 380–391. doi:10.1111/jcpp.12991. PMC 7379308. PMID 30317644.
Ford-Jones PC (May 2015). "Misdiagnosis of attention deficit hyperactivity disorder: 'Normal behaviour' and relative maturity". Paediatrics & Child Health. 20 (4): 200–202. doi:10.1093/pch/20.4.200. PMC 4443828. PMID 26038639.
Elder TE (September 2010). "The importance of relative standards in ADHD diagnoses: evidence based on exact birth dates". Journal of Health Economics. 29 (5): 641–656. doi:10.1016/j.jhealeco.2010.06.003. PMC 2933294. PMID 20638739.
Coker TR, Elliott MN, Toomey SL, Schwebel DC, Cuccaro P, Tortolero Emery S, et al. (September 2016). "Racial and Ethnic Disparities in ADHD Diagnosis and Treatment". Pediatrics. 138 (3): e20160407. doi:10.1542/peds.2016-0407. PMC 5684883. PMID 27553219. There are various improvements in care that may help in closing this gap in diagnosis and treatment. These include actively and universally eliciting parental concerns about child behavior and academic performance (at home and school) at well-visits,32,33 providing care that is culturally relevant in families' preferred languages,34 and linking with community resources to provide mental health education, guidance, and services to families (eg, parent training courses for parents of children with ADHD).35–39 Pediatric clinicians also may need to consider universal behavioral health screening tools for children to improve diagnostic capabilities and recognize when a child has ADHD symptoms, even if the problem is not recognized by the parent. Because the rates of diagnosis and treatment are rising in the general population of US children, a significant need remains to identify and treat African-American and Latino children who have ADHD and avoid a widening of these disparities.
Staley BS (2024). "Attention-Deficit/Hyperactivity Disorder Diagnosis, Treatment, and Telehealth Use in Adults — National Center for Health Statistics Rapid Surveys System, United States, October–November 2023". MMWR. Morbidity and Mortality Weekly Report. 73 (40): 890–895. doi:10.15585/mmwr.mm7340a1. ISSN 0149-2195. PMC 11466376. PMID 39388378.
National Collaborating Centre for Mental Health (2009). "Diagnosis". Attention Deficit Hyperactivity Disorder: Diagnosis and Management of ADHD in Children, Young People and Adults. NICE Clinical Guidelines. Vol. 72. Leicester: British Psychological Society. pp. 116–7, 119. ISBN 978-1-85433-471-8. Archived from the original on 13 January 2016 – via NCBI Bookshelf.
Patrick KS, Straughn AB, Perkins JS, González MA (January 2009). "Evolution of stimulants to treat ADHD: transdermal methylphenidate". Human Psychopharmacology. 24 (1): 1–17. doi:10.1002/hup.992. PMC 2629554. PMID 19051222.

nimh.nih.gov

"Attention Deficit Hyperactivity Disorder (Easy-to-Read)". National Institute of Mental Health. 2013. Archived from the original on 14 April 2016. Retrieved 17 April 2016.
"Attention-Deficit/Hyperactivity Disorder". National Institute of Mental Health. September 2023. Retrieved 2 January 2024.
"Attention-Deficit/Hyperactivity Disorder in Adults: What You Need to Know". National Institute of Mental Health. Retrieved 2 January 2024.

nottingham.ac.uk

eprints.nottingham.ac.uk

Daley D, Van Der Oord S, Ferrin M, Cortese S, Danckaerts M, Doepfner M, et al. (September 2018). "Practitioner Review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 59 (9). Wiley: 932–947. doi:10.1111/jcpp.12825. hdl:11343/293788. PMID 29083042. S2CID 31044370. Archived from the original on 25 September 2017. Retrieved 21 November 2018.

nytimes.com

Schwarz A (14 December 2013). "The Selling of Attention Deficit Disorder". The New York Times. Archived from the original on 1 March 2015. Retrieved 26 February 2015.

psu.edu

citeseerx.ist.psu.edu

Berry MD (January 2007). "The potential of trace amines and their receptors for treating neurological and psychiatric diseases". Reviews on Recent Clinical Trials. 2 (1): 3–19. CiteSeerX 10.1.1.329.563. doi:10.2174/157488707779318107. PMID 18473983. Although there is little direct evidence, changes in trace amines, in particular PE, have been identified as a possible factor for the onset of attention deficit/hyperactivity disorder (ADHD). ... Further, amphetamines, which have clinical utility in ADHD, are good ligands at trace amine receptors. Of possible relevance in this aspect is modafanil, which has shown beneficial effects in ADHD patients and has been reported to enhance the activity of PE at TAAR1. Conversely, methylphenidate, ...showed poor efficacy at the TAAR1 receptor. In this respect it is worth noting that the enhancement of functioning at TAAR1 seen with modafanil was not a result of a direct interaction with TAAR1.
Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-Quiroga JA, et al. (August 2015). "Attention-deficit/hyperactivity disorder". Nature Reviews. Disease Primers (Review). 1: 15020. CiteSeerX 10.1.1.497.1346. doi:10.1038/nrdp.2015.20. PMID 27189265. S2CID 7171541.

psychiatrictimes.com

Jummani RR, Hirsch E, Hirsch GS (31 May 2019). "Are We Overdiagnosing and Overtreating ADHD?". Psychiatric Times. 34 (5).
Connor DF (2011). "Problems of overdiagnosis and overprescribing in ADHD: are they legitimate?". Psychiatric Times. Vol. 28, no. 8. p. 14. Archived from the original on 12 August 2021.

researchgate.net

Ibrahim K, Donyai P (July 2015). "Drug Holidays From ADHD Medication: International Experience Over the Past Four Decades". Journal of Attention Disorders. 19 (7): 551–568. doi:10.1177/1087054714548035. PMID 25253684. S2CID 19949563. Archived (PDF) from the original on 30 June 2016.

reuters.com

Singh P (10 October 2024). "More than 15 million US adults have ADHD, new study estimates". Reuters.

ru.nl

repository.ubn.ru.nl

Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-Quiroga JA, et al. (August 2015). "Attention-deficit/hyperactivity disorder" (PDF). Nature Reviews. Disease Primers. 1: 15020. doi:10.1038/nrdp.2015.20. PMID 27189265. S2CID 7171541.
Hoogman M, Stolte M, Baas M, Kroesbergen E (December 2020). "Creativity and ADHD: A review of behavioral studies, the effect of psychostimulants and neural underpinnings" (PDF). Neuroscience and Biobehavioral Reviews. 119: 66–85. doi:10.1016/j.neubiorev.2020.09.029. hdl:1874/409179. PMID 33035524. S2CID 222142805. Archived (PDF) from the original on 6 September 2023. Retrieved 28 August 2023.

rug.nl

pure.rug.nl

https://pure.rug.nl/ws/portalfiles/portal/1124067910/s41572-024-00495-0.pdf

sdu.dk

findresearcher.sdu.dk

Storebø OJ, Rasmussen PD, Simonsen E (February 2016). "Association Between Insecure Attachment and ADHD: Environmental Mediating Factors" (PDF). Journal of Attention Disorders. 20 (2): 187–196. doi:10.1177/1087054713501079. PMID 24062279. S2CID 23564305. Archived (PDF) from the original on 9 December 2021. Retrieved 22 November 2021.

semanticscholar.org

api.semanticscholar.org

Brown TE (October 2008). "ADD/ADHD and Impaired Executive Function in Clinical Practice". Current Psychiatry Reports. 10 (5): 407–411. doi:10.1007/s11920-008-0065-7. PMID 18803914. S2CID 146463279.
Retz W, Stieglitz RD, Corbisiero S, Retz-Junginger P, Rösler M (October 2012). "Emotional dysregulation in adult ADHD: What is the empirical evidence?". Expert Review of Neurotherapeutics. 12 (10): 1241–1251. doi:10.1586/ern.12.109. PMID 23082740. S2CID 207221320.
Barkley RA, Fischer M (July 2019). "Hyperactive Child Syndrome and Estimated Life Expectancy at Young Adult Follow-Up: The Role of ADHD Persistence and Other Potential Predictors". Journal of Attention Disorders. 23 (9): 907–923. doi:10.1177/1087054718816164. PMID 30526189. S2CID 54472439.
Cattoi B, Alpern I, Katz JS, Keepnews D, Solanto MV (April 2022). "The Adverse Health Outcomes, Economic Burden, and Public Health Implications of Unmanaged Attention Deficit Hyperactivity Disorder (ADHD): A Call to Action Resulting from CHADD Summit, Washington, DC, October 17, 2019". Journal of Attention Disorders. 26 (6): 807–808. doi:10.1177/10870547211036754. PMID 34585995. S2CID 238218526.
Worthington R, Wheeler S (January 2023). "Hyperfocus and offending behaviour: a systematic review" (PDF). The Journal of Forensic Practice. 25 (3): 185–200. doi:10.1108/JFP-01-2022-0005. ISSN 2050-8794. S2CID 258330884.
Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-Quiroga JA, et al. (August 2015). "Attention-deficit/hyperactivity disorder" (PDF). Nature Reviews. Disease Primers. 1: 15020. doi:10.1038/nrdp.2015.20. PMID 27189265. S2CID 7171541.
Eme R (April 2012). "ADHD: an integration with pediatric traumatic brain injury". Expert Review of Neurotherapeutics. 12 (4): 475–483. doi:10.1586/ern.12.15. PMID 22449218. S2CID 35718630.
Gershon J (January 2002). "A meta-analytic review of gender differences in ADHD". Journal of Attention Disorders. 5 (3): 143–154. doi:10.1177/108705470200500302. PMID 11911007. S2CID 8076914.
Racine MB, Majnemer A, Shevell M, Snider L (April 2008). "Handwriting performance in children with attention deficit hyperactivity disorder (ADHD)". Journal of Child Neurology. 23 (4): 399–406. doi:10.1177/0883073807309244. PMID 18401033. S2CID 206546871.
Sexton CC, Gelhorn HL, Bell JA, Classi PM (November 2012). "The co-occurrence of reading disorder and ADHD: epidemiology, treatment, psychosocial impact, and economic burden". Journal of Learning Disabilities. 45 (6): 538–564. doi:10.1177/0022219411407772. PMID 21757683. S2CID 385238.
Nicolson RI, Fawcett AJ (January 2011). "Dyslexia, dysgraphia, procedural learning and the cerebellum". Cortex; A Journal Devoted to the Study of the Nervous System and Behavior. 47 (1): 117–127. doi:10.1016/j.cortex.2009.08.016. PMID 19818437. S2CID 32228208.
Frazier TW, Demaree HA, Youngstrom EA (July 2004). "Meta-analysis of intellectual and neuropsychological test performance in attention-deficit/hyperactivity disorder". Neuropsychology. 18 (3): 543–555. doi:10.1037/0894-4105.18.3.543. PMID 15291732. S2CID 17628705.
Rommelse N, van der Kruijs M, Damhuis J, Hoek I, Smeets S, Antshel KM, et al. (December 2016). "An evidenced-based perspective on the validity of attention-deficit/hyperactivity disorder in the context of high intelligence". Neuroscience and Biobehavioral Reviews. 71: 21–47. doi:10.1016/j.neubiorev.2016.08.032. hdl:2066/163023. PMID 27590827. S2CID 6698847.
Rubia K (June 2011). ""Cool" inferior frontostriatal dysfunction in attention-deficit/hyperactivity disorder versus "hot" ventromedial orbitofrontal-limbic dysfunction in conduct disorder: a review". Biological Psychiatry. 69 (12). Elsevier BV/The Society of Biological Psychiatry: e69–e87. doi:10.1016/j.biopsych.2010.09.023. PMID 21094938. S2CID 14987165.
Bendz LM, Scates AC (January 2010). "Melatonin treatment for insomnia in pediatric patients with attention-deficit/hyperactivity disorder". The Annals of Pharmacotherapy. 44 (1): 185–191. doi:10.1345/aph.1M365. PMID 20028959. S2CID 207263711.
Storebø OJ, Rasmussen PD, Simonsen E (February 2016). "Association Between Insecure Attachment and ADHD: Environmental Mediating Factors" (PDF). Journal of Attention Disorders. 20 (2): 187–196. doi:10.1177/1087054713501079. PMID 24062279. S2CID 23564305. Archived (PDF) from the original on 9 December 2021. Retrieved 22 November 2021.
Barkley RA (January 2014). "Sluggish cognitive tempo (concentration deficit disorder?): current status, future directions, and a plea to change the name" (PDF). Journal of Abnormal Child Psychology. 42 (1): 117–125. doi:10.1007/s10802-013-9824-y. PMID 24234590. S2CID 8287560. Archived (PDF) from the original on 9 August 2017.
Nazar BP, Bernardes C, Peachey G, Sergeant J, Mattos P, Treasure J (December 2016). "The risk of eating disorders comorbid with attention-deficit/hyperactivity disorder: A systematic review and meta-analysis". The International Journal of Eating Disorders. 49 (12): 1045–1057. doi:10.1002/eat.22643. PMID 27859581. S2CID 38002526. Archived from the original on 8 December 2022. Retrieved 26 October 2022.
Schneider M, VanOrmer J, Zlomke K (2019). "Adverse Childhood Experiences and Family Resilience Among Children with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder". Journal of Developmental and Behavioral Pediatrics. 40 (8): 573–580. doi:10.1097/DBP.0000000000000703. PMID 31335581. S2CID 198193637.
Ford JD, Connor DF (1 June 2009). "ADHD and post-traumatic stress disorder". Current Attention Disorders Reports. 1 (2): 60–66. doi:10.1007/s12618-009-0009-0. ISSN 1943-457X. S2CID 145508751.
Szymanski K, Sapanski L, Conway F (1 January 2011). "Trauma and ADHD – Association or Diagnostic Confusion? A Clinical Perspective". Journal of Infant, Child, and Adolescent Psychotherapy. 10 (1). Philadelphia PA: Taylor & Francis Group: 51–59. doi:10.1080/15289168.2011.575704. eISSN 1940-9214. ISSN 1528-9168. S2CID 144348893.
Nguyen MN, Watanabe-Galloway S, Hill JL, Siahpush M, Tibbits MK, Wichman C (June 2019). "Ecological model of school engagement and attention-deficit/hyperactivity disorder in school-aged children". European Child & Adolescent Psychiatry. 28 (6): 795–805. doi:10.1007/s00787-018-1248-3. PMID 30390147. S2CID 53263217.
Miodus S, Allwood MA, Amoh N (5 January 2021). "Childhood ADHD Symptoms in Relation to Trauma Exposure and PTSD Symptoms Among College Students: Attending to and Accommodating Trauma". Journal of Emotional and Behavioral Disorders. 29 (3): 187–196. doi:10.1177/1063426620982624. ISSN 1063-4266. S2CID 234159064.
Hsu TW, Chen MH, Chu CS, Tsai SJ, Bai YM, Su TP, et al. (May 2022). "Attention deficit hyperactivity disorder and risk of migraine: A nationwide longitudinal study". Headache. 62 (5): 634–641. doi:10.1111/head.14306. PMID 35524451. S2CID 248553863.
Salem H, Vivas D, Cao F, Kazimi IF, Teixeira AL, Zeni CP (March 2018). "ADHD is associated with migraine: a systematic review and meta-analysis". European Child & Adolescent Psychiatry. 27 (3). Springer Science and Business Media LLC: 267–277. doi:10.1007/s00787-017-1045-4. PMID 28905127. S2CID 3949012.
Cannon Homaei S, Barone H, Kleppe R, Betari N, Reif A, Haavik J (January 2022). "ADHD symptoms in neurometabolic diseases: Underlying mechanisms and clinical implications". Neuroscience and Biobehavioral Reviews. 132: 838–856. doi:10.1016/j.neubiorev.2021.11.012. PMID 34774900. S2CID 243983688.
Brunkhorst-Kanaan N, Libutzki B, Reif A, Larsson H, McNeill RV, Kittel-Schneider S (June 2021). "ADHD and accidents over the life span - A systematic review". Neuroscience and Biobehavioral Reviews. 125. Elsevier: 582–591. doi:10.1016/j.neubiorev.2021.02.002. PMID 33582234. S2CID 231885131.
Dullur P, Krishnan V, Diaz AM (2021). "A systematic review on the intersection of attention-deficit hyperactivity disorder and gaming disorder". Journal of Psychiatric Research. 133. Elsevier: 212–222. doi:10.1016/j.jpsychires.2020.12.026. PMID 33360866. S2CID 229687229.
Santos RM, Mendes CG, Miranda DM, Romano-Silva MA (2022). "The Association between Screen Time and Attention in Children: A Systematic Review". Developmental Neuropsychology. 47 (4). Routledge: 175–192. doi:10.1080/87565641.2022.2064863. PMID 35430923. S2CID 248228233.
Liu H, Chen X, Huang M, Yu X, Gan Y, Wang J, et al. (2023). "Screen time and childhood attention deficit hyperactivity disorder: a meta-analysis". Reviews on Environmental Health. De Gruyter. doi:10.1515/reveh-2022-0262. PMID 37163581. S2CID 258591184.
Augner C, Vlasak T, Barth A (2023). "The relationship between problematic internet use and attention deficit, hyperactivity and impulsivity: A meta-analysis". Journal of Psychiatric Research. 168. Elsevier: 1–12. doi:10.1016/j.jpsychires.2023.10.032. PMID 37866293. S2CID 264190691.
Septier M, Stordeur C, Zhang J, Delorme R, Cortese S (August 2019). "Association between suicidal spectrum behaviors and Attention-Deficit/Hyperactivity Disorder: A systematic review and meta-analysis". Neuroscience and Biobehavioral Reviews. 103: 109–118. doi:10.1016/j.neubiorev.2019.05.022. PMID 31129238. S2CID 162184004. Archived from the original on 4 November 2021. Retrieved 7 December 2021.
Biederman J (June 2005). "Attention-deficit/hyperactivity disorder: a selective overview". Biological Psychiatry. 57 (11): 1215–1220. doi:10.1016/j.biopsych.2004.10.020. PMID 15949990. S2CID 23671547.
Faraone SV, Larsson H (April 2019). "Genetics of attention deficit hyperactivity disorder". Molecular Psychiatry. 24 (4): 562–575. doi:10.1038/s41380-018-0070-0. PMC 6477889. PMID 29892054. S2CID 47016805.
Biederman J, Spencer T (November 1999). "Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder". Biological Psychiatry. 46 (9). Elsevier: 1234–1242. doi:10.1016/S0006-3223(99)00192-4. PMID 10560028. S2CID 45497168.
Baron-Cohen S (June 2002). "The extreme male brain theory of autism". Trends in Cognitive Sciences. 6 (6). Elsevier: 248–254. doi:10.1016/S1364-6613(02)01904-6. PMID 12039606. S2CID 8098723. Archived from the original on 3 July 2013. Retrieved 9 July 2020.
Kebir O, Joober R (December 2011). "Neuropsychological endophenotypes in attention-deficit/hyperactivity disorder: a review of genetic association studies". European Archives of Psychiatry and Clinical Neuroscience. 261 (8): 583–594. doi:10.1007/s00406-011-0207-5. PMID 21409419. S2CID 21383749.
Gizer IR, Ficks C, Waldman ID (July 2009). "Candidate gene studies of ADHD: a meta-analytic review". Human Genetics. 126 (1): 51–90. doi:10.1007/s00439-009-0694-x. PMID 19506906. S2CID 166017.
Sonuga-Barke EJ, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M, et al. (March 2013). "Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments". The American Journal of Psychiatry. 170 (3): 275–289. doi:10.1176/appi.ajp.2012.12070991. eISSN 1535-7228. LCCN 22024537. OCLC 1480183. PMID 23360949. S2CID 434310. Free fatty acid supplementation and artificial food color exclusions appear to have beneficial effects on ADHD symptoms, although the effect of the former are small and those of the latter may be limited to ADHD patients with food sensitivities...
Burger PH, Goecke TW, Fasching PA, Moll G, Heinrich H, Beckmann MW, et al. (September 2011). "[How does maternal alcohol consumption during pregnancy affect the development of attention deficit/hyperactivity syndrome in the child]" [How does maternal alcohol consumption during pregnancy affect the development of attention deficit/hyperactivity syndrome in the child]. Fortschritte der Neurologie-Psychiatrie (Review) (in German). 79 (9): 500–506. doi:10.1055/s-0031-1273360. PMID 21739408. S2CID 140766296.
de Cock M, Maas YG, van de Bor M (August 2012). "Does perinatal exposure to endocrine disruptors induce autism spectrum and attention deficit hyperactivity disorders? Review". Acta Paediatrica (Review. Research Support, Non-U.S. Gov't). 101 (8): 811–818. doi:10.1111/j.1651-2227.2012.02693.x. PMID 22458970. S2CID 41748237.
Abbott LC, Winzer-Serhan UH (April 2012). "Smoking during pregnancy: lessons learned from epidemiological studies and experimental studies using animal models". Critical Reviews in Toxicology (Review). 42 (4): 279–303. doi:10.3109/10408444.2012.658506. PMID 22394313. S2CID 38886526.
Millichap JG (February 2008). "Etiologic classification of attention-deficit/hyperactivity disorder". Pediatrics (Review). 121 (2): e358–e365. doi:10.1542/peds.2007-1332. PMID 18245408. S2CID 24339363.
Eme R (April 2012). "ADHD: an integration with pediatric traumatic brain injury". Expert Review of Neurotherapeutics (Review). 12 (4): 475–483. doi:10.1586/ern.12.15. PMID 22449218. S2CID 35718630.
Millichap JG, Yee MM (February 2012). "The diet factor in attention-deficit/hyperactivity disorder". Pediatrics. 129 (2): 330–337. doi:10.1542/peds.2011-2199. PMID 22232312. S2CID 14925322. Archived from the original on 11 September 2015.
Damiani S, Tarchi L, Scalabrini A, Marini S, Provenzani U, Rocchetti M, et al. (April 2021). "Beneath the surface: hyper-connectivity between caudate and salience regions in ADHD fMRI at rest". European Child & Adolescent Psychiatry. 30 (4): 619–631. doi:10.1007/s00787-020-01545-0. hdl:2318/1755224. PMID 32385695. S2CID 218540328.
Lesch KP, Merker S, Reif A, Novak M (June 2013). "Dances with black widow spiders: dysregulation of glutamate signalling enters centre stage in ADHD". European Neuropsychopharmacology. 23 (6): 479–491. doi:10.1016/j.euroneuro.2012.07.013. PMID 22939004. S2CID 14701654.
Skodzik T, Holling H, Pedersen A (February 2017). "Long-Term Memory Performance in Adult ADHD". Journal of Attention Disorders. 21 (4): 267–283. doi:10.1177/1087054713510561. PMID 24232170. S2CID 27070077.
Modesto-Lowe V, Chaplin M, Soovajian V, Meyer A (July 2013). "Are motivation deficits underestimated in patients with ADHD? A review of the literature". Postgraduate Medicine. 125 (4): 47–52. doi:10.3810/pgm.2013.07.2677. PMID 23933893. S2CID 24817804. Behavioral studies show altered processing of reinforcement and incentives in children with ADHD. These children respond more impulsively to rewards and choose small, immediate rewards over larger, delayed incentives. Interestingly, a high intensity of reinforcement is effective in improving task performance in children with ADHD. Pharmacotherapy may also improve task persistence in these children. ... Previous studies suggest that a clinical approach using interventions to improve motivational processes in patients with ADHD may improve outcomes as children with ADHD transition into adolescence and adulthood.
Singh I (December 2008). "Beyond polemics: science and ethics of ADHD". Nature Reviews. Neuroscience. 9 (12): 957–964. doi:10.1038/nrn2514. PMID 19020513. S2CID 205504587.
Owens JA (October 2008). "Sleep disorders and attention-deficit/hyperactivity disorder". Current Psychiatry Reports. 10 (5): 439–444. doi:10.1007/s11920-008-0070-x. PMID 18803919. S2CID 23624443.
Wigal SB (2009). "Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults". CNS Drugs. 23 (Suppl 1): 21–31. doi:10.2165/00023210-200923000-00004. PMID 19621975. S2CID 11340058.
Mayes R, Bagwell C, Erkulwater J (2008). "ADHD and the rise in stimulant use among children". Harvard Review of Psychiatry. 16 (3): 151–166. doi:10.1080/10673220802167782. PMID 18569037. S2CID 18481191.
Daley D, Van Der Oord S, Ferrin M, Cortese S, Danckaerts M, Doepfner M, et al. (September 2018). "Practitioner Review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 59 (9). Wiley: 932–947. doi:10.1111/jcpp.12825. hdl:11343/293788. PMID 29083042. S2CID 31044370. Archived from the original on 25 September 2017. Retrieved 21 November 2018.
Bjornstad G, Montgomery P (April 2005). Bjornstad GJ (ed.). "Family therapy for attention-deficit disorder or attention-deficit/hyperactivity disorder in children and adolescents". The Cochrane Database of Systematic Reviews (2): CD005042. doi:10.1002/14651858.CD005042.pub2. PMID 15846741. S2CID 27339381.
Frodl T, Skokauskas N (February 2012). "Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects". Acta Psychiatrica Scandinavica. 125 (2): 114–126. doi:10.1111/j.1600-0447.2011.01786.x. PMID 22118249. S2CID 25954331. Basal ganglia regions like the right globus pallidus, the right putamen, and the nucleus caudatus are structurally affected in children with ADHD. These changes and alterations in limbic regions like ACC and amygdala are more pronounced in non-treated populations and seem to diminish over time from child to adulthood. Treatment seems to have positive effects on brain structure.
Stuhec M, Lukić P, Locatelli I (February 2019). "Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis". The Annals of Pharmacotherapy. 53 (2): 121–133. doi:10.1177/1060028018795703. PMID 30117329. S2CID 52019992.
Faraone SV, Biederman J, Roe C (October 2002). "Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis". Journal of Clinical Psychopharmacology. 22 (5): 468–473. doi:10.1097/00004714-200210000-00005. PMID 12352269. S2CID 19726926.
Wynchank D, Bijlenga D, Beekman AT, Kooij JJ, Penninx BW (October 2017). "Adult Attention-Deficit/Hyperactivity Disorder (ADHD) and Insomnia: an Update of the Literature". Current Psychiatry Reports. 19 (12). Springer Science and Business Media LLC: 98. doi:10.1007/s11920-017-0860-0. PMID 29086065. S2CID 38064951. In varying percentages of trial participants, insomnia is a treatment-emergent adverse effect in triple-bead mixed amphetamine salts (40–45%), dasotraline (35–45%), lisdexamfetamine (10–19%), and extended-release methylphenidate (11%).
Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R (February 2009). "Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children". Pediatrics. 123 (2): 611–616. doi:10.1542/peds.2008-0185. PMID 19171629. S2CID 22391693.
Ashton H, Gallagher P, Moore B (September 2006). "The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorder". Journal of Psychopharmacology. 20 (5): 602–610. doi:10.1177/0269881106061710. PMID 16478756. S2CID 32073083.
Kiely B, Adesman A (June 2015). "What we do not know about ADHD… yet". Current Opinion in Pediatrics. 27 (3): 395–404. doi:10.1097/MOP.0000000000000229. PMID 25888152. S2CID 39004402. In addition, a consensus has not been reached on the optimal diagnostic criteria for ADHD. Moreover, the benefits and long-term effects of medical and complementary therapies for this disorder continue to be debated. These gaps in knowledge hinder the ability of clinicians to effectively recognise and treat ADHD.
Hazell P (July 2011). "The challenges to demonstrating long-term effects of psychostimulant treatment for attention-deficit/hyperactivity disorder". Current Opinion in Psychiatry. 24 (4): 286–290. doi:10.1097/YCO.0b013e32834742db. PMID 21519262. S2CID 21998152. Archived from the original on 26 July 2020. Retrieved 19 July 2019.
Kraemer M, Uekermann J, Wiltfang J, Kis B (July 2010). "Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature". Clinical Neuropharmacology. 33 (4): 204–206. doi:10.1097/WNF.0b013e3181e29174. PMID 20571380. S2CID 34956456.
van de Loo-Neus GH, Rommelse N, Buitelaar JK (August 2011). "To stop or not to stop? How long should medication treatment of attention-deficit hyperactivity disorder be extended?". European Neuropsychopharmacology. 21 (8): 584–599. doi:10.1016/j.euroneuro.2011.03.008. PMID 21530185. S2CID 30068561.
Ibrahim K, Donyai P (July 2015). "Drug Holidays From ADHD Medication: International Experience Over the Past Four Decades". Journal of Attention Disorders. 19 (7): 551–568. doi:10.1177/1087054714548035. PMID 25253684. S2CID 19949563. Archived (PDF) from the original on 30 June 2016.
Turner D (April 2006). "A review of the use of modafinil for attention-deficit hyperactivity disorder". Expert Review of Neurotherapeutics. 6 (4): 455–468. doi:10.1586/14737175.6.4.455. PMID 16623645. S2CID 24293088.
Bushe C, Day K, Reed V, Karlsdotter K, Berggren L, Pitcher A, et al. (May 2016). "A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients". Journal of Psychopharmacology. 30 (5): 444–458. doi:10.1177/0269881116636105. PMID 27005307. S2CID 104938.
Hazell PL, Kohn MR, Dickson R, Walton RJ, Granger RE, Wyk GW (November 2011). "Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis". Journal of Attention Disorders. 15 (8): 674–683. doi:10.1177/1087054710379737. PMID 20837981. S2CID 43503227.
Faraone SV, Gomeni R, Hull JT, Busse GD, Melyan Z, O'Neal W, et al. (February 2021). "Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials". Psychiatry Research. 296: 113664. doi:10.1016/j.psychres.2020.113664. PMID 33418457. S2CID 230716405.
Mohammadi MR, Kazemi MR, Zia E, Rezazadeh SA, Tabrizi M, Akhondzadeh S (November 2010). "Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial". Human Psychopharmacology. 25 (7–8): 560–565. doi:10.1002/hup.1154. PMID 21312290. S2CID 30677758.
Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, et al. (SPD503 Study Group) (January 2008). "A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder". Pediatrics. 121 (1): e73–e84. doi:10.1542/peds.2006-3695. PMID 18166547. S2CID 25551406.
Kessler S (January 1996). "Drug therapy in attention-deficit hyperactivity disorder". Southern Medical Journal. 89 (1): 33–38. doi:10.1097/00007611-199601000-00005. PMID 8545689. S2CID 12798818.
Ertürk E, Wouters S, Imeraj L, Lampo A (August 2020). "Association of ADHD and Celiac Disease: What Is the Evidence? A Systematic Review of the Literature". Journal of Attention Disorders (Review). 24 (10): 1371–1376. doi:10.1177/1087054715611493. PMID 26825336. S2CID 33989148. Up till now, there is no conclusive evidence for a relationship between ADHD and CD. Therefore, it is not advised to perform routine screening of CD when assessing ADHD (and vice versa) or to implement GFD as a standard treatment in ADHD. Nevertheless, the possibility of untreated CD predisposing to ADHD-like behavior should be kept in mind. ... It is possible that in untreated patients with CD, neurologic symptoms such as chronic fatigue, inattention, pain, and headache could predispose patients to ADHD-like behavior (mainly symptoms of inattentive type), which may be alleviated after GFD treatment.
Krause J (April 2008). "SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder". Expert Review of Neurotherapeutics. 8 (4): 611–625. doi:10.1586/14737175.8.4.611. PMID 18416663. S2CID 24589993. Zinc binds at ... extracellular sites of the DAT, serving as a DAT inhibitor. In this context, controlled double-blind studies in children are of interest, which showed positive effects of zinc [supplementation] on symptoms of ADHD. It should be stated that at this time [supplementation] with zinc is not integrated in any ADHD treatment algorithm.
Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-Quiroga JA, et al. (August 2015). "Attention-deficit/hyperactivity disorder". Nature Reviews. Disease Primers (Review). 1: 15020. CiteSeerX 10.1.1.497.1346. doi:10.1038/nrdp.2015.20. PMID 27189265. S2CID 7171541.
Staller J, Faraone SV (2006). "Attention-deficit hyperactivity disorder in girls: epidemiology and management". CNS Drugs. 20 (2): 107–123. doi:10.2165/00023210-200620020-00003. PMID 16478287. S2CID 25835322.
Slobodin O, Masalha R (June 2020). "Challenges in ADHD care for ethnic minority children: A review of the current literature". Transcultural Psychiatry. 57 (3): 468–483. doi:10.1177/1363461520902885. PMID 32233772. S2CID 214768588.
Faraone SV (February 2005). "The scientific foundation for understanding attention-deficit/hyperactivity disorder as a valid psychiatric disorder". European Child & Adolescent Psychiatry. 14 (1): 1–10. doi:10.1007/s00787-005-0429-z. PMID 15756510. S2CID 143646869.
Rasmussen N (July 2006). "Making the first anti-depressant: amphetamine in American medicine, 1929-1950". Journal of the History of Medicine and Allied Sciences. 61 (3): 288–323. doi:10.1093/jhmas/jrj039. PMID 16492800. S2CID 24974454.
Hoogman M, Stolte M, Baas M, Kroesbergen E (December 2020). "Creativity and ADHD: A review of behavioral studies, the effect of psychostimulants and neural underpinnings" (PDF). Neuroscience and Biobehavioral Reviews. 119: 66–85. doi:10.1016/j.neubiorev.2020.09.029. hdl:1874/409179. PMID 33035524. S2CID 222142805. Archived (PDF) from the original on 6 September 2023. Retrieved 28 August 2023.

soton.ac.uk

eprints.soton.ac.uk

Septier M, Stordeur C, Zhang J, Delorme R, Cortese S (August 2019). "Association between suicidal spectrum behaviors and Attention-Deficit/Hyperactivity Disorder: A systematic review and meta-analysis". Neuroscience and Biobehavioral Reviews. 103: 109–118. doi:10.1016/j.neubiorev.2019.05.022. PMID 31129238. S2CID 162184004. Archived from the original on 4 November 2021. Retrieved 7 December 2021.

theguardian.com

Boseley S (30 September 2010). "Hyperactive children may have genetic disorder, says study". The Guardian. Archived from the original on 8 July 2017.

thelancet.com

Institute for Health Metrics and Evaluation (17 October 2020). "Global Burden of Disease Study 2019: Attention-deficit/hyperactivity disorder—Level 3 cause" (PDF). The Lancet. 396 (10258). Table 1. Archived (PDF) from the original on 7 January 2021. Retrieved 7 January 2021.. Both DSM-IV-TR and ICD-10 criteria were used.

uclan.ac.uk

clok.uclan.ac.uk

Worthington R, Wheeler S (January 2023). "Hyperfocus and offending behaviour: a systematic review" (PDF). The Journal of Forensic Practice. 25 (3): 185–200. doi:10.1108/JFP-01-2022-0005. ISSN 2050-8794. S2CID 258330884.

uiowa.edu

psychology.uiowa.edu

Barkley RA (January 2014). "Sluggish cognitive tempo (concentration deficit disorder?): current status, future directions, and a plea to change the name" (PDF). Journal of Abnormal Child Psychology. 42 (1): 117–125. doi:10.1007/s10802-013-9824-y. PMID 24234590. S2CID 8287560. Archived (PDF) from the original on 9 August 2017.

uptodate.com

Krull KR (5 December 2007). "Evaluation and diagnosis of attention deficit hyperactivity disorder in children". Uptodate. Wolters Kluwer Health. Archived from the original on 5 June 2009. Retrieved 12 September 2008.

web.archive.org

Young K (9 February 2017). "Anxiety or ADHD? Why They Sometimes Look the Same and How to Tell the Difference". Hey Sigmund. Archived from the original on 26 January 2023. Retrieved 27 January 2023.
Institute for Health Metrics and Evaluation (17 October 2020). "Global Burden of Disease Study 2019: Attention-deficit/hyperactivity disorder—Level 3 cause" (PDF). The Lancet. 396 (10258). Table 1. Archived (PDF) from the original on 7 January 2021. Retrieved 7 January 2021.. Both DSM-IV-TR and ICD-10 criteria were used.
"Attention Deficit Hyperactivity Disorder (Easy-to-Read)". National Institute of Mental Health. 2013. Archived from the original on 14 April 2016. Retrieved 17 April 2016.
"Facts About ADHD". Centers for Disease Control and Prevention. 6 January 2016. Archived from the original on 22 March 2016. Retrieved 20 March 2016.
Dobie C, Donald WB, Hanson M, Heim C, Huxsahl J, Karasov R, et al. (March 2012). "Diagnosis and management of attention deficit hyperactivity disorder in primary care for school-age children and adolescents". National Guideline Clearinghous. p. 79. Archived from the original on 1 March 2013. Retrieved 10 October 2012.
"ADHD Anger Management Directory". Webmd.com. Archived from the original on 5 November 2013. Retrieved 17 January 2014.
"F90 Hyperkinetic disorders". International Statistical Classification of Diseases and Related Health Problems 10th Revision. World Health Organisation. 2010. Archived from the original on 2 November 2014. Retrieved 2 November 2014.
"Dyslexia and ADHD". Archived from the original on 21 February 2023. Retrieved 19 May 2022.
"ADHD Symptoms". nhs.uk. 20 October 2017. Archived from the original on 1 February 2021. Retrieved 15 May 2018.
Bailey E (5 September 2007). "ADHD and Learning Disabilities: How can you help your child cope with ADHD and subsequent Learning Difficulties? There is a way". Remedy Health Media, LLC. Archived from the original on 3 December 2013. Retrieved 15 November 2013.
Krull KR (5 December 2007). "Evaluation and diagnosis of attention deficit hyperactivity disorder in children". Uptodate. Wolters Kluwer Health. Archived from the original on 5 June 2009. Retrieved 12 September 2008.
Hofvander B, Ossowski D, Lundström S, Anckarsäter H (2009). "Continuity of aggressive antisocial behavior from childhood to adulthood: The question of phenotype definition". International Journal of Law and Psychiatry. 32 (4): 224–234. doi:10.1016/j.ijlp.2009.04.004. PMID 19428109. Archived from the original on 17 May 2022. Retrieved 22 November 2021.
National Collaborating Centre for Mental Health (2009). "Attention Deficit Hyperactivity Disorder". Attention Deficit Hyperactivity Disorder: Diagnosis and Management of ADHD in Children, Young People and Adults. NICE Clinical Guidelines. Vol. 72. Leicester: British Psychological Society. pp. 18–26, 38. ISBN 978-1-85433-471-8. Archived from the original on 13 January 2016 – via NCBI Bookshelf.
Storebø OJ, Rasmussen PD, Simonsen E (February 2016). "Association Between Insecure Attachment and ADHD: Environmental Mediating Factors" (PDF). Journal of Attention Disorders. 20 (2): 187–196. doi:10.1177/1087054713501079. PMID 24062279. S2CID 23564305. Archived (PDF) from the original on 9 December 2021. Retrieved 22 November 2021.
Barkley RA (January 2014). "Sluggish cognitive tempo (concentration deficit disorder?): current status, future directions, and a plea to change the name" (PDF). Journal of Abnormal Child Psychology. 42 (1): 117–125. doi:10.1007/s10802-013-9824-y. PMID 24234590. S2CID 8287560. Archived (PDF) from the original on 9 August 2017.
Nazar BP, Bernardes C, Peachey G, Sergeant J, Mattos P, Treasure J (December 2016). "The risk of eating disorders comorbid with attention-deficit/hyperactivity disorder: A systematic review and meta-analysis". The International Journal of Eating Disorders. 49 (12): 1045–1057. doi:10.1002/eat.22643. PMID 27859581. S2CID 38002526. Archived from the original on 8 December 2022. Retrieved 26 October 2022.
Septier M, Stordeur C, Zhang J, Delorme R, Cortese S (August 2019). "Association between suicidal spectrum behaviors and Attention-Deficit/Hyperactivity Disorder: A systematic review and meta-analysis". Neuroscience and Biobehavioral Reviews. 103: 109–118. doi:10.1016/j.neubiorev.2019.05.022. PMID 31129238. S2CID 162184004. Archived from the original on 4 November 2021. Retrieved 7 December 2021.
Baron-Cohen S (June 2002). "The extreme male brain theory of autism". Trends in Cognitive Sciences. 6 (6). Elsevier: 248–254. doi:10.1016/S1364-6613(02)01904-6. PMID 12039606. S2CID 8098723. Archived from the original on 3 July 2013. Retrieved 9 July 2020.
CDC (16 March 2016). "Attention-Deficit / Hyperactivity Disorder (ADHD)". Centers for Disease Control and Prevention. Archived from the original on 14 April 2016. Retrieved 17 April 2016.
Botting N, Powls A, Cooke RW, Marlow N (November 1997). "Attention deficit hyperactivity disorders and other psychiatric outcomes in very low birthweight children at 12 years". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 38 (8): 931–941. doi:10.1111/j.1469-7610.1997.tb01612.x. PMID 9413793. Archived from the original on 17 May 2022. Retrieved 22 March 2022.
Millichap JG, Yee MM (February 2012). "The diet factor in attention-deficit/hyperactivity disorder". Pediatrics. 129 (2): 330–337. doi:10.1542/peds.2011-2199. PMID 22232312. S2CID 14925322. Archived from the original on 11 September 2015.
"Background Document for the Food Advisory Committee: Certified Color Additives in Food and Possible Association with Attention Deficit Hyperactivity Disorder in Children" (PDF). U.S. Food and Drug Administration. March 2011. Archived (PDF) from the original on 6 November 2015.
"Mental health of children and adolescents" (PDF). WHO Europe. 15 January 2005. Archived from the original (PDF) on 24 October 2009. Retrieved 13 October 2011.
National Collaborating Centre for Mental Health (2009). Attention Deficit Hyperactivity Disorder: Diagnosis and Management of ADHD in Children, Young People and Adults. NICE Clinical Guidelines. Vol. 72. Leicester: British Psychological Society. ISBN 978-1-85433-471-8. Archived from the original on 13 January 2016 – via NCBI Bookshelf.
"ADHD –Pathophysiology". MerckMedicus Modules. Whitehouse Station, NJ, USA: Merck & Co., Inc. August 2002. Archived from the original on 1 May 2010.
Caroline SC, ed. (2010). Encyclopedia of Cross-Cultural School Psychology. Springer Science & Business Media. p. 133. ISBN 978-0-387-71798-2. Archived from the original on 22 December 2020. Retrieved 1 February 2016.
Wiener JM, Dulcan MK (2004). Textbook Of Child and Adolescent Psychiatry (illustrated ed.). American Psychiatric Publishing. ISBN 978-1-58562-057-9. Archived from the original on 6 May 2016. Retrieved 2 November 2014.
"Adult ADHD: Diagnosis". CAMH. Archived from the original on 21 June 2021. Retrieved 17 April 2022.
Berger I (September 2011). "Diagnosis of attention deficit hyperactivity disorder: much ado about something" (PDF). The Israel Medical Association Journal. 13 (9): 571–574. PMID 21991721. Archived (PDF) from the original on 28 July 2020. Retrieved 23 May 2013.
Consumer Reports, Drug Effectiveness Review Project (March 2012). "Evaluating Prescription Drugs Used to Treat: Attention Deficit Hyperactivity Disorder (ADHD) Comparing Effectiveness, Safety, and Price" (PDF). Best Buy Drugs: 2. Archived (PDF) from the original on 15 November 2012. Retrieved 12 April 2013.
Coghill DR, Banaschewski T, Soutullo C, Cottingham MG, Zuddas A (November 2017). "Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder". European Child & Adolescent Psychiatry. 26 (11): 1283–1307. doi:10.1007/s00787-017-0986-y. PMC 5656703. PMID 28429134. Text was copied from this source, which is available under a Creative Commons Attribution 4.0 International License "CC BY 4.0 Deed | Attribution 4.0 International | Creative Commons". Archived from the original on 16 October 2017. Retrieved 22 October 2022.{{cite web}}: CS1 maint: bot: original URL status unknown (link).
Daley D, Van Der Oord S, Ferrin M, Cortese S, Danckaerts M, Doepfner M, et al. (September 2018). "Practitioner Review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 59 (9). Wiley: 932–947. doi:10.1111/jcpp.12825. hdl:11343/293788. PMID 29083042. S2CID 31044370. Archived from the original on 25 September 2017. Retrieved 21 November 2018.
"Adderall XR Prescribing Information" (PDF). United States Food and Drug Administration. Shire US Inc. December 2013. Archived (PDF) from the original on 30 December 2013. Retrieved 30 December 2013. Treatment-emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without prior history of psychotic illness or mania can be caused by stimulants at usual doses. ... In a pooled analysis of multiple short-term, placebo controlled studies, such symptoms occurred in about 0.1% (4 patients with events out of 3482 exposed to methylphenidate or amphetamine for several weeks at usual doses) of stimulant-treated patients compared to 0 in placebo-treated patients.
Hazell P (July 2011). "The challenges to demonstrating long-term effects of psychostimulant treatment for attention-deficit/hyperactivity disorder". Current Opinion in Psychiatry. 24 (4): 286–290. doi:10.1097/YCO.0b013e32834742db. PMID 21519262. S2CID 21998152. Archived from the original on 26 July 2020. Retrieved 19 July 2019.
Kemper AR, Maslow GR, Hill S, Namdari B, Allen Lapointe NM, Goode AP, et al. (January 2018). "Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment in Children and Adolescents". Comparative Effectiveness Reviews (203). Rockville (MD): Agency for Healthcare Research and Quality (US). PMID 29558081. Archived from the original on 17 May 2022. Retrieved 7 November 2021.
Ibrahim K, Donyai P (July 2015). "Drug Holidays From ADHD Medication: International Experience Over the Past Four Decades". Journal of Attention Disorders. 19 (7): 551–568. doi:10.1177/1087054714548035. PMID 25253684. S2CID 19949563. Archived (PDF) from the original on 30 June 2016.
McDonagh MS, Christensen V, Peterson K, Thakurta S (October 2009). "Black box warnings of ADHD drugs approved by the US Food and Drug Administration". Drug Class Review: Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder: Final Report Update 3 [Internet]. Portland, Oregon: Oregon Health & Science University. Appendix G: Black box warnings of ADHD drugs approved by the US Food and Drug Administration. Archived from the original on 8 September 2017. Retrieved 17 January 2014 – via United States National Library of Medicine.
McDonagh MS, Peterson K, Thakurta S, Low A (December 2011). Drug Class Review: Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder (Report). Drug Class Reviews. United States Library of Medicine. PMID 22420008. Archived from the original on 31 August 2016.
National Institute for Health and Care Excellence (2019). Attention deficit hyperactivity disorder: diagnosis and management. NICE Guideline, No. 87. London: National Guideline Centre (UK). ISBN 978-1-4731-2830-9. OCLC 1126668845. Archived from the original on 12 January 2021. Retrieved 9 January 2021.
"Canadian ADHD Practice Guidelines" (PDF). Canadian ADHD Resource Alliance. Archived (PDF) from the original on 21 January 2021. Retrieved 4 February 2011.
Young JL (20 December 2010). "Individualizing Treatment for Adult ADHD: An Evidence-Based Guideline". Medscape. Archived from the original on 8 May 2022. Retrieved 8 May 2022.
Biederman J (21 November 2003). "New-Generation Long-Acting Stimulants for the Treatment of Attention-Deficit/Hyperactivity Disorder". Medscape. Archived from the original on 8 May 2022. Retrieved 8 May 2022. As most treatment guidelines and prescribing information for stimulant medications relate to experience in school-aged children, prescribed doses for older patients are lacking. Emerging evidence for both methylphenidate and Adderall indicate that when weight-corrected daily doses, equipotent with those used in the treatment of younger patients, are used to treat adults with ADHD, these patients show a very robust clinical response consistent with that observed in pediatric studies. These data suggest that older patients may require a more aggressive approach in terms of dosing, based on the same target dosage ranges that have already been established – for methylphenidate, 1–1.5–2 mg/kg/day, and for D,L-amphetamine, 0.5–0.75–1 mg/kg/day....
In particular, adolescents and adults are vulnerable to underdosing, and are thus at potential risk of failing to receive adequate dosage levels. As with all therapeutic agents, the efficacy and safety of stimulant medications should always guide prescribing behavior: careful dosage titration of the selected stimulant product should help to ensure that each patient with ADHD receives an adequate dose, so that the clinical benefits of therapy can be fully attained.
"State-based Prevalence Data of Parent Reported ADHD". Centers for Disease Control and Prevention. 13 February 2017. Archived from the original on 30 March 2019. Retrieved 31 March 2020.
Faraone SV (2011). "Ch. 25: Epidemiology of Attention Deficit Hyperactivity Disorder". In Tsuang MT, Tohen M, Jones P (eds.). Textbook of Psychiatric Epidemiology (3rd ed.). John Wiley & Sons. p. 450. ISBN 978-0-470-97740-8. Archived from the original on 22 December 2020. Retrieved 1 February 2016.
Crawford N (February 2003). "ADHD: a women's issue". Monitor on Psychology. 34 (2): 28. Archived from the original on 9 April 2017.
Schwarz A (14 December 2013). "The Selling of Attention Deficit Disorder". The New York Times. Archived from the original on 1 March 2015. Retrieved 26 February 2015.
Connor DF (2011). "Problems of overdiagnosis and overprescribing in ADHD: are they legitimate?". Psychiatric Times. Vol. 28, no. 8. p. 14. Archived from the original on 12 August 2021.
"ADHD Throughout the Years" (PDF). Center For Disease Control and Prevention. Archived (PDF) from the original on 7 August 2013. Retrieved 2 August 2013.
Crichton A (1976) [1798]. An inquiry into the nature and origin of mental derangement: comprehending a concise system of the physiology and pathology of the human mind and a history of the passions and their effects. United Kingdom: AMS Press. p. 271. ISBN 978-0-404-08212-3. Archived from the original on 3 April 2019. Retrieved 17 January 2014 – via Google Books.
Millichap JG (2010). "Definition and History of ADHD". Attention Deficit Hyperactivity Disorder Handbook (2nd ed.). Springer Science. pp. 2–3. doi:10.1007/978-1-4419-1397-5_1. ISBN 978-1-4419-1396-8. LCCN 2009938108. Archived from the original on 14 January 2023. Retrieved 8 May 2022 – via Google Books.
Boseley S (30 September 2010). "Hyperactive children may have genetic disorder, says study". The Guardian. Archived from the original on 8 July 2017.
National Collaborating Centre for Mental Health (2009). "Diagnosis". Attention Deficit Hyperactivity Disorder: Diagnosis and Management of ADHD in Children, Young People and Adults. NICE Clinical Guidelines. Vol. 72. Leicester: British Psychological Society. pp. 116–7, 119. ISBN 978-1-85433-471-8. Archived from the original on 13 January 2016 – via NCBI Bookshelf.
Barkley R (2006). Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. New York: Guilford. pp. 42–5. ISBN 978-1-60623-750-2. Archived from the original on 2 October 2023. Retrieved 19 July 2022.
Hoogman M, Stolte M, Baas M, Kroesbergen E (December 2020). "Creativity and ADHD: A review of behavioral studies, the effect of psychostimulants and neural underpinnings" (PDF). Neuroscience and Biobehavioral Reviews. 119: 66–85. doi:10.1016/j.neubiorev.2020.09.029. hdl:1874/409179. PMID 33035524. S2CID 222142805. Archived (PDF) from the original on 6 September 2023. Retrieved 28 August 2023.

webmd.com

"ADHD Anger Management Directory". Webmd.com. Archived from the original on 5 November 2013. Retrieved 17 January 2014.
"Dyslexia and ADHD". Archived from the original on 21 February 2023. Retrieved 19 May 2022.

who.int

icd.who.int

"6A05 Attention deficit hyperactivity disorder". International Classification of Diseases (11th ed.). February 2022 [2019]. Archived from the original on 1 August 2018. Retrieved 8 May 2022.

apps.who.int

"F90 Hyperkinetic disorders". International Statistical Classification of Diseases and Related Health Problems 10th Revision. World Health Organisation. 2010. Archived from the original on 2 November 2014. Retrieved 2 November 2014.

euro.who.int

"Mental health of children and adolescents" (PDF). WHO Europe. 15 January 2005. Archived from the original (PDF) on 24 October 2009. Retrieved 13 October 2011.

wiley.com

onlinelibrary.wiley.com

Botting N, Powls A, Cooke RW, Marlow N (November 1997). "Attention deficit hyperactivity disorders and other psychiatric outcomes in very low birthweight children at 12 years". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 38 (8): 931–941. doi:10.1111/j.1469-7610.1997.tb01612.x. PMID 9413793. Archived from the original on 17 May 2022. Retrieved 22 March 2022.

worldcat.org

search.worldcat.org

Faraone SV, Bellgrove MA, Brikell I, Cortese S, Hartman CA, Hollis C, et al. (22 February 2024). "Attention-deficit/hyperactivity disorder". Nature Reviews Disease Primers. 10 (1): 1–21. doi:10.1038/s41572-024-00495-0. ISSN 2056-676X.
Faraone SV, Bellgrove MA, Brikell I, Cortese S, Hartman CA, Hollis C, et al. (22 February 2024). "Attention-deficit/hyperactivity disorder". Nature Reviews Disease Primers. 10 (1): 1–21. doi:10.1038/s41572-024-00495-0. ISSN 2056-676X.
Diagnostic and Statistical Manual of Mental Disorders (Fifth, Text Revision (DSM-5-TR) ed.). Washington, D.C.: American Psychiatric Publishing. February 2022. ISBN 978-0-89042-575-6. OCLC 1288423302.
Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, et al. (September 2021). "The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder". Neuroscience and Biobehavioral Reviews. 128. Elsevier BV: 789–818. doi:10.1016/j.neubiorev.2021.01.022. ISSN 0149-7634. PMC 8328933. PMID 33549739.
Barkley RA (December 2002). "International Consensus Statement on ADHD". Journal of the American Academy of Child and Adolescent Psychiatry. 41 (12): 1389. doi:10.1097/00004583-200212000-00001. ISSN 0890-8567. PMID 12447019.
Barkley RA, Murphy KR (1 June 2011). "The Nature of Executive Function (EF) Deficits in Daily Life Activities in Adults with ADHD and Their Relationship to Performance on EF Tests". Journal of Psychopathology and Behavioral Assessment. 33 (2): 137–158. doi:10.1007/s10862-011-9217-x. ISSN 1573-3505.
Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, et al. (1 September 2021). "The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder". Neuroscience & Biobehavioral Reviews. 128: 789–818. doi:10.1016/j.neubiorev.2021.01.022. ISSN 0149-7634. PMC 8328933. PMID 33549739.
Barkley RA, Murphy KR (1 June 2011). "The Nature of Executive Function (EF) Deficits in Daily Life Activities in Adults with ADHD and Their Relationship to Performance on EF Tests". Journal of Psychopathology and Behavioral Assessment. 33 (2): 137–158. doi:10.1007/s10862-011-9217-x. ISSN 1573-3505.
Barkley RA, Murphy KR (1 June 2011). "The Nature of Executive Function (EF) Deficits in Daily Life Activities in Adults with ADHD and Their Relationship to Performance on EF Tests". Journal of Psychopathology and Behavioral Assessment. 33 (2): 137–158. doi:10.1007/s10862-011-9217-x. ISSN 1573-3505.
Worthington R, Wheeler S (January 2023). "Hyperfocus and offending behaviour: a systematic review" (PDF). The Journal of Forensic Practice. 25 (3): 185–200. doi:10.1108/JFP-01-2022-0005. ISSN 2050-8794. S2CID 258330884.
Brown TE (March 2009). "ADD/ADHD and impaired executive function in clinical practice". Current Attention Disorders Reports. 1 (1): 37–41. doi:10.1007/s12618-009-0006-3. ISSN 1943-457X.
Larsson H, Chang Z, D'Onofrio BM, Lichtenstein P (July 2014). "The heritability of clinically diagnosed Attention-Deficit/Hyperactivity Disorder across the life span". Psychological Medicine. 44 (10): 2223–2229. doi:10.1017/S0033291713002493. ISSN 0033-2917. PMC 4071160. PMID 24107258.
Ford JD, Connor DF (1 June 2009). "ADHD and post-traumatic stress disorder". Current Attention Disorders Reports. 1 (2): 60–66. doi:10.1007/s12618-009-0009-0. ISSN 1943-457X. S2CID 145508751.
Szymanski K, Sapanski L, Conway F (1 January 2011). "Trauma and ADHD – Association or Diagnostic Confusion? A Clinical Perspective". Journal of Infant, Child, and Adolescent Psychotherapy. 10 (1). Philadelphia PA: Taylor & Francis Group: 51–59. doi:10.1080/15289168.2011.575704. eISSN 1940-9214. ISSN 1528-9168. S2CID 144348893.
Miodus S, Allwood MA, Amoh N (5 January 2021). "Childhood ADHD Symptoms in Relation to Trauma Exposure and PTSD Symptoms Among College Students: Attending to and Accommodating Trauma". Journal of Emotional and Behavioral Disorders. 29 (3): 187–196. doi:10.1177/1063426620982624. ISSN 1063-4266. S2CID 234159064.
Sonuga-Barke EJ, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M, et al. (March 2013). "Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments". The American Journal of Psychiatry. 170 (3): 275–289. doi:10.1176/appi.ajp.2012.12070991. eISSN 1535-7228. LCCN 22024537. OCLC 1480183. PMID 23360949. S2CID 434310. Free fatty acid supplementation and artificial food color exclusions appear to have beneficial effects on ADHD symptoms, although the effect of the former are small and those of the latter may be limited to ADHD patients with food sensitivities...
Tomaska LD, Brooke-Taylor S (2014). "Food Additives – General". In Motarjemi Y, Moy GG, Todd EC (eds.). Encyclopedia of Food Safety. Vol. 3 (1st ed.). Amsterdam: Elsevier/Academic Press. pp. 449–54. ISBN 978-0-12-378613-5. OCLC 865335120.
Cortese S, Kelly C, Chabernaud C, Proal E, Di Martino A, Milham MP, et al. (October 2012). "Toward systems neuroscience of ADHD: a meta-analysis of 55 fMRI studies". The American Journal of Psychiatry. 169 (10): 1038–1055. doi:10.1176/appi.ajp.2012.11101521. eISSN 1535-7228. LCCN 22024537. OCLC 1480183. PMC 3879048. PMID 22983386.
Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U (March 2012). "Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis". The American Journal of Psychiatry. 169 (3): 264–272. doi:10.1176/appi.ajp.2011.11060940. eISSN 1535-7228. hdl:11577/2482784. LCCN 22024537. OCLC 1480183. PMID 22294258.
Song P, Zha M, Yang Q, Zhang Y, Li X, Rudan I (February 2021). "The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis". Journal of Global Health. 11. International Global Health Society: 04009. doi:10.7189/jogh.11.04009. eISSN 2047-2986. OCLC 751737736. PMC 7916320. PMID 33692893.
National Institute for Health and Care Excellence (2019). Attention deficit hyperactivity disorder: diagnosis and management. NICE Guideline, No. 87. London: National Guideline Centre (UK). ISBN 978-1-4731-2830-9. OCLC 1126668845. Archived from the original on 12 January 2021. Retrieved 9 January 2021.
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (June 2007). "The worldwide prevalence of ADHD: a systematic review and metaregression analysis". The American Journal of Psychiatry. 164 (6): 942–948. doi:10.1176/appi.ajp.164.6.942. eISSN 1535-7228. LCCN 22024537. OCLC 1480183. PMID 17541055.
Staley BS (2024). "Attention-Deficit/Hyperactivity Disorder Diagnosis, Treatment, and Telehealth Use in Adults — National Center for Health Statistics Rapid Surveys System, United States, October–November 2023". MMWR. Morbidity and Mortality Weekly Report. 73 (40): 890–895. doi:10.15585/mmwr.mm7340a1. ISSN 0149-2195. PMC 11466376. PMID 39388378.
Lahey BB, Applegate B, McBurnett K, Biederman J, Greenhill L, Hynd GW, et al. (November 1994). "DSM-IV field trials for attention deficit hyperactivity disorder in children and adolescents". The American Journal of Psychiatry. 151 (11): 1673–1685. doi:10.1176/ajp.151.11.1673. eISSN 1535-7228. LCCN 22024537. OCLC 1480183. PMID 7943460.
Gross MD (February 1995). "Origin of stimulant use for treatment of attention deficit disorder". The American Journal of Psychiatry. 152 (2): 298–299. doi:10.1176/ajp.152.2.298b. eISSN 1535-7228. LCCN 22024537. OCLC 1480183. PMID 7840374.
Brown W (1998). "Charles Bradley, M.D.". American Journal of Psychiatry. 155 (7): 968. doi:10.1176/ajp.155.7.968. eISSN 1535-7228. ISSN 0002-953X. LCCN 22024537. OCLC 1480183.

zenodo.org

Hazell P (July 2011). "The challenges to demonstrating long-term effects of psychostimulant treatment for attention-deficit/hyperactivity disorder". Current Opinion in Psychiatry. 24 (4): 286–290. doi:10.1097/YCO.0b013e32834742db. PMID 21519262. S2CID 21998152. Archived from the original on 26 July 2020. Retrieved 19 July 2019.